SG172632A1 - Pyrrolopyrimidine compounds and their uses - Google Patents
Pyrrolopyrimidine compounds and their uses Download PDFInfo
- Publication number
- SG172632A1 SG172632A1 SG2011037637A SG2011037637A SG172632A1 SG 172632 A1 SG172632 A1 SG 172632A1 SG 2011037637 A SG2011037637 A SG 2011037637A SG 2011037637 A SG2011037637 A SG 2011037637A SG 172632 A1 SG172632 A1 SG 172632A1
- Authority
- SG
- Singapore
- Prior art keywords
- substituted
- alkyl
- mmol
- ethyl
- compound
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 78
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims description 232
- -1 anti-cancer Substances 0.000 claims description 107
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 208000035475 disorder Diseases 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 208000023275 Autoimmune disease Diseases 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical group 0.000 claims description 21
- 206010052779 Transplant rejections Diseases 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 230000001363 autoimmune Effects 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 6
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 208000007475 hemolytic anemia Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 5
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 claims description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 5
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 238000002689 xenotransplantation Methods 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 claims description 3
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 3
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- 108010057466 NF-kappa B Proteins 0.000 claims description 3
- 102000003945 NF-kappa B Human genes 0.000 claims description 3
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 claims description 3
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000025237 Polyendocrinopathy Diseases 0.000 claims description 3
- 206010037549 Purpura Diseases 0.000 claims description 3
- 241001672981 Purpura Species 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 claims description 3
- 230000001800 adrenalinergic effect Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 229960003896 aminopterin Drugs 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 230000005784 autoimmunity Effects 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims description 3
- 229930188550 carminomycin Natural products 0.000 claims description 3
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 claims description 3
- 229950001725 carubicin Drugs 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 206010014801 endophthalmitis Diseases 0.000 claims description 3
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 3
- 229960000752 etoposide phosphate Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 150000002344 gold compounds Chemical class 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 208000037906 ischaemic injury Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
- 208000030372 neonatal thrombocytopenia Diseases 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 3
- 229960001237 podophyllotoxin Drugs 0.000 claims description 3
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 229950004406 porfiromycin Drugs 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 3
- 229960000977 trabectedin Drugs 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- NEJNGXMIDTXQPE-UHFFFAOYSA-N n-ethyl-n-methoxyethanamine Chemical compound CCN(CC)OC NEJNGXMIDTXQPE-UHFFFAOYSA-N 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 101100272279 Beauveria bassiana Beas gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 57
- 108060006633 protein kinase Proteins 0.000 abstract description 57
- 201000010099 disease Diseases 0.000 abstract description 34
- 230000002062 proliferating effect Effects 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 150000002894 organic compounds Chemical class 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 182
- 239000000203 mixture Substances 0.000 description 122
- 238000000034 method Methods 0.000 description 97
- 239000000243 solution Substances 0.000 description 93
- 235000019439 ethyl acetate Nutrition 0.000 description 79
- 239000011541 reaction mixture Substances 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 58
- 239000007787 solid Substances 0.000 description 54
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 51
- 239000012043 crude product Substances 0.000 description 45
- 125000000217 alkyl group Chemical group 0.000 description 43
- 239000011734 sodium Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000012267 brine Substances 0.000 description 37
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 37
- 239000007858 starting material Substances 0.000 description 36
- 239000007864 aqueous solution Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- 125000000304 alkynyl group Chemical group 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 125000003342 alkenyl group Chemical group 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- 239000000460 chlorine Substances 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000002953 preparative HPLC Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 15
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 229910052681 coesite Inorganic materials 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 229910052906 cristobalite Inorganic materials 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 229910052682 stishovite Inorganic materials 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 229910052905 tridymite Inorganic materials 0.000 description 14
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 13
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 108091000080 Phosphotransferase Proteins 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 102000020233 phosphotransferase Human genes 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 11
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 235000012239 silicon dioxide Nutrition 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 101150069380 JAK3 gene Proteins 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 10
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 10
- 125000001769 aryl amino group Chemical group 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000004986 diarylamino group Chemical group 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 125000005129 aryl carbonyl group Chemical group 0.000 description 9
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 9
- 125000004663 dialkyl amino group Chemical group 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 9
- YWICSOZDCVYNQD-UHFFFAOYSA-N 2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C=CC2=C1 YWICSOZDCVYNQD-UHFFFAOYSA-N 0.000 description 8
- 108010024121 Janus Kinases Proteins 0.000 description 8
- 102000015617 Janus Kinases Human genes 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 8
- 125000002877 alkyl aryl group Chemical group 0.000 description 8
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000005110 aryl thio group Chemical group 0.000 description 8
- 150000007942 carboxylates Chemical class 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- AFVUJJNEILZYJQ-UHFFFAOYSA-N 1-[4-(4-aminophenyl)-1-piperazinyl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=C1 AFVUJJNEILZYJQ-UHFFFAOYSA-N 0.000 description 7
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 7
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 7
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 7
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 7
- WNSYXBQMDQKCGD-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carbaldehyde Chemical compound N1=C2N(C(CC)CC)C(C=O)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 WNSYXBQMDQKCGD-UHFFFAOYSA-N 0.000 description 6
- JPNZFPOGAMFPDY-UHFFFAOYSA-N 5-bromo-2-chloro-n-pentan-3-ylpyrimidin-4-amine Chemical compound CCC(CC)NC1=NC(Cl)=NC=C1Br JPNZFPOGAMFPDY-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 6
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 6
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 6
- 101150009057 JAK2 gene Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- PJXISGLJRLXGRA-UHFFFAOYSA-N 2-chloro-6-methyl-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C)=CC2=C1 PJXISGLJRLXGRA-UHFFFAOYSA-N 0.000 description 5
- SVETYNQVUITPHO-UHFFFAOYSA-N 2-chloro-9-pentan-3-yl-7h-purin-8-one Chemical compound ClC1=NC=C2NC(=O)N(C(CC)CC)C2=N1 SVETYNQVUITPHO-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101150012716 CDK1 gene Proteins 0.000 description 5
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 5
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229910052792 caesium Inorganic materials 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- RSNATXCAQPANIV-UHFFFAOYSA-N n-prop-2-enylpentan-3-amine Chemical compound CCC(CC)NCC=C RSNATXCAQPANIV-UHFFFAOYSA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- QRHYQELVWYDCFU-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-9-pentan-3-yl-7h-purin-8-one Chemical compound N=1C=C2NC(=O)N(C(CC)CC)C2=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 QRHYQELVWYDCFU-UHFFFAOYSA-N 0.000 description 4
- UAJPTLDIFCCFJS-UHFFFAOYSA-N 2-chloro-7-methyl-9-pentan-3-ylpurin-8-one Chemical compound ClC1=NC=C2N(C)C(=O)N(C(CC)CC)C2=N1 UAJPTLDIFCCFJS-UHFFFAOYSA-N 0.000 description 4
- MKDZXFUXPZTKFF-UHFFFAOYSA-N 2-chloro-7-pentan-3-yl-5h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(=O)CC2=C1 MKDZXFUXPZTKFF-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 102000016736 Cyclin Human genes 0.000 description 4
- 108050006400 Cyclin Proteins 0.000 description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 4
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 4
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 4
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000003909 protein kinase inhibitor Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- RMULRXHUNOVPEI-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=C1 RMULRXHUNOVPEI-UHFFFAOYSA-N 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- UPONUQZSLNRFIQ-UHFFFAOYSA-N 1-(2-chloro-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)ethanone Chemical compound C12=NC(Cl)=NC=C2C(C(=O)C)=CN1C1CCCC1 UPONUQZSLNRFIQ-UHFFFAOYSA-N 0.000 description 3
- RZQCTGLTFGMWMT-UHFFFAOYSA-N 1-(2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-yl)ethanol Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(C)O)=CC2=C1 RZQCTGLTFGMWMT-UHFFFAOYSA-N 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- UJJSEKAPLWBJKX-UHFFFAOYSA-N 1-[4-[4-[[6-(diethoxymethyl)-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C(C(OCC)OCC)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 UJJSEKAPLWBJKX-UHFFFAOYSA-N 0.000 description 3
- LTDXESLNHKOSKH-FPLPWBNLSA-N 2-chloro-5-[(z)-2-ethoxyethenyl]-n-pentan-3-ylpyrimidin-4-amine Chemical compound CCO\C=C/C1=CN=C(Cl)N=C1NC(CC)CC LTDXESLNHKOSKH-FPLPWBNLSA-N 0.000 description 3
- ORRREBLUXQMYQY-UHFFFAOYSA-N 2-chloro-5-methyl-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C=C(C)C2=C1 ORRREBLUXQMYQY-UHFFFAOYSA-N 0.000 description 3
- VANYVMUNLQUYNO-UHFFFAOYSA-N 2-chloro-5-methyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=C2C(C)=CNC2=N1 VANYVMUNLQUYNO-UHFFFAOYSA-N 0.000 description 3
- TVLYJEDJJGVGKA-UHFFFAOYSA-N 2-chloro-5-nitro-n-pentan-3-ylpyrimidin-4-amine Chemical compound CCC(CC)NC1=NC(Cl)=NC=C1[N+]([O-])=O TVLYJEDJJGVGKA-UHFFFAOYSA-N 0.000 description 3
- PNNSPFXVYVMTJZ-UHFFFAOYSA-N 2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(O)=O)=CC2=C1 PNNSPFXVYVMTJZ-UHFFFAOYSA-N 0.000 description 3
- BYWUMPDTAOCUHQ-UHFFFAOYSA-N 2-chloro-n-pentan-3-yl-5-prop-1-ynylpyrimidin-4-amine Chemical compound CCC(CC)NC1=NC(Cl)=NC=C1C#CC BYWUMPDTAOCUHQ-UHFFFAOYSA-N 0.000 description 3
- DIVUXBABVYOIOT-UHFFFAOYSA-N 5-bromo-2-chloro-n-cyclopentylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC2CCCC2)=N1 DIVUXBABVYOIOT-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010068192 Cyclin A Proteins 0.000 description 3
- 102000002554 Cyclin A Human genes 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 108060006706 SRC Proteins 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VOWCLPDNZOYXBP-UHFFFAOYSA-N methyl 7-cyclopentyl-5-methyl-2-[[5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-2-yl]amino]pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C2N(C3CCCC3)C(C(=O)OC)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 VOWCLPDNZOYXBP-UHFFFAOYSA-N 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- RXFHRKPNLPBDGE-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RXFHRKPNLPBDGE-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- WARKYKQCOXTIAO-UHFFFAOYSA-N tributyl(2-ethoxyethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C/OCC WARKYKQCOXTIAO-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RHJBYOWZVMUYJY-UHFFFAOYSA-N 1-(2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-yl)ethanone Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(C)=O)=CC2=C1 RHJBYOWZVMUYJY-UHFFFAOYSA-N 0.000 description 2
- JZFFDLKBYUMVDE-UHFFFAOYSA-N 1-[1-[4-[(7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-2-yl)amino]phenyl]piperidin-4-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C=CC2=CN=C1NC(C=C1)=CC=C1N1CCC(C(C)=O)CC1 JZFFDLKBYUMVDE-UHFFFAOYSA-N 0.000 description 2
- LRVRKLVYCYWZNS-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C(C(C)=O)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 LRVRKLVYCYWZNS-UHFFFAOYSA-N 0.000 description 2
- ZYZXXAVJRIWEOD-UHFFFAOYSA-N 1-[4-[4-[(9-pentan-3-ylpurin-2-yl)amino]phenyl]piperazin-1-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C=NC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 ZYZXXAVJRIWEOD-UHFFFAOYSA-N 0.000 description 2
- RDLXQNSYEVZBJG-UHFFFAOYSA-N 1-[4-[4-[[6-(1-hydroxyethyl)-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C(C(C)O)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 RDLXQNSYEVZBJG-UHFFFAOYSA-N 0.000 description 2
- BAXYBFLKEBIHGG-UHFFFAOYSA-N 1-[4-[4-[[6-(hydroxymethyl)-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N1=C2N(C(CC)CC)C(CO)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 BAXYBFLKEBIHGG-UHFFFAOYSA-N 0.000 description 2
- NUDFGAQPDHEKON-UHFFFAOYSA-N 1-[7-cyclopentyl-6-methyl-2-(4-piperazin-1-ylanilino)pyrrolo[2,3-d]pyrimidin-5-yl]ethanone Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C(=O)C)=C(C)N1C1CCCC1 NUDFGAQPDHEKON-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 2
- OZCRJDRURBTGFV-UHFFFAOYSA-N 2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7-pentan-3-yl-5h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C2N(C(CC)CC)C(=O)CC2=CN=C1NC(C=C1F)=CC=C1N1CCN(C)CC1 OZCRJDRURBTGFV-UHFFFAOYSA-N 0.000 description 2
- UONGKNMPWKRTNG-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-5,5-dimethyl-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C2N(C(CC)CC)C(=O)C(C)(C)C2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 UONGKNMPWKRTNG-UHFFFAOYSA-N 0.000 description 2
- ZVAFSYSVWUMNOU-UHFFFAOYSA-N 2-chloro-4-n-pentan-3-ylpyrimidine-4,5-diamine Chemical compound CCC(CC)NC1=NC(Cl)=NC=C1N ZVAFSYSVWUMNOU-UHFFFAOYSA-N 0.000 description 2
- MZVGBMPXYWYYMB-UHFFFAOYSA-N 2-chloro-6-(diethoxymethyl)-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(OCC)OCC)=CC2=C1 MZVGBMPXYWYYMB-UHFFFAOYSA-N 0.000 description 2
- CKJCCNNUHXLCJL-UHFFFAOYSA-N 2-chloro-7-cyclopentyl-6-methylpyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 CKJCCNNUHXLCJL-UHFFFAOYSA-N 0.000 description 2
- HTOFDHQAQBKLFP-UHFFFAOYSA-N 2-chloro-n,n-dimethyl-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(=O)N(C)C)=CC2=C1 HTOFDHQAQBKLFP-UHFFFAOYSA-N 0.000 description 2
- RGUXEWWHSQGVRZ-UHFFFAOYSA-N 3,3-diethoxyprop-1-yne Chemical compound CCOC(C#C)OCC RGUXEWWHSQGVRZ-UHFFFAOYSA-N 0.000 description 2
- GTPBCPAHXKMYPJ-UHFFFAOYSA-N 4-[2-chloro-4-(pentan-3-ylamino)pyrimidin-5-yl]but-3-yn-2-ol Chemical compound CCC(CC)NC1=NC(Cl)=NC=C1C#CC(C)O GTPBCPAHXKMYPJ-UHFFFAOYSA-N 0.000 description 2
- VURNQRXJWGUBMM-UHFFFAOYSA-N 5,5-dibromo-2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(=O)C(Br)(Br)C2=C1 VURNQRXJWGUBMM-UHFFFAOYSA-N 0.000 description 2
- QOZHHZIFJBEYDM-UHFFFAOYSA-N 5-bromo-2-chloro-n-prop-2-enylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NCC=C)=N1 QOZHHZIFJBEYDM-UHFFFAOYSA-N 0.000 description 2
- ATXXLNCPVSUCNK-UHFFFAOYSA-N 5-bromo-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)C=N1 ATXXLNCPVSUCNK-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- IXJZQZQNZLDLRN-UHFFFAOYSA-N 7-cyclopentyl-5-methyl-2-[[5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-2-yl]amino]pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCN(CC3)C(=O)OC(C)(C)C)=NC=C2C(C)=C(C(O)=O)N1C1CCCC1 IXJZQZQNZLDLRN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010060273 Cyclin A2 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- JAGVWWODOUHTKG-UHFFFAOYSA-N methyl 2-[4-(4-acetylpiperazin-1-yl)anilino]-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C2N(C(CC)CC)C(C(=O)OC)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 JAGVWWODOUHTKG-UHFFFAOYSA-N 0.000 description 2
- UJWRXMIUUYLSRJ-UHFFFAOYSA-N methyl 2-chloro-7-cyclopentyl-5-methylpyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C1=C(C)C2=CN=C(Cl)N=C2N1C1CCCC1 UJWRXMIUUYLSRJ-UHFFFAOYSA-N 0.000 description 2
- OJFGEKCHVCQKFE-UHFFFAOYSA-N methyl 2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C(=O)OC)=CC2=C1 OJFGEKCHVCQKFE-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- KCQJLTOSSVXOCC-UHFFFAOYSA-N tributyl(prop-1-ynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC KCQJLTOSSVXOCC-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- SOCAXRLFGRNEPK-IFZYUDKTSA-N (1r,3s,5r)-2-n-[1-carbamoyl-5-(cyanomethoxy)indol-3-yl]-3-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)NC1=CN(C2=CC=C(OCC#N)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F SOCAXRLFGRNEPK-IFZYUDKTSA-N 0.000 description 1
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- ZULOTYWZYPALJU-UHFFFAOYSA-N (3-aminophenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(N)=C1 ZULOTYWZYPALJU-UHFFFAOYSA-N 0.000 description 1
- HGRWHBQLRXWSLV-DEOSSOPVSA-N (4s)-3'-(3,6-dihydro-2h-pyran-5-yl)-1'-fluoro-7'-(3-fluoropyridin-2-yl)spiro[5h-1,3-oxazole-4,5'-chromeno[2,3-c]pyridine]-2-amine Chemical compound C1OC(N)=N[C@]21C1=CC(C=3COCCC=3)=NC(F)=C1OC1=CC=C(C=3C(=CC=CN=3)F)C=C12 HGRWHBQLRXWSLV-DEOSSOPVSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- DNDNCMRKDFGVKF-UHFFFAOYSA-N 1-(2-chloro-7-cyclopentyl-5-methylpyrrolo[2,3-d]pyrimidin-6-yl)ethanol Chemical compound CC(O)C1=C(C)C2=CN=C(Cl)N=C2N1C1CCCC1 DNDNCMRKDFGVKF-UHFFFAOYSA-N 0.000 description 1
- RNPWPESLLCUROD-UHFFFAOYSA-N 1-(4-nitrophenyl)piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC=C([N+]([O-])=O)C=C1 RNPWPESLLCUROD-UHFFFAOYSA-N 0.000 description 1
- CRGRJUULGQHKOZ-UHFFFAOYSA-N 1-(4-nitrophenyl)piperidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCC(=O)CC1 CRGRJUULGQHKOZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- JLHKBGOWYGVITM-UHFFFAOYSA-N 1-[4-(4-aminophenyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CC=C(N)C=C1 JLHKBGOWYGVITM-UHFFFAOYSA-N 0.000 description 1
- AKVVIIAPJJWDRI-UHFFFAOYSA-N 1-[4-(4-nitrophenyl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CC=C([N+]([O-])=O)C=C1 AKVVIIAPJJWDRI-UHFFFAOYSA-N 0.000 description 1
- AVPNJCGJPXIQOG-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)N=C1 AVPNJCGJPXIQOG-UHFFFAOYSA-N 0.000 description 1
- XRKWOGZOQWSBCT-UHFFFAOYSA-N 1-[4-(6-nitropyridin-3-yl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C([N+]([O-])=O)N=C1 XRKWOGZOQWSBCT-UHFFFAOYSA-N 0.000 description 1
- CZNCQGCWPPMUAH-UHFFFAOYSA-N 1-[7-cyclopentyl-2-(4-piperazin-1-ylanilino)pyrrolo[2,3-d]pyrimidin-5-yl]ethanone Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C(=O)C)=CN1C1CCCC1 CZNCQGCWPPMUAH-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- WMASLRCNNKMRFP-UHFFFAOYSA-N 1-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1 WMASLRCNNKMRFP-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- PAJALBWYDSQWAV-UHFFFAOYSA-N 1-isocyanosulfonyl-4-methylbenzene Chemical compound CC1=CC=C(S(=O)(=O)[N+]#[C-])C=C1 PAJALBWYDSQWAV-UHFFFAOYSA-N 0.000 description 1
- KRYROZZRYCYKMZ-UHFFFAOYSA-N 1-methyl-4-[1-(4-nitrophenyl)piperidin-4-yl]piperazine Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(=CC=2)[N+]([O-])=O)CC1 KRYROZZRYCYKMZ-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- AGUVEHIDPWRKBQ-UHFFFAOYSA-N 2,5-dichloro-7-cyclopentyl-6-methylpyrrolo[2,3-d]pyrimidine Chemical compound CC1=C(Cl)C2=CN=C(Cl)N=C2N1C1CCCC1 AGUVEHIDPWRKBQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- RYGPHYIAMPDRBL-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-7-methyl-9-pentan-3-ylpurin-8-one Chemical compound N=1C=C2N(C)C(=O)N(C(CC)CC)C2=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 RYGPHYIAMPDRBL-UHFFFAOYSA-N 0.000 description 1
- LOFLYBUEIGOTON-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1=C2N(C(CC)CC)C(C(O)=O)=CC2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 LOFLYBUEIGOTON-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- UWOXJFZWGWPTNR-UHFFFAOYSA-N 2-chloro-5,5-dimethyl-7-pentan-3-ylpyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(=O)C(C)(C)C2=C1 UWOXJFZWGWPTNR-UHFFFAOYSA-N 0.000 description 1
- CBCRBGKXCFPRQP-UHFFFAOYSA-N 2-chloro-5-(3,3-diethoxyprop-1-ynyl)-n-pentan-3-ylpyrimidin-4-amine Chemical compound CCOC(OCC)C#CC1=CN=C(Cl)N=C1NC(CC)CC CBCRBGKXCFPRQP-UHFFFAOYSA-N 0.000 description 1
- QOGHKQDMOFKJQR-UHFFFAOYSA-N 2-chloro-5-methyl-7-pyridin-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound C12=NC(Cl)=NC=C2C(C)=CN1C1=CC=CC=N1 QOGHKQDMOFKJQR-UHFFFAOYSA-N 0.000 description 1
- UQDZRJQDDWVKMQ-UHFFFAOYSA-N 2-chloro-7-cyclopentyl-5-propan-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound C12=NC(Cl)=NC=C2C(C(C)C)=CN1C1CCCC1 UQDZRJQDDWVKMQ-UHFFFAOYSA-N 0.000 description 1
- WMSVIIGYNRLEAY-UHFFFAOYSA-N 2-chloro-7-cyclopentylpyrrolo[2,3-d]pyrimidine Chemical compound C12=NC(Cl)=NC=C2C=CN1C1CCCC1 WMSVIIGYNRLEAY-UHFFFAOYSA-N 0.000 description 1
- HPZTYNRXBVTJII-UHFFFAOYSA-N 2-chloro-7-pentan-3-ylpyrrolo[2,3-d]pyrimidine-6-carbaldehyde Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C(C=O)=CC2=C1 HPZTYNRXBVTJII-UHFFFAOYSA-N 0.000 description 1
- KSBVEPFHGGPDEW-UHFFFAOYSA-N 2-chloro-9-pentan-3-ylpurine Chemical compound N1=C(Cl)N=C2N(C(CC)CC)C=NC2=C1 KSBVEPFHGGPDEW-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- VMPYFWTYGZZUMY-UHFFFAOYSA-N 2-morpholin-4-ylphenol Chemical compound OC1=CC=CC=C1N1CCOCC1 VMPYFWTYGZZUMY-UHFFFAOYSA-N 0.000 description 1
- SNWNAYNBLUCNIV-UHFFFAOYSA-N 2-pentan-3-yl-7H-purine Chemical compound C(C)C(CC)C1=NC=C2N=CNC2=N1 SNWNAYNBLUCNIV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- RZIYRKYHMDDHCK-UHFFFAOYSA-N 265654-77-1 Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCCN1CCCC1 RZIYRKYHMDDHCK-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- YJDXLUSVVAGFFS-UHFFFAOYSA-N 3-(2-pyrrolidin-1-ylethoxy)aniline Chemical compound NC1=CC=CC(OCCN2CCCC2)=C1 YJDXLUSVVAGFFS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- PYAZCFCEURLPSU-UHFFFAOYSA-N 3-methoxy-4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1OC PYAZCFCEURLPSU-UHFFFAOYSA-N 0.000 description 1
- BKQOBAHHUMROEP-UHFFFAOYSA-N 3-n-(2-pyrrolidin-1-ylethyl)benzene-1,3-diamine Chemical compound NC1=CC=CC(NCCN2CCCC2)=C1 BKQOBAHHUMROEP-UHFFFAOYSA-N 0.000 description 1
- VBIZMIROIBMBKP-UHFFFAOYSA-N 3-n-[2-(4-methylpiperazin-1-yl)ethyl]benzene-1,3-diamine Chemical compound C1CN(C)CCN1CCNC1=CC=CC(N)=C1 VBIZMIROIBMBKP-UHFFFAOYSA-N 0.000 description 1
- VVEDHFCHDSVZMA-UHFFFAOYSA-N 3-nitro-n-(2-pyrrolidin-1-ylethyl)aniline Chemical compound [O-][N+](=O)C1=CC=CC(NCCN2CCCC2)=C1 VVEDHFCHDSVZMA-UHFFFAOYSA-N 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- CDSJZBOLNDWPAA-UHFFFAOYSA-N 4-(4-nitrophenyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1CCNCC1 CDSJZBOLNDWPAA-UHFFFAOYSA-N 0.000 description 1
- MSPNKVDLRJIFRZ-UHFFFAOYSA-N 4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(N)=CC=2)CC1 MSPNKVDLRJIFRZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RUFOHZDEBFYQSV-UHFFFAOYSA-N 4-methoxy-3-nitroaniline Chemical compound COC1=CC=C(N)C=C1[N+]([O-])=O RUFOHZDEBFYQSV-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
- CRMSVJAOZAUGPA-UHFFFAOYSA-N 5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=NC=C2C(C)(C)C(=O)NC2=N1 CRMSVJAOZAUGPA-UHFFFAOYSA-N 0.000 description 1
- QDMPMBFLXOWHRY-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(N)N=C1 QDMPMBFLXOWHRY-UHFFFAOYSA-N 0.000 description 1
- NANAAQBKCZUTJR-UHFFFAOYSA-N 5-chloro-7-cyclopentyl-6-methyl-n-(4-piperazin-1-ylphenyl)pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C2N(C3CCCC3)C(C)=C(Cl)C2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 NANAAQBKCZUTJR-UHFFFAOYSA-N 0.000 description 1
- XVCCHAMVUYNVAY-UHFFFAOYSA-N 5-methyl-n-(5-piperazin-1-ylpyridin-2-yl)-7-pyridin-2-ylpyrrolo[2,3-d]pyrimidin-2-amine Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=CN1C1=CC=CC=N1 XVCCHAMVUYNVAY-UHFFFAOYSA-N 0.000 description 1
- XKSYNAXYOHZBFS-UHFFFAOYSA-N 5H-pyrrolo[2,3-d]pyrimidine-6-carbaldehyde Chemical compound N1=CN=CC2=C1N=C(C2)C=O XKSYNAXYOHZBFS-UHFFFAOYSA-N 0.000 description 1
- DFRRALWXTFSAEC-UHFFFAOYSA-N 5H-tetrazole Chemical compound C1N=NN=N1 DFRRALWXTFSAEC-UHFFFAOYSA-N 0.000 description 1
- IDPWOROYKYSYMZ-UHFFFAOYSA-N 6-(1-methoxyethyl)-7-pentan-3-yl-n-(4-piperazin-1-ylphenyl)pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C2N(C(CC)CC)C(C(C)OC)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 IDPWOROYKYSYMZ-UHFFFAOYSA-N 0.000 description 1
- XMTSMMOMRMGUBB-UHFFFAOYSA-N 6-methyl-7-pentan-3-yl-n-(4-piperazin-1-ylphenyl)pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C2N(C(CC)CC)C(C)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 XMTSMMOMRMGUBB-UHFFFAOYSA-N 0.000 description 1
- YVQVMPXTKXNMIV-UHFFFAOYSA-N 657410-79-2 Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)N=C1 YVQVMPXTKXNMIV-UHFFFAOYSA-N 0.000 description 1
- BKSIMAHBHUPBPD-UHFFFAOYSA-N 7-cyclopentyl-5-methyl-n-(4-piperazin-1-ylphenyl)-6-prop-1-en-2-ylpyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C2N(C3CCCC3)C(C(=C)C)=C(C)C2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 BKSIMAHBHUPBPD-UHFFFAOYSA-N 0.000 description 1
- BLEFCTDTYUZLEG-UHFFFAOYSA-N 7-cyclopentylpyrrolo[2,3-d]pyrimidine Chemical compound C1CCCC1N1C2=NC=NC=C2C=C1 BLEFCTDTYUZLEG-UHFFFAOYSA-N 0.000 description 1
- RKHMLOLIPXZOOY-UHFFFAOYSA-N 7-pentan-3-yl-2-(4-piperazin-1-ylanilino)pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1=C2N(C(CC)CC)C(C(O)=O)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 RKHMLOLIPXZOOY-UHFFFAOYSA-N 0.000 description 1
- CDWBPLFZSMNBDG-UHFFFAOYSA-N 7-pentan-3-yl-n-(4-piperazin-1-ylphenyl)pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C2N(C(CC)CC)C=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 CDWBPLFZSMNBDG-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100495314 Caenorhabditis elegans cdk-5 gene Proteins 0.000 description 1
- 101100495324 Caenorhabditis elegans cdk-7 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102000002435 Cyclin T Human genes 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- ZBEPMOZEXLGCTF-UHFFFAOYSA-N O=C(C1CC1)N1CCCC(C1)NC1=NC(=CC=N1)N1C(CC#N)=CN=C1C1=CC2=C(OC=C2)C=C1 Chemical compound O=C(C1CC1)N1CCCC(C1)NC1=NC(=CC=N1)N1C(CC#N)=CN=C1C1=CC2=C(OC=C2)C=C1 ZBEPMOZEXLGCTF-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- KJDSKNMKNAEMCG-UHFFFAOYSA-N [1-(4-aminophenyl)piperidin-4-yl] benzoate Chemical compound C1=CC(N)=CC=C1N1CCC(OC(=O)C=2C=CC=CC=2)CC1 KJDSKNMKNAEMCG-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001341 alkaline earth metal compounds Chemical class 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- GKPOMITUDGXOSB-UHFFFAOYSA-N but-3-yn-2-ol Chemical compound CC(O)C#C GKPOMITUDGXOSB-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical compound CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- DMXITDHTUYCREX-UHFFFAOYSA-N methyl 2-chloro-7-cyclopentyl-6-methylpyrrolo[2,3-d]pyrimidine-5-carboxylate Chemical compound C12=NC(Cl)=NC=C2C(C(=O)OC)=C(C)N1C1CCCC1 DMXITDHTUYCREX-UHFFFAOYSA-N 0.000 description 1
- FPXZDZISGOSIQV-UHFFFAOYSA-N methyl 2-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C1=C(C2=C(N=C(N=C2)C2CCCC2)N1)C FPXZDZISGOSIQV-UHFFFAOYSA-N 0.000 description 1
- GCBZOULTDNPELH-UHFFFAOYSA-N methyl 5H-pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1CC2=C(N=CN=C2)N=1 GCBZOULTDNPELH-UHFFFAOYSA-N 0.000 description 1
- JDYYZYBPXBVDOT-UHFFFAOYSA-N methyl 7-cyclopentyl-6-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-5-carboxylate Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C(=O)OC)=C(C)N1C1CCCC1 JDYYZYBPXBVDOT-UHFFFAOYSA-N 0.000 description 1
- UJQCANQILFWSDJ-UHFFFAOYSA-N methyl but-2-ynoate Chemical compound COC(=O)C#CC UJQCANQILFWSDJ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- WDLUXISYBICWFR-UHFFFAOYSA-N n,n-dimethyl-7-pentan-3-yl-2-(4-piperazin-1-ylanilino)pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C(CC)CC)C(C(=O)N(C)C)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 WDLUXISYBICWFR-UHFFFAOYSA-N 0.000 description 1
- INNHQJUOPSTQPT-UHFFFAOYSA-N n-(3-amino-4-methoxyphenyl)pyridine-4-carboxamide Chemical compound C1=C(N)C(OC)=CC=C1NC(=O)C1=CC=NC=C1 INNHQJUOPSTQPT-UHFFFAOYSA-N 0.000 description 1
- HQMLGAACGOQSPN-UHFFFAOYSA-N n-(4-methoxy-3-nitrophenyl)pyridine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1NC(=O)C1=CC=NC=C1 HQMLGAACGOQSPN-UHFFFAOYSA-N 0.000 description 1
- FPMMQVDDBNLMRW-UHFFFAOYSA-N n-[2-(4-methylpiperazin-1-yl)ethyl]-3-nitroaniline Chemical compound C1CN(C)CCN1CCNC1=CC=CC([N+]([O-])=O)=C1 FPMMQVDDBNLMRW-UHFFFAOYSA-N 0.000 description 1
- SKZIIJMGBBJBDT-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]-9-pentan-3-ylpurin-2-amine Chemical compound N1=C2N(C(CC)CC)C=NC2=CN=C1NC(C=C1)=CC=C1N1CCN(C)CC1 SKZIIJMGBBJBDT-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- DOWVMJFBDGWVML-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-carboxamide Chemical compound C1=NC(C=2C=[N+]([O-])C=CC=2)=CN1C(=O)N(C)C1CCCCC1 DOWVMJFBDGWVML-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 208000023983 oral cavity neoplasm Diseases 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- HJFRLXPEVRXBQZ-UHFFFAOYSA-N pent-3-yn-2-ol Chemical compound CC#CC(C)O HJFRLXPEVRXBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- BOUNFBOFBGBYBT-UHFFFAOYSA-N purin-8-one Chemical compound C1=NC=NC2=NC(=O)N=C21 BOUNFBOFBGBYBT-UHFFFAOYSA-N 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- HMOPBGFCZBTBMX-UHFFFAOYSA-N pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=NC=NC2=NC(=O)C=C21 HMOPBGFCZBTBMX-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YANZKRJGYIYOJE-UHFFFAOYSA-N tert-butyl 4-[6-[[6-(acetamidocarbamoyl)-7-cyclopentyl-5-methylpyrrolo[2,3-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylate Chemical compound N1=C2N(C3CCCC3)C(C(=O)NNC(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 YANZKRJGYIYOJE-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010518 undesired secondary reaction Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
Abstract
PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USESThe present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.(No suitable figures)
Description
PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES oo on Background oo .
The search for new therapeutic agents has been greatly aided in recent years by a better understanding of the structure of enzymes and other biomolecules associated with iE + diseases. One important class of enzymes that has been the subject of extensive study is protein kinases. | oo Co oo oo Protein Kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell. ~ (Hardie, G. and Hanks, S. The Protein Kinase Facts Book, I and II, Academic Press, San
Diego, Calif.: 1995). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into - - - families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, lipids, etc.). Sequence motifs have been identified that generally correspond to each of these - kinase families (See, for example, Hanks, S. K., Hunter, T., FASEB J. 1995, 9, 576-596; :
Knighton et al., Science 1991, 253, 407-414; Hiles et al., Cell 1992, 70, 419-429; Kunz et al.,
Cell 1993, 73, 585-596; Garcia-Bustos et al., EMBO J. 1994, 13, 2352-2361).
In general, protein kinases mediate intracellular signaling by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. These phosphorylation events act as molecular on/off switches that can modulate Co or regulate the target protein biological function. These phosphorylation events are ~ ultimately triggered in response to a variety of extracellular and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, and H,0,), cytokines (e.g., interleukin-1 (IL- 1) and tumor necrosis factor-a (TNF-a)), and growth factors (e.g., granulocyte macrophage- colony-stimulating factor (GM-CSF), and fibroblast growth factor (FGF)). An extracellular stimulus may affect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.
Many diseases are associated with abnormal cellular responses triggered by protein : kinase-mediated events as described above. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological = and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Co
Alzheimer’s disease, and hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic ~~ agents. oo
The Janus kinases (JAK) are a family of tyrosine kinases consisting of JAK 1, JAK?2, :
JAK3 and TYK2. The J AKs play a critical role in cytokine signaling. The down-stream substrates of the JAK family of kinases include the signal transducer and activator of ) transcription (STAT) proteins. JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematologic malignancies such as leukemias and lymphomas. The pharmaceutical intervention in the JAK/STAT pathway has been reviewed [F rank Mol. Med. 5: 432-456 (1999) & Seidel, et al, Oncogene 19: 2645-2656 (2000)]. Co - ~~ JAKI1,JAK2, and TYK2 are ubiquitously expressed, while JAK3 is predominantly expressed in hematopoietic cells. JAK3 binds exclusively to the common cytokine receptor gamma chain (y.) and is activated by IL-2, IL-4, IL-7, IL-9, and IL-15. The proliferation and survival of murine mast cells induced by IL-4 and IL-9 have, in fact, been shown to be dependent on JAK3- and 65.-signaling [Suzuki et al, Blood 96: 2172-2180 (2000)].
Cross-linking of the high-affinity immunoglobulin (Ig) E receptors of sensitized mast cells leads to a release of proinflammatory mediators, including a number of vasoactive cytokines resulting in acute allergic, or immediate (type I) hypersensitivity reactions [Gordon etal, Nature 346: 274-276 (1990) & Galli, N. Engl. J. Med., 328: 257-265 (1993)]. A crucial role for JAK3 in IgE receptor-mediated mast cell responses in vitro and in vivo has been established [Malaviya, et al, Biochem. Biophys. Res. Commun. 257: 807-813 ( 1999)]. In © addition, the prevention of type I hypersensitivity reactions, including anaphylaxis, mediated by mast cell-activation through inhibition of JAK3 has also been reported [Malaviyaetal, J.
Biol. Chem. 274:27028-27038 (1999)]. oo + The JAK family of tyrosine kinases have also been shown to play arolein immunosuppression and allograft acceptance [Kirken, Transpl. Proc. 33: 3268-3270 (2001)], rheumatoid arthritis [Muller-Ladner, et al., J. Immunol. 164: 3894-3901 (2000)], Familial amyotrophic lateral sclerosis [Trieu, et al., Biochem. Biophys. Res. Commun. 267 122-25 (2000), and leukemia [Sudbeck, et al., Clin. Cancer Res. 5: 1569-1582 (1999)]. =
Initiation, progression, and completion of the mammalian cell cycle are regulated by various cyclin-dependent kinase (CDK) complexes, which are critical for cell growth. These : complexes comprise at least a catalytic (the CDK itself) and a regulatory (cyclin) subunit. .
Some of the more important complexes for cell cycle regulation include cyclin A{CDK-also oo | 2
‘known as cdc2, and CDK?2), cyclin B1-B3 (CDK 1) and cyclin D1-D3 (CDK2, CDK4, CDKS,
CDK®6), cyclin E (CDK2). Each of these complexes is involved ina particular phase of the cell cycle. Not all members of the CDK family are involved exclusively in cell cycle control, however. Thus CDKs 7, 8, and 9 are implicated in the regulation of transcription, and CDK5 plays a role in neuronal and secretory cell function. : oo The activity of CDKs is regulated post-translationally, by transitory associations with - other proteins, and by alterations of their intracellular localization. Tumor development is closely associated with — alteration and deregulation of CDKs and their regulators, suggesting that inhibitors of CDKs may be useful anti-cancer therapeutics. Indeed, early results suggest that transformed and normal cells differ in their requirement for, e.g., cyclin
A/CDK2 and that it may be possible to develop novel antineoplastic agents devoid of the N general host toxicity observed with conventional cytotoxic and cytostatic drugs. While inhibition of cell cycle-related CDKs is clearly relevant in, e.g., oncology applications, this may not be the case for the inhibition of RNA polymerase-regulating CDKs. On the other hand, inhibition of CDK9/cyclin T function was recently linked to prevention of HIV oo replication and the discovery of new CDK biology thus continues to open up new therapeutic indications for CDK inhibitors (Sausville, E. A. Trends Molec. Med. 2002, 8, $32-S37). ~The function of CDKs is to phosphorylate and thus activate or deactivate certain proteins, including e.g. retinoblastoma proteins, lamins, histone Hi, and components of the 20° mitotic spindle. The catalytic step mediated by CDKs involves a phospho-transfer reaction oo from ATP to the macromolecular enzyme substrate. Several groups of compounds (reviewed in e.g. Fischer, P. M. Curr. Opin. Drug Discovery Dev. 2001, 4, 623-634) have been found to : possess anti-proliferative properties by virtue of CDK-specific ATP antagonism. :
Thus, there is a continued need to find new therapeutic agents to treat human diseases.
Accordingly, there is a great need to develop inhibitors of protein Kinases, such as Jakl1, Jak2 - and Jak3, as well as CDK 1, CDK2, CDK4, CDK 5, CDK6, CDK 7, CDK8 and CDK9.- | -
There remains a need for new treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or - amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein . ~ kinases, such as Jak1, Jak2 and Jak3, as well as CDK 1, CDK2, CDK4, CDKS, CDKS6, CDK7,
CDK8 and CDKO, using the compounds provided herein. In one aspect, the invention provides a compound of Formula I: oo oo
PP { , RY | | oo
In one aspect of the invention, the protein kinase is a protein tyrosine kinase. In one embodiment, the protein kinase is selected from the group consisting of abl, ATK, ber-abl,
Blk, Brk, Bik, c-fins, e- kit, c- met, c-src, CDK, cRafl, CSFIR, CSK, EGFR, ErbB2, ErbB3,
ErbB4, ERK, Fak, fes, FGFRI, 25 FGFR2, FGFR3, FGFR4, FGFRS, Fer, FLK-4, flt-1, Fps, ‘Frk, Fyn, GSK, Gst-FIKI, Hck, Her-2, Her-4, IGF- IR, INS-R, Jak, INK, KDR; Lck, Lyn, | -
MEK, p38, PANHER, PDGFR, PLK, PKC, PYK2, Raf, Rho, ros, SRC, tell t’e2, TRK,
TYK2,UL97, VEGFR, Yes, and Zap70. In another embodiment, the protein kinase is selected from the group consisting of CDK1, CDK2, CDKA4, CDKS5, CDKaG6, CDK7, CDKS$ : and CDK9. In yet another embodiment, the protein kinase is selected from the group oo consisting of Jak1, Jak2 and Jak3. In still another embodiment, the protein kinase is selected from the group consisting of Jak3 and CDK4. | oo oo
In another aspect of the invention, the protein kinase is in a cell culture. In still another aspect, the protein kinase is in a mammal.
In another aspect, the invention provides a method of treating a protein kinase- ~~ oo associated disorder, wherein the method includes administering to a subject in need thereof a pharmaceutically acceptable amount of a. compound of the Formula I, such that the protein oo kinase-associated disorder is treated. In one embodiment, the protein kinase is selected from the group consisting of CDK 1, CDK2, CDK4, CDK, CDK6, CDK7, CDKS, CDK9, Jak, ~ Jak2 and Jak3. In a particular embodiment, the protein kinase is selected from the group consisting of Jak3 and CDK4. oo | | Co oo
In another embodiment, the protein kinase-associated disorder is selected from the group consisting of blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system ~ diseases and cancer. :
In another embodiment, the protein kinase-associated disorder is cancer. In yet another embodiment, the cancer is selected from the group consisting of breast, stomach, h 4 ovary, colon, lung, brain, larynx, lymphatic system, genitourinary tract (including bladder and prostate), ovarian, gastric, bone, and pancreatic cancer. : | -
In another embodiment, the protein kinase-associated disorder is selected from the group consisting of organ transplant rejection, xeno transplantation, lupus, multiple sclerosis, - rheumatoid arthritis, psoriasis, Type 1 diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn’s disease,
Alzheimer’s disease and leukemia. | oo
In still another embodiment, the disease is selected from an immune response, an autoimmune disease, a neurodegenerative disease, or a solid or hematologic malignancy. In yet another embodiment, the disease is selected from an allergic or type I hypersensitivity reaction, asthma, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple sclerosis, Familial amyotrophic lateral sclerosis, leukemia, or lymphoma oC “In another aspect, the invention provides a method of treating an autoimmune disease,wherein the treatment includes administering to a subject in need thereof a pharmaceutically acceptable amount of a compound of the Formula I, such that the autoimmune disease is treated. In one embodiment, the autoimmune disease is selected from the group consisting of autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis, multiple sclerosis, neuritis, uveitis ophthalmia, oo polyendocrinopathies, purpura, Reiter’s Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes . mellitis, autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism, systemic lupus erhythematosus, Goodpasture’s syndrome, Pemphigus, Receptor autoimmunities, autoinunune hemolytic anemia, autoimmune thrombocytopenic purpura, theumatoid arthritis, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison’s disease, infertility, glomerulonephritis, bullous pemphigoid, Sjogren’s syndrome, diabetes millitus, adrenergic drug resistance, chronic active hepatitis, primary : biliary cirrhosis, vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, chronic active hepatitis, primary biliary cirrhosis and T-cell mediated hypersensitivity diseases.
In another aspect, the invention provides a method of treating transplant rejection, Co wherein the treatment includes administering to a subj ect in need thereof a pharmaceutically acceptable amount of a compound of the Formula I such that the wansplant rejection is treated. Tn one embodiment, the transplant rej ection is selected from the group consisting of graft versus host disease; rej ection related to xeno transplantation, rejection related to organ ~~ transplant, rejection related to acute transplant, heterograft or homograft rejection and . ischemic or reperfusion injury incurred during organ transplantation.
In another aspect, the invention provides a method of treating cancer, wherein the oo method includes administering to a subject in need thereof a pharmaceutically acceptable | : amount of a compound of the Formula I such that the cancer disease or disorder is treated. In one embodiment, the cancer is selected from the group consisting of bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small-cell lung, glioma, colorectal and oo pancreatic cancer. - | So
In another aspect of the invention, the Formula I or salt thereof is administered, simultaneously or sequentially, with an antiinflammatory, antiproliferative, chemotherapeutic agent, immunosuppressant, anti-cancer, cytotoxic agent or kinase inhibitor other than a compound of the Formula I or salt thereof. In one embodiment, the compound of the : :
Formula I or salt thereof is administered, simultaneously or sequentially, with one or more of a PTK inhibitor, cyclosporin A, CTLA4-Ig, antibodies selected from anti-ICAM-3, anti-IL-2 receptor, anti-CD45RB, anti-CD2, anti-CD3, anti-CD4, anti-CD80, anti-CD86, and : monoclonal antibody OKT3, agents blocking the interaction between CD40 and gp39, fusion proteins constructed from CD40 and gp39, inhibitors of NF-kappa B function, non-steroidal antiinflammatory drugs, steroids, gold compounds, antiproliferative agents, FK506, - mycophenolate mofetil, cytotoxic drugs, TNF-a inhibitors, anti-TNF antibodies or soluble
TNF receptor, rapamycin, leflunimide, cyclooxygenase-2 inhibitors, paclitaxel, cisplatin, carboplatin, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, mitomycin C, ecteinascidin 743, porfiromycin, 5-fluorouracil, 6- "mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosidine, epothilone, vindesine, leurosine, or derivatives thereof.
In another aspect, the invention provides a packaged protein kinase-associated disorder treatment, wherein the treatment includes a protein kinase-modulating compound of =~ the Formula I, packaged with instructions for using an effective amount of the protein kinase- modulating compound to treat a protein kinase-associated disorder. oo
This invention is directed to compounds, e.g., pyrrolopyrimidine compounds, and intermediates thereto, as well as pharmaceutical compositions containing the compounds for © use in treatment of protein kinase-associated disorders. This invention is also directed to the compounds of the invention or compositions thereof as modulators of Jak1, Jak2 and Jak3,as well as CDK1, CDK2, CDKA4, CDKS5, CDK6, CDK7, CDK8 and CDK9. The present | oo invention is also directed to methods of combination therapy for inhibiting protein kinase activity in cells, or for treating, preventing or ameliorating of one or more symptoms of ; cancer, transplant rejections, and autoimmune diseases in patients using the compounds of the invention or pharmaceutical compositions, or kits thereof. | : ~ Inone aspect, the invention provides compounds of the Formula I:
A XX : \ -M or a pharmaceutically acceptable salt or solvate thereof, wherein: So : the dashed line indicates a single or double bond; oo oo © AisNor CR’, wherein R® is hydrogen or C;-Cs-alkyl; - .
R? and R® are each, independently, selected from the group consisting of hydrogen, hydroxyl, C,-Cs-alkyl, C3-Cg-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C,-C3- ~~ alkyl, substituted C;-Cs-cycloalkyl, substituted heterocyclyl, substituted aryl and substituted heteroaryl;
R* is selected from the group consisting of hydrogen, C;-Csg-alkyl, substituted C,-Cs- } . alkyl, C;-Cg-cycloalkyl, substituted C3-Cg-cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; | when the bond between X and Y is a single bond, X is CR®R”, NR? or C=0, and Y is
CR°R' or C=0; when the bond between X and Y is a double bond, X is N or CR!!, and Y is CR'%; wherein R® and R are each, independently selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydrogen, C,-Cs-alkyl, C3-Cg-cycloalkyl, heterocyclyl, substituted alkyl, substituted cycloalkyl, and substituted heterocyclyl;
R® is hydrogen, C;-Cs-alkyl, and Cs-Cg-cycloalkyl; oo
RR’ and R' are each, independently, hydrogen, C,-Cs-alkyl, or C3-Cg-cycloalkyl; oo
R! and R"? are each, independently, selected from the group consisting of halo, hydrogen, C,-Cs-alkyl, C,-C;-alkoxy, CN, C=NOH, C=NOCH;, C(O)H, C(0)C,-Cs-alkyl,
C3-Cs-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C;-Cs-alkyl, substituted C;-Cs- : cycloalkyl, substituted heterocyclyl, substituted aryl, substituted heteroaryl, -BNRPRY, -
BOR", -BC(O)R", -BC(O)OR", -BC(O)NR"R"; wherein B is a bond, C,-Cs-alkyl or branched C;-Cs-alkyl; wherein R'* and R" are each, independently, selected from the group consisting of hydrogen, C,-Cs-alkyl, C;-Cg-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and oo substituted heteroaryl. . :
In one embodiment, Ris branched or linear C,-Cs-alkyl, wherein the branched C;-
Cs-alkyl group may be interrupted by one or more heteroatoms, andor substituted with one or more heteroatoms, halogens, C;-Cs cycloalkyl groups, substituted C3-Cg cycloalkyl groups,
C3-Cs hetrocyclyl groups, aryl groups, heteroaryl groups, substituted aryl groups, or : substituted heteroaryl groups. oo - oo
In another embodiment, R' is not hydrogen, R* is selected from the group consisting of hydrogen, C,-Cg-alkyl, C;-Cs-cycloalkyl, C3-Cg-substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl. :
In still another embodiment, R'? is not hydrogen, R* is branched or linear C,-Cs-alkyl, wherein the branched C,-Cs-alkyl group may be interrupted by one or more heteroatoms, = and/or substituted with one or more heteroatoms, halogens, C;-Cs cycloalkyl groups, substituted C3-Cs cycloalkyl groups, C3-Cg hetrocyclyl groups, aryl groups, heteroaryl Co groups, substituted aryl groups, or substituted heteroaryl groups.
In yet another embodiment, A is N. oo
In another embodiment, R* is selected from the group consisting of hydrogen, branched Ci-Cs-alkyl, branched C,-Cs-alkyl substituted by phenyl and C-Ce-cycloalkyl.
In yet another embodiment, R*is C(H)(CH,CH;),, C(H)(CH,CH;)Ph, CH,CHs, oo cyclopropyl, cyclopentyl or cyclohexyl. oo | In still another embodiment, the dashed line is a single bond, X is CH;, C(C;-Cs- CL alkyl); or N(C,-Cs-alkyl), and Y is C=O. In another embodiment, X is CH; or C(CH3); and © Yis C=0. In yet another embodiment, the dashed line is a double bond, X is CH, N, C- : C(0)C,;-Cs-alkyl or C-(C;-Cs-alkyl), and Y is CH, C-CHO, C-C,;-C;-alkyl, C-Cy-Cs-alkoxy, C-C(0)C,-Cs-alkyl, C-C=NOH or C-C=NOCH3,. | a wo 2007/140222 PCT/US2007/069595
In another embodiment, R%is H. oo | oo BE
In yet another embodiment, R? is an aryl group, which is further independently : substituted one or more times by halogen, C,-C4-alkoxy, R'%-amine, R'*-heterocycle, or R"- ~ heteroaryl, wherein R"? is a bond, C(O), N(H)C(O), N(H)SO», OC(O) or (CHp)14, wherein the (CHa)1.4 group may be interrupted by O, N(CHj3) or N(H). : :
In still another embodiment, the aryl group is phenyl.
In another embodiment, the phenyl group is independently substituted one or more times with fluoro, methoxy, diethylamine, R">-piperazinyl, R"*-morpholinyl, R"-piperidinyl, ~ R%-triazolyl, R">-phenyl, R"-pyridinyl, R"*-piperazinyl, R'*-indazolyl, R'*-pyrrolidinyl or
R"-imidazolyl, wherein the piperazinyl, morpholinyl, piperidinyl, triazolyl, phenyl, pyridinyl, piperazinyl, indazolyl, pyrrolidinyl or imidazolyl groups may be further substituted with C;-Cy-alkyl, C(0)C,-Ca-alkyl, S(0)2C1-Cy-alkyl, OH, C(O)(CH2)13CN or N(H)C(0)C- © Cyualkyl.
In yet another embodiment, the phenyl group is substituted by N(H)C(O)aryl,
C(O)N(H)C,-Cs-alkyl, C(O)N(C,-Cy-alkyl), or C(O)N(H)C;3-Cs-cycloalkyl. oo } oo Preferred embodiments of Formula I (including pharmaceutically acceptable salts thereof, as well as enantiomers, stereoisomers, rotamers, tautomers, diastereomers, : ~ atropisomers or racemates thereof) are shown below in Table A, Table B, Table C and Table
D, and are also considered to be “compounds of the invention.” The compounds of the invention are also referred to herein as “protein kinase inhibitors.” | : Co . ;
: TABLE A oo oo
Jak-3/ IC50(nM) : a | : ) HN TL .
AE Co
CO EEE
HN ES . ’
Al N ° ) :
N N— | ! - : oo } 10 .
wo 2007/140222 PCT/US2007/069595 o . 7. N ~ | } .
CO — : o
I. 7 = oo HN N _ oo
SO . -
EE
. . xk | } } .
CT = | - oo . : N | .
Oo oo * a . ’
NT 0 . Co . HN N™ . : . . } . ~~ . ’ - N o Lo ’
NN / oo ou
B
HN N A ’
NR .
NT : . I= } aA oo
Io o
SO oo —/. wk : :
Nt | : :
Ho
AH I
Y \ J \ N dk
EE EEN .. ee CO " | oo
CS wO 2007/140222 PCT/US2007/069595
Ly = ) . Co :
Ne o
Nt av | : oo . . HN NN } ) ‘ i }
N ) } } . oo oo kk ’ } :
NY : - oo HN N A .
CQ oo oo .. kk ’ ’
HN N x ; oo _~N } ’ }
J oo *% :
CN ES i . = } HN N A : . . oO” N : Co } *ok oo | 13
} NTT TX . .
HN NZ TN : oo 0 oo . NT TX : on WN : So - 0) ) co
JP oo
HN n> TN . :
J
HN NZ TN Co . . : . So :
So oo 14 a
. “HN N° N . } } } . i .
Ear CE . Ce Kk oo } } }
BY _ o Co : : HN" ON A Co oo } . Cen | . .
So Alo N ° ’ . ] . . . - ; . Sel ‘ ~ .
Co ol } “3 : } } . . *k
A : - . . nk : . . : oo HN N : : o—b—o : Lo . . kk oo Bh 15 :
NTN
HN N A Co .
N : i NT
Ow . . *k :
NT : ‘ ON A . : *k . EE . : cl NT ON : Co © MN N EN : oo : : Er. . . } . oo : : . oo a - oo Co oo oo 16
. = : . . Co
To
NTT ’ 1 “A . > . - ’ - NT : : HN N A : - o—s=0 : )
CN | : : dk . : :
HN N A
Co x oo
La oo
NT TX .
HN N A oo oo } od _ . 3
Ad) oo nN *h .
NT TX : ‘
X= “HN N A . . ~~) : | | . : N IE . : ’
HNN A . : . o—g$—o0
J wo 2007/140222 PCT/US2007/069595 i : HN N > : ‘ . i 0 fs | I
N
° ,
NTO : Co
HN N = .
TQ oo
PN :
A oo - ~~ J .
A
. | NC N . oo
N ry : . ~~ N : . : / ~
LL oo 20
N : . . i : o . ry 9 - ’ : . oo . ’ I= . :
HN NZ TN : } } 0 EN : ke Co } oo . NT TX } BE = . Co }
HN NZ TN . : . . TN <8
CO oo oLa- oo
CO)
wo 2007/140222 PCT/US2007/069595
Cn “ . : Bh ; :
PN :
HN "A : } : ’ HN ’ \, / . | : ol Kk So
NT SX :
T= oo : . PN Co . | } : Ho *ok : : oo oo NTT : a BB | ;
H *
I } . o NTN } .
H . .
TT } o N } . . H : nk ’ . ’ .
HN "A
NX :
HN SN EN : ‘ . : - :
H ok = . i . ° NT oo . ’ . . wk ’ .
HN N A . . : ) © NEN } :
H kk : } }
NT TX : : . : HN N A . } Co : °” NT xk ’ ’ : © HN “A ’ ’ Co
Ly LP : -
H - . *k ) . ’ [gS . ’ ’ HN "A . ’ Co ) ° Hk } ‘ } ) in SN A aS So
NN i SNE TN :
CITA oo
LL N :
J
} . FY .
HN no TN ‘ : x | :
Ee oo oo
TX - : : 0 a
HN "A 3 . } ’ . 0” IAN | ‘ :
A | oo ) : * . : } }
HN nF TN } : . .
NT TX ~~
N
. . } ws : C a oo
HN NZ TN : } :
BY ~ | oo . P | -
N . ’ : .
Oo . . A . } oo 26 -
: - TableAKey ~~ ~~ *<1000M oo - | 100M So
° TABLEB | oo
Jak-3 Lance / IC50 [nmol I-1] : :
NT TX | .
As A oo - ’ | NH } | .
TX } oO N . . . : NN
FN : | . | . } o LD
A A J oo : : ‘ HN "4 : .
N_ os | . oo oo o : . HN " | : .
HN n> TN : Co : oO I
PS
© HN NT : . . oo i .
HN NT N : . oo
A ~ e | | oo
N - pp 3 ° | | oo
Oo oo oo 30
© HN "A Co : :
Oo NH . - .
To .
A | SE : HN NT N B
N :
I Co So . - x | : ge
J oo | oo
Ce oo 32 .
wo 2007/140222 | PCT/US2007/069595
No | | oo 5s
EE @ TEE
B oo 3 wo 2007/140222 | PCT/US2007/069595
CJ we BS © a )
CO | oo
Ne }
RE | oo
HN "L oo : oo . 0” A *% : } . oo - . _ . = ’ . } | Co ’ TD . nN = 77 : | C ’ Bessy : LL
CO EE
8 ) oo
N SN . : gq : oo oo 37 i
. oo J ) . | . ne oo | oo
SO IE
> oo
Ae So 0 x
0 oo | 39 B we “N ° | :
QO oo - . Ne } )
TS . : . . . al So
CTS
Co PB } TS B ) eo | | . - o
N N\
TT }
Co oo . Table B Key : * <100 nmol! oo 100 nmol” < **
= | ~ TABLEC ~~ Co
CDKAICS0, uM CDK2 IC50, uM : LO : ex : * : . HN NT N 1. . | . ’ . Ce N ol
AA | | | oo oo Ll wo 2007/140222 | | PCT/US2007/069595~ oo oo ya
S oo Oo | oo
ENE
- | - 43 TT
‘Wo 2007/140222 PCT/US2007/069595 oO | | | - 5s 0 oo
CO Sa
Cu
NTT :
I =e : HN N A : CL
HN Na o
INS . . : pg o Lo E . HN N N . Co .
B
. H . ’ : .
HN N
/) ’ . HN N N } oo
AO B
_ | Co
C -
H *
- ~ HN NT x : : oC . - | HN NF N :
HN NZ N
Co ~- :
HN NT N :
LL oo
H Lo .
Table C Key . * <10uM : : 10pM < H+ «
oo TABLED oo | | )
CATA 90 0 09
EE bdo gr 90 oO Qo
HO QC 90
Ty RA so X Cos
In certain embodiments, the compound of the present invention is further = oo characterized as a modulator of a protein kinase, including, but not limited to, protein kinases selected from the group consisting of abl, ATK, ber-abl, Blk, Brk, Btk, c-fms, e- kit, c- met, : cssrc, CDK, cRafl, CSFIR, CSK, EGFR, ErbB2, ErbB3, ErbB4, ERK, Fak, fes, FGFRI, 25 FGFR2, FGFR3, FGFR4, FGFRS, Fgr, FLK-4, flt-1, Fps, Frk, Fyn, GSK, Gst-FIk, Hek, Her- 2, Her-4, IGF- IR, INS-R, Jak, JNK, KDR, Lck, Lyn, MEK, p38, PANHER, PDGFR, PLK, :
PKC, PYK2, Raf, Rho, ros, SRC, t’ell t’e2, TRK, TYK2, UL97, VEGFR, Yes, and Zap70. = . In a preferred embodiment, the protein kinase is selected from the group consisting of ; CDK, CDK2, CDK4, CDKS5, CDK6, CDK7, CDK8 and CDK9. In another preferred embodiment, the protein kinase is selected from the group consisting of Jak1, Jak2 and Jak3.
In a particularly preferred embodiment, the protein kinase is selected from the group . | oo consisting of Jak3 and CDK4. | | }
In other embodiments, the compounds of the present invention are used for the treatment of protein kinase-associated disorders. As used herein, the term “protein kinase- associated disorder” includes disorders and states (e.g. , a disease state) that are associated with the activity of a protein kinase, e.g., CDK4 and Jak3. Non-limiting examples of a : protein kinase-associated disorder include blood vessel proliferative disorders, fibrotic - disorders, mesangial cell proliferative disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, organ transplant rejection, autoimmune diseases, and 200 | cancer. In another embodiment, the compound of the present invention is further ) . characterized as a modulator of a combination of protein kinases, e.g., J ak3 and CDKA4.
In certain embodiments, a compound of the present invention is used for protein kinase-associated diseases, and use of the compound of the present invention as an inhibitor BE of any one or more protein kinases. It is envisioned that a use can be a treatment of inhibiting one or more isoforms of protein kinases. :
The compounds of the invention are inhibitors of cyclin-dependent kinase enzymes (CDKs). Without being bound by theory, inhibition of the CDK4/cyclin D1 complex blocks phosphorylation of the Rb/inactive E2F complex, thereby preventing release of activated E2F and ultimately blocking E2F-dependent DNA transcription. This has the effect of inducing BN
Gj cell cycle arrest. In particular, the CDK4 pathway has been shown to have tumor-specific deregulation and cytotoxic effects.
Furthermore, the compounds of this invention have the potential to block the expansion of auto- or alloreactive T cells, and thus have beneficial effects on autoimmune diseases, as well as transplant rejections.
The present invention includes treatment of one or more symptoms of cancer, transplant rejections, and autoimmune diseases, as well as protein kinase-associated ~~ = disorders, as described above, but the invention is not intended to be limited to the manner by which the compound performs its intended function of treatment of a disease. The present invention includes treatment of diseases described herein in any manner that allows treatment to occur, e.g., cancer, transplant rejections, and autoimmune diseases. ER ~ In certain embodiments, the invention provides a pharmaceutical composition of any : of the compounds of the present invention.” In a related embodiment, the invention provides a pharmaceutical composition of any of the compounds of the present invention and a pharmaceutically acceptable carrier or excipient of any of these compounds. In certain : ‘embodiments, the invention includes the compounds as novel chemical entities.
In one embodiment, the invention includes a packaged protein kinase-associated disorder treatment. The packaged treatment includes a compound of the invention packaged with instructions for using an effective amount of the compound of the invention for an intended use. - : | oo : The compounds of the present invention are suitable as active agents in | Co pharmaceutical compositions that are efficacious particularly for treating protein kinase- : associated disorders, e.g, cancer, transplant rejections, and autoimmune diseases. The =~ pharmaceutical composition in various embodiments has a pharmaceutically effective amount of the present active agent along with other pharmaceutically acceptable excipients, carriers, fillers, diluents and the like. The phrase, “pharmaceutically effective amount” as used herein indicates an amount necessary to administer to a host, or to a cell, issue, or organ of a host, to ~~ achieve a therapeutic result, especially the regulating, modulating, or inhibiting protein kinase activity, e.g., inhibition of the activity of a protein kinase, or treatment of cancer, transplant "rejections, or autoimmune diseases. | oo
In other embodiments, the present invention provides a method for inhibiting the activity of a protein kinase. The method includes contacting a cell with any of the compounds of the present invention. In a related embodiment, the method further provides - that the compound is present in an amount effective to selectively inhibit the activity of a protein kinase. :
In other embodiments, the present invention provides a use of any of the compounds of the invention for manufacture of a medicament to treat cancer, transplant rejections, or “autoimmune diseases in a subject. oo :
In other embodiments, the invention provides a method of manufacture of a medicament, including formulating any of the compounds of the present invention for treatment of a subject. | | - I
Definitions | | oo ~~ The term “treat,” “treated,” “treating” or “treatment” includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease . being treated. In certain embodiments, the treatment comprises the induction ofaprotein ~~ kinase-associated disorder, followed by the activation of the compound of the invention, which would in turn diminish or alleviate at least one symptom associated or caused by the . protein kinase-associated disorder being treated. For example, treatment can be . diminishment of one or several symptoms of a disorder or complete eradication of a disorder. ~The term “subject” is intended to include organisms, e.g., prokaryotes and eukaryotes, which are capable of suffering from or afflicted with a disease, disorder or condition associated with the activity of a protein kinase. Examples of subjects include mammals, e.g, : humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non- human animals. In certain embodiments, the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from cancer, transplant rejections, and autoimmune diseases, and for other diseases or conditions described herein. oo
In another embodiment, the subject is a cell. -
The language “protein kinase-modulating compound,” “modulator of protein kinase” or “protein kinase inhibitor” refers to compounds that modulate, e.g., inhibit, or otherwise alter, the activity of a protein kinase. Examples of protein kinase-modulating compounds include compounds of Formula I, as well as Table A, Table B, Table C, Table D, Table E, and other examples as described herein (including pharmaceutically acceptable salts thereof, : as well as enantiomers, stereoisomers, rotamers, tautomers, diastereomers, atropisomers or racemates thereof). :
Additionally, a method of the invention includes administering to a subj ectan effective amount of a protein kinase-modulating compound of the invention, e.g., protein kinase-modulating compounds of F ormula I, as well as Table A, Table B, Table C, Table D,
Table E, and other examples as described herein (including pharmaceutically acceptable salts thereof, as well as enantiomers, stereoisomers, rotamers, tautomers, diastereomers, atropisomers or racemates thereof).
The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl ~~ groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc), : branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, efc.), cycloalkyl (alicyclic) : groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term “alkyl” also includes. oo alkenyl groups and alkynyl — Furthermore, the expression “Cy-Cy-alkyl”, wherein x is : 1-5 and y is 2-10 indicates a particular alkyl group (straight- or branched-chain) of a - : particular range of carbons. For example, the expression C;-C,-alkyl includes, but is not limited to, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl and isobutyl. Moreover, the term
Cs.-cycloalkyl includes, but is not limited to, cyclopropyl, cyclopentyl, and cyclohexyl, As. discussed below, these alkyl groups, as well as cycloalkyl groups, may be further substituted. :
The term “halo” as used herein means halogen, and includes fluorine, chlorine, - bromine, or iodine, especially fluorine and chlorine. | )
The term alkyl further includes alkyl groups which can further include oxygen, ) nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In an embodiment, a straight chain or branched chain alkyl has 10 or fewer carbon atoms in its backbone (e.g., C;-C) for straight chain, C; -Cyo for branched chain), and more preferably 6 or fewer carbons. Likewise, preferred cycloalkyls have from 4-7 carbon atoms in their ring structure, and more preferably have 5S or 6 carbons in the ring structure.
Moreover, alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, etc) include both “unsubstituted alkyl” and “substituted alkyl”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon oo backbone, which allow the molecule to perform its intended function. | Co Co
The term “substituted” is intended to describe moieties having substituents replacing a hydrogen on one or more atoms, e.g. C, O or N, of a molecule. Such substituents can include, for example, oxo, alkyl, alkoxy, alkenyl, alkynyl, halogen, hydroxyl, : alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, | oo dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl! and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoy], sulfonamido, nitro, trifluoromethyl, — azido, heterocyclyl, = alkylaryl, morpholino, phenol, benzyl, phenyl, piperizine, cyclopentane, cyclohexane,
pyridine, SH-tetrazole, triazole, piperidine, or an aromatic or heteroaromatic moiety, and any combination thereof. oo -
Further examples of substituents of the invention, which are not intended to be limiting, include moieties selected from straight or branched alkyl (preferably C,-Cs), a cycloalkyl (preferably C3-Cy), alkoxy (preferably C;-Cs), thioalkyl (preferably C;-Cg), alkenyl (preferably C,-Cs), alkynyl (preferably C,-Cy), heterocyclic, carbocyclic, aryl | : . (e.g., phenyl), aryloxy (e.g., phenoxy), aralkyl (e.g., benzyl), aryloxyalkyl : (e.g., phenyloxyalkyl), arylacetamidoyl, alkylaryl, heteroaralkyl, alkylcarbonyl and oo arylcarbonyl or other such acyl group, heteroarylcarbonyl, or heteroaryl group, oo (CR’R”)3NR’R” (e.g., -NH,), (CR’R”)p.3CN (e.g., CN), -NO,, halogen (e.g., -F, -Cl, -Br, or 1), (CR’R")osC(halogen); (e.g., -CFs), (CR'R”)osCH(halogen)y, (CR’R”)o.:CHa(halogen), (CR’R”)3CONR’R”, (CR’R™)o.3(CNH)NR’R”, (CR’R”)038(0)12NR’R”, (CR’R”),.;CHO, (CR’R”)430(CR’R™)g3H, (CR’R™)038(0)3R’ (e.g., -SO3H, -OSO;H), oo (CR’R”)030(CR’R”)03H (e.g., -CH,OCHj3 and -OCHj), (CR’R”)03S(CR’R”)o3H (e.g., -SH - and SCH»), (CR’R”)030H (e.g., -OH), (CR’R”)0.sCOR’, (CR’R”)o.3(substituted or ) BN unsubstituted phenyl), (CR’R”)g2(Cs-Cs cycloalkyl), (CR’R”)o3COR’ (e.g., -CO,H), or (CR’R”)o30R’ group, or the side chain of any naturally occurring amino acid; wherein R’ and R” are each independently hydrogen, a C,-Cs alkyl, C>-Cs alkenyl, C,-Cs alkynyl, or aryl group. - Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, | arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, - : alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, Co carbamoyl and ureido), amidino, imino, oxime, sulfhydryl, alkylthio, arylthio, oo thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety, and any combination thereof.
In certain embodiments, a carbonyl moiety (C=0) may be further derivatized with an oxime moiety, e.g., an aldehyde moiety may be derivatized as its oxime (-C=N-OH) analog. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “aralkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (i.e., benzyl). -
The term “alkenyl” includes unsaturated aliphatic groups analogous in length and oo possible substitution to the alkyls described above, but which contain at least one double bond. | — : For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched- chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups that include —— nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C,-Cs for straight chain, C3-Cg¢ for branched chain). Likewise, cycloalkenyl groups may have from 3-8 ) carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring - structure. The term C,-Cg includes alkenyl ‘groups containing 2 to 6 carbon atoms.
Moreover, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can. : include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, | Co arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including - alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino oo (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, - : sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, - sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. | oo - ~
The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. ~ For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, efc.), branched- ~~ chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-Cq for straight chain, C3-Cg for branched chain). “The term C,-Cg includes alkynyl groups containing 2 to 6 carbon atoms.
Moreover, the term alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can ~ include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, - alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. oo | - - The term “amine” or “amino” should be understood as being broadly applied to both amolecule, or a moiety or functional group, as generally understood in the art, and may be primary, secondary, or tertiary. The term “amine” or “amino” includes compounds where a oo nitrogen atom is covalently bonded to at least one carbon, hydrogen or heteroatom. The : terms include, for example, but are not limited to, “alkylamino,” “arylamino,” “diarylamino,” ~ “alkylarylamino,” “alkylaminoaryl,” “arylaminoalkyl,” “alkaminoalkyl,” “amide,” “amido,” and “aminocarbonyl.” The term “alkyl amino” comprises groups and compounds wherein | the nitrogen is bound to at least one additional alkyl group. The term “dialkyl amino” So includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. ~The term “arylamino” and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term “alkylarylamino,” “alkylaminoaryl” or | : “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term “alkaminoalkyl” refers to an alkyl, alkenyl, or alkynyl group - bound to a nitrogen atom which is also bound to an alkyl group. : ~~ The term “amide,” “amido” or “aminocarbonyl” includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl and arylcarbonylamino groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or Co thiocarbonyl group. The terms “alkylaminocarbonyl,” “alkenylaminocarbonyl,” : “alkynylaminocarbonyl,” “arylaminocarbonyl,” “alkylcarbonylamino,”
CC ’ Ce 54 .
) “alkenylcarbonylamino,” “alkynylcarbonylamino,” and “arylcarbonylamino® are included in term “amide.” Amides also include urea groups (aminocarbonylamino) and carbamates oo (oxycarbonylamino). | CL
The term “aryl” includes groups, including 5- and 6-membered single-ring aromatic | : groups that may include from zero to four heteroatoms, for example, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term “aryl” : includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, - quinoline, isoquinoline, anthryl, phenanthryl, napthridine, indole, benzofuran, purine; benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring = - structure may also be referred to as “aryl heterocycles”, “heterocycles,” “heteroaryls” or “heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with : such substituents as described above, as for example, alkyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, : : alkylcarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, oo : aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino oo (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), Co amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, ~~ sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, N + alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin). EE oo ~The term heteroaryl, as used herein, represents a stable monocyclic or bicyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S. Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, = quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinoline. As with the definition of heterocycle below, “heteroaryl” is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl: In cases where the heteroaryl substituent is bicyclic and one ring is non-aromatic oo 55 or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the oo heteroatom containing ring, respectively. oo - )
The term “heterocycle” or “heterocyclyl” as used herein is intended to mean a 5- to ~~ 10-membered aromatic or nonaromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S, and includes bicyclic groups. “Heterocyclyl” therefore includes the above mentioned heteroaryls, as well as dihydro and tetrathydro analogs thereof. Further examples of “heterocyclyl” include, but are not limited . to the following: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, . benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl,
Co pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, B tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, BN oo pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, ~ dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazoly], dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, | dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, : tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof. Attachment of a heterocyclyl substituent can occur via a carbon atom or via a heteroatom. Co
The term “acyl” includes compounds and moieties which contain the acyl radical oo (CH;CO-) or a carbonyl group. The term “substituted acyl” includes acyl groups where one . or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, | : halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, oo aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, : aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, Lo thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. : | oo -
The term “acylamino” includes moieties wherein an acyl moiety is bonded to an ‘amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, Co carbamoyl and ureido groups. oo oo
Co ~ The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl : groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, So ethoxy, isopropyloxy, POPU, butoxy, and pentoxy groups and may include cyclic groups oo such as cyclopentoxy. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arslcabonylony, alkoxycarbonyloxy, aryloxycarbonyloxy, oo carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, Co alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, Co phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, : thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, oo trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc. R
The term “carbonyl” or “carboxy” includes compounds and moieties which contain a : carbon connected with a double bond to an oxygen atom, and tautomeric forms thereof. + Examples of moieties that contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, efc. The term “carboxy moiety” or “carbonyl moiety” refers to groups such as “alkylcarbonyl” groups wherein an alkyl group is covalently bound to a carbonyl group, “alkenylcarbonyl” groups wherein an alkenyl group is covalently bound to a carbonyl group, “alkynylcarbonyl” groups wherein an alkynyl group is covalently bound toa carbonyl group, “arylcarbonyl” groups wherein an aryl group is covalently attached to the carbonyl group. Furthermore, the term also refers to groups wherein one or more heteroatoms are covalently bonded to the carbonyl moiety. For example, the term includes Co moieties such as, for example, aminocarbonyl moieties, (wherein a nitrogen atom is bound to the carbon of the carbonyl group, e.g., an amide), aminocarbonyloxy moieties, wherein an - oxygen and a nitrogen atom are both bond to the carbon of the carbonyl group (e.g., also referred to as a “carbamate”). Furthermore, aminocarbonylamino groups (e.g., ureas) are also -
Co include as well as other combinations of carbonyl groups bound to heteroatoms (e.g., nitrogen, oxygen, sulfur, etc. as well as carbon atoms). Furthermore, the heteroatom can be further substituted with one or more alkyl, alkenyl, alkynyl, aryl, aralkyl, acyl, etc. moieties. ~The term “thiocarbonyl” or “thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom. The term “thiocarbonyl oo moiety” includes moieties that are analogous to carbonyl moieties. For example, - “thiocarbonyl” moieties include aminothiocarbonyl, wherein an amino group is bound to the = carbon atom of the thiocarbonyl group, furthermore other thiocarbonyl moieties include, . oxythiocarbonyls (oxygen bound to the carbon atom), aminothiocarbonylamino groups, elc.
The term “ether” includes compounds or moieties that contain an oxygen bonded to two different carbon atoms or heteroatoms. F or example, the term includes “alkoxyalkyl” . which refirs to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom that is covalently bonded to another alkyl group. - : oo ~The term “ester” includes compounds and moieties that contain a carbonora - heteroatom bound to an oxygen atom that is bonded to the carbon of a carbonyl group. The } term “ester” includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl ~ groups are as defined above. :
The term “thioether” includes compounds and moieties which contain a sulfur atom | bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term “alkthioalkyls” include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom that is bonded to an alkyl group. Similarly, the term “alkthioalkenyls” and alkthioalkynyls” refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom whichis covalently bonded to an alkynyl group. : : The term “hydroxy” or “hydroxyl” includes groups with an OH or —O". - ~The term “halogen” includes fluorine, bromine, chlorine, iodine, etc. The term “perhalogenated” generally refers to a moiety wherein all hydrogens are replaced by halogen atoms. | oo -
The terms “polycyclyl” or “polycyclic radical” include moieties with two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which - two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”.
Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for
) example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, - aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, : alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, Co phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, oo carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, : azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety. "The term “heteroatom” includes atoms of any element other than carbon or hydrogen.
Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus. Co
Additionally, the phrase “any combination thereof” implies that any number of the listed functional groups and molecules may be combined to create a larger molecular } : architecture. For example, the terms “phenyl,” “carbonyl” (or “=0”), “-O-,” “~OH,” and C,.¢ (ie.,-CH; and —CH,CH,CH,-) can be combined to form a 3-methoxy-4-propoxybenzoic acid : substituent. It is to be understood that when combining functional groups and molecules to create a larger molecular architecture, hydrogens can be removed or added, as required to satisfy the valence of each atom. : oo oo
It is to be understood that all of the compounds of the invention described above will . further include bonds between adjacent atoms and/or hydrogens as required to satisfy the ~~ valence of each atom. That is, bonds and/or hydrogen atoms are added to provide the Co Co following number of total bonds to each of the following types of atoing carbon: four bonds; © nitrogen: three bonds; oxygen: two bonds; and sulfur: two-six bonds. oo oo :
It will be noted that the structures of some of the compounds of this invention include asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates) are included within the scope of this invention. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Compounds described herein may be obtained ~ through art recognized synthesis strategies.
It will also be noted that the substituents of some of the compounds of this invention include isomeric cyclic structures. It is to be understood accordingly that constitutional isomers of particular substituents are included within the scope of this invention, unless :
indicated otherwise. For example, the term “tetrazole” includes tetrazole, 2 H-tetrazole, 3H- tetrazole, 4H-tetrazole and 5H-tetrazole. a ; oo
Use in cancer, transplant rejections, and autoimmune diseases
The compounds of the present invention have valuable pharmacological properties ~~ and are useful in the treatment of diseases. In certain embodiments, compounds of the | oo invention are useful in the treatment of a proliferative disease, or cancer. : I » A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). - The inventive compounds are particularly useful for treating a tumor which is a breast cancer, . genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, oo or in a broader sense renal, brain or gastric cancer; in particular (ia breast tumor; an oo ~~ epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for - example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor oo (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease thatis oo refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to h treatment with other chemotherapeutics due to multidrug resistance. B
In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, ~~ but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following . angioplasty. | .
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also ) metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis. : | : ~The inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the : compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis. Co I co In other certain embodiments, compounds of the invention are useful in the treatment of transplant rejections. Examples of transplant rejections that may be treated by the Co compounds of the invention include, but are not limited to, graft versus host disease, rej ection . } related to xeno transplantation, rejection related to organ transplant, rej ection related to acute oo | 60
Bh transplant, heterograft or homograft rejection and ischemic or reperfusion injury incurred during organ transplantation. : :
In still other certain embodiments, compounds of the invention are useful in the - treatment of autoimmune diseases. Examples of autoimmune diseases to be treated by the compounds of the invention include, but are not limited to, autoimmune hemolytic anemia, : autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, B autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis, multiple sclerosis, neuritis, uveitis ophthalmia, polyendocrinopathies, purpura, Reiter’s Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, oo autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, autoimmune = : inflammatory eye, autoimmune thyroiditis, hypothyroidism, systemic lupus erhythematosus,’
Goodpasture’s syndrome, Pemphigus, Receptor autoimmunities, autoinunune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison’s : : disease, infertility, glomerulonephritis, bullous pemphigoid, Sjogren’s syndrome, diabetes millitus, adrenergic drug resistance, chronic active hepatitis, primary biliary cirrhosis, | : vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, oo inflammatory myopathies, chronic active hepatitis, primary biliary cirrhosis and T-cell mediated hypersensitivity diseases. : ~The term “use” includes any one or more of the following embodiments of the invention, respectively: the use in the treatment of protein kinase-associated disorders; the use for the manufacture of pharmaceutical compositions for use in the treatment of these - diseases, e. g., in the manufacture of a medicament; methods of use of compounds of the- invention in the treatment of these diseases; pharmaceutical preparations having compounds of the invention for the treatment of these diseases; and compounds of the invention for use in the treatment of these diseases; as appropriate and expedient, if not stated otherwise. In particular, diseases to be treated and are thus preferred for use of a compound of the present = invention are selected from cancer, transplant rejections, or autoimmune diseases, as well as those diseases that depend on the activity of protein kinases. The term “use” further includes ~ embodiments of compositions herein which bind to a protein kinase sufficiently to serve as tracers or labels, so that when coupled to a fluor or tag, or made radioactive, can be used as a research reagent or as a diagnostic or an imaging agent.
Assays . | Co oo The inhibition of protein kinase activity by the compounds of the invention may be measured using a number of assays available in the art. Examples of such assays are described in the Exemplification section below. .
Pharmaceutical Compositions : ~The language “effective amount” of the compound is that amount necessary or : : sufficient to treat or prevent a protein kinase-associated disorder, e. g. prevent the various . morphological and somatic symptoms of a protein inase-associnied disorder, and/or a disease or condition described herein. In an example, an effective amount of the compound of the invention is the amount sufficient to treat a protein kinase-associated disorder in a subject. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular compound of the invention. For example, the choice of the compound of the invention can affect what constitutes an “effective amount.” Oneof ordinary skill in the art would be able to study the factors contained herein and make the determination regarding the effective amount of the compounds of the invention without
Co undue experimentation. : ) . ~The regimen of administration can affect what constitutes an effective amount. The compound of the invention can be administered to the subject either prior to or after the onset | of a protein kinase-associated disorder. Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused, or can be a bolus injection. Further, the dosages of the compound(s) of the invention can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or Lo prophylactic situation. | : | oo
Compounds of the invention may be used in the treatment of states, disorders or diseases as described herein, or for the manufacture of pharmaceutical compositions for use : in the treatment of these diseases. Methods of use of compounds of the present invention in the treatment of these diseases, or pharmaceutical preparations having compounds of the : : present invention for the treatment of these diseases. Co | The language “pharmaceutical composition” includes preparations suitable for
Bh administration to mammals, e.g., humans. When the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a Co pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 05t0 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. a 62
) The phrase “pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, : diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the | : subject agent from one organ, or portion of the body, to another organ, or portion of the body.
Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and’ : sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as. sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; oo malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; Co glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic : saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. oo oo - Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and © magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. oo : Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, a-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. oo : Formulations of the present invention include those suitable for oral, nasal, topical, ~~. buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well p known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient,
preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent. | | Co | a
Methods of preparing these formulations or compositions include the step of bringing ~ into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. So
Formulations of the invention suitable for oral administration may be in the form of : capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous Or non-aqueous © liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as ~~ mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may alsobe administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, : dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, | mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; Co absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for exaniple, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. Inthe case of capsules, tablets and pills, the pharmaceutical compositions may also comprise : ‘buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant
(for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), ~~ surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. =
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scoredor ~~ prepared with coatings and shells, such as enteric coatings and other coatings well knownin the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration Lo through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed oo : manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. oo oo oo Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain . : inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ~~ ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures : thereof. | Co : p + Besides inert diluents, the oral compositions can also include adjuvants such as Co wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. | B
Suspensions, in addition to the active compounds, may contain suspending agents as, ~ for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, : ‘microcrystalline cellulose, aluminum metahydroxide, bentoniis, agar-agar and tragacanth, and mixtures thereof. SE
Cw
~ Formulations of the pharmaceutical compositions of the invention for rectal or vaginal ~~ administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or : carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
So Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing - such carriers as are known in the art to be appropriate. ~~.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches. and inhalants. The active compound may be mixed under sterile conditions witha ~~ pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required. oo oo
The ointments, pastes, creams and gels may contain, in addition to an active BN compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. ‘Powders and sprays can contain, in addition to a compound of this invention, | oo excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain : customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Co - Transdermal patches have the added advantage of providing controlled delivery ofa compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also ) be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound - in a polymer matrix or gel. oo -
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. : Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions,
suspensions or emulsions, or sterile powders which may be reconstituted into sterile : injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended Co recipient or suspending or thickening — oo | Co
Examples of suitable aqueous and nonaqueous carriers that may be employed in the . pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by - the maintenance of the required particle size in the case of dispersions, and by the use of oo E surfactants. | | )
These compositions may also contain adjuvants such as preservatives, wetting agents, ) emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In } addition, prolonged absorption of the injectable pharmaceutical form may be brought about oo by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin, :
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be oo : accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in tum, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For “example, they are administered in tablets or capsule form; by injection, inhalation, eye lotion, oo : Co 67 :
ointment, suppository, etc., administration by injection, infusion or inhalation; topical by oo lotion or ointment; and rectal by suppositories. Oral and/or IV administration is preferred.
The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, : intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and Co . intrasternal injection and infusion. : ; oo The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. ~ These compounds may be administered to. humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually. : : ) Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical | compositions of the present invention, are formulated into pharmaceutically acceptable Co . dosage forms by conventional methods known to those of skill in the art. :
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. : | The selected dosage level will depend upon a variety of factors including the activity . of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the ~~ particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, - weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. | Co
A physician or veterinarian having ordinary skill in the art can readily determine and oo prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the - pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous : and subcutaneous doses of the compounds of this invention for a patient, when used for the : indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still morte preferably from about 1.0 to about 100 mg per kg per day. An effective amount is . that amount treats a protein kinase-associated disorder.
If desired, the effective daily dose of the active compound may be administered as = two, three, four, five, six or more sub-doses administered separately at appropriate intervals . throughout the day, optionally, in unit dosage forms. :
While it is possible for a compound of the present invention to be administered alone, - : it is preferable to administer the compound as a pharmaceutical composition. - .
Synthetic Procedure oo : :
Compounds of the present invention are prepared from commonly available compounds using procedures known to those skilled in the art, including any one or more of the following conditions without limitation:
Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a “protecting group,” unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as e. g, Science of
Synthesis: Houben-Weyl Methods of Molecular Transformation. Georg Thieme Verlag,
Stuttgart, Germany. 2005.-41627 pp. (URL: http://www.science-of-synthesis.com (Electronic oo
Version, 48 Volumes)); J. F. W. McOmie, "Protective Groups in Organic Chemistry",
Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "Protective i
Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in "The Peptides";
Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York : 1981, in "Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben
Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and
Co 69
H. Jeschkeit, "Aminosduren, Peptide, Proteine" (Amino acids, Peptides, Proteins), Verlag
Chemie, Weinheim, Deerfield Beach, and Basel 1 982, and in Jochen Lehmann, "Chemie der
Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of Carbohydrates: Monosaccha- rides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting i groups is that they can be removed readily (i.e., without the occurrence of undesired secon- dary reactions) for example by solvolysis, reduction, photolysis or alternatively under physio- logical conditions (e.g., by enzymatic cleavage). : . Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known per se. For example, salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g., the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding : calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or BN only a small excess of the salt-forming agent preferably being used. Acid addition salts of oo compounds of the present invention are obtained in customary manner, e.g., by treating the oo compounds with an acid or a suitable anion exchange reagent. Internal salts of compounds of the present invention containing acid and basic salt-forming groups, e.g.,a free carboxy oo group and a free amino group, may be formed, e.g., by the neutralisation of salts, suchas acid ~~ addition salts, to the isoelectric point, e.g., with weak bases, or by treatment with jon’ exchangers. | | Co : Salts can be converted in customary manner into the free compounds; metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent. :
Mixtures of isomers obtainable according to the invention can be separated in a : manner known per se into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by, e.g., medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials. - Intermediates and final products can be worked up and/or purified according to standard methods, e.g., using chromatographic methods, distribution methods, (re-) © crystallization, and the like. | | :
General process conditions }
The following applies in general to all processes mentioned throughout this disclosure. | | oo
The process steps to synthesize the compounds of the invention can be catried out under reaction conditions that are known per se, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, ) such as cation exchangers, e. 2, inthe H" form, depending on the nature of the reaction and/or ; of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about -100 °C to about 190°C, including, for example, from approximately - 80°C to approximately 150°C, for example at from -80 to -60°C, at room temperature, at from -20 to 40°C or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or Co nitrogen atmosphere. oo : : : At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described in Science of Synthesis: Houben-Weyl Methods of
Molecular Transformation. Georg Thieme Verlag, Stuttgart, Germany. 2005. :
The solvents from which those solvents that are suitable for any particular reaction maybe selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid ~~ aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- ~~ or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, ~ bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2- one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic . anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, or mixtures of those solvents, for example aqueous solutions, unless otherwise wo 2007/140222 PCT/US2007/069595 indicated in the description of the processes. Such solvent mixtures may also be used in Co working up, for example by chromatography or partitioning,
The compounds, including their salts, may also be obtained in the form of hydrates, or ~ their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present. :
The invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the
Lo reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ. | } ~~ Prodrugs Lo oo ~ This invention also encompasses pharmaceutical compositions containing, and oo methods of treating protein kinase-associated disorders through administering, : pharmaceutically acceptable prodrugs of compounds of the compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, ora polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid } group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters - of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups - including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type mn :
oo are described in J. Med. Chem. 1996, 39, 10. Frée amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities. - | :
Any reference to a compound of the present invention is therefore to be understood as referring also to the corresponding pro-drugs of the compound of the present invention, as - appropriate and expedient.
Combinations oo
A compound of the present invention may also be used in combination with other agents, e.g., an additional protein kinase inhibitor that is or is not a compound of the oo Co invention, for treatment of a protein kinase-associated disorder in a subject. )
By the term “combination” is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the present invention and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners showa : cooperative, e.g., synergistic, effect, or any combination thereof. - ‘The compounds of the invention may be administered, simultaneously or sequentially, : with an antiinflammatory, antiproliferative, chemotherapeutic agent, immunosuppressant, anti-cancer, cytotoxic agent or kinase inhibitor other than a compound of the Formula I or salt thereof. Further examples of agents that may be administered in combination withthe =~ compounds of the invention include, but are not limited to, a PTK inhibitor, cyclosporin A, -
CTLAA4-Ig, antibodies selected from anti-ICAM-3, anti-IL-2 receptor, anti-CD45RB, anti-
CD2, anti-CD3, anti-CD4, anti-CD80, anti-CD86, and monoclonal antibody OKT3, agents blocking the interaction between CD40 and gp39; fusion proteins constructed from CD40 and gp39, inhibitors of NF-kappa B function, non-steroidal antiinflammatory drugs, steroids, gold compounds, antiproliferative agents, FK506, mycophenolate mofetil, cytotoxic drugs, TNF-a inhibitors, anti-TNF antibodies or soluble TNF receptor, rapamycin, leflunimide, cyclooxygenase-2 inhibitors, paclitaxel, cisplatin, carboplatin, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, mitomycin C, ecteinascidin 743, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, ~ podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosidine, epothilone, vindesine, leurosine, or derivatives thereof. oo The compound of the invention and any additional agent may be formulated in “separate dosage forms. Alternatively, to decrease the number of dosage forms administered oo 73 wo 2007/140222 PCT/US2007/069595 to a patient, the compound of the invention and any additional agent may be formulated together in any combination. For example, the compound of the invention inhibitor may be formulated in one dosage form and the additional agent may be formulated togetherin ~~ : another dosage form. Any separate dosage forms may be administered at the same time or different times. ~~ | } : oo :
Alternatively, a composition of this invention comprises an additional agent as | | oo described herein. Each component may be present in individual compositions, combination : ) compositions, or in a single composition. | oo oo ) ‘ Exemplification of the Invention SE | -
The invention is further illustrated by the following examples, which should not be ) construed as further limiting. The practice of the present invention will employ, unless } otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology and immunology, which are within the skill of the art. - GENERAL SYNTHESIS METHODS Le oo All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either oo commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, | Volume 21). Further, the compounds of the present invention can be produced by organic = synthesis methods known to one of ordinary skill in the art-as shown in the following examples. | SE | Co
LIST OF ABBREVIATONS
BINAP (#)-(1,1 *-binaphthalene-2-2*diyl)bis(diphenylphosphine) | oo
DIEA Diethylamine | I
DIPEA Diisoproylethylamine oo ) - oo ~ DMF ‘Dimethylformamide oo oo
HPLC High pressure liquid chromatography oo
HRMS High resolution mass spectrometry Co -
HBTU oo O-Benzotriazol-1-yl-N,N,;N',N"tetramethyluronium hexafluorophosphate
HOBt 1-Hydroxy-1H-benzotriazol ~~
LC/MS Liquid chromatography / mass spectrometry | oo . Co ~~ NMM N-methylmorpholine | | oo
NMP oo | N-methylpyrrolidine oo | . 74
RT room temperature ~~ - N EE ~ THF Tetrahydrofuran . - : a
Et Ethyl SE co -
NBS N-Bromosuccinimide
DIAD Diisopropyl azo dicarboxylate Fo ) | Ts Tosyl | | )
TBAF Tetra-n-butylammonium fluoride =~ Co
Example 1 Co | : | } (5-Bromo-2-chloro-pyrimidin-4-y1)-(1-cthyl-propyl)-amine 0° - - . oo | Co . : x oo oo - To a solution of 5-Bromo-2,4-dichloropyrimidine(4.56 o 20 mmol) in Ethanol OmL) is added I-Ethylpropylamine (2.6 mL, 22 mmol) and DIEA (7 mL, 40 mmol) at ambient oo temperature. The reaction mixture is stirred at ambient temperature for 16 hrs, then is concentrated in vacuo and the residue is purified by flash chromatography (silica gel, ethyl Co : acetate: hexane=3:97 to 30:70) to give (5-Bromo-2-chloro-pyrimidin-4-yl)-(1-ethyl-propyl)- amine. MS (ESDm/z 280 (M+H)". 'H NMR (CDCl, 400 MHz) & 8.1(s, 1H), 5.24(d, 1H), IE © 4.1(m, 1H), 1.58(m, 4H), 0.93(t, 6H). N
Example 2 Co | oo ~~ Tributyl-((Z)-2-ethoxy-vinyl)-stannane
Sem u—sn 0” oo oo
Bu oo :
To a solution of Ethyl ethynyl ether (2.26 mL, 50% in hexane, 15 mmol) in toluene a (40mL)is added Tri-n-butyl hydride (2.7 mL, 10 mmol) and AIBN (81 mg, 0.5 mmol) at Co ambient temperature. The reaction mixture is heated at 100 °C for 16 hrs. After cooling oo down, the mixture is concentrated in vacuo to give tributyl-((Z)-2-ethoxy-vinyl)-stannane. ~~ The crude product is used as is. | | | | :
Co | 75 | oo
Example 3 : [2-Chloro-5-((Z)-2-ethoxy-vinyl)-pyrimidin-4-y1]-( 1 -ethyl-propyl)-amine
NXT No | . . cc” ON XK EE
To a solution of crude compound from example 2 (4.25g, ~75%, 8.8 mmol) in CH- ~~ 3CN (10 mL) is added (5-Bromo-2-chloro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine 225¢,8 mmol), E4NCI (1.33g, 8 mmol) and Pd(PPhs),Cl, (280 mg, 0.4 mmol) at ambient temperature. The reaction mixture is purged with Na, sealed in a microwave reactor and oo heated at 100 °C for 17 mins. After cooling down the mixture is concentrated in vacuo and ~~ the residue is purified by flash chromatography (silica gel, ethyl acetate : hexane=5:95t0 : 10. 40:60) to give [2-Chloro-5-((Z)-2-ethoxy-vinyl)-pyrimidin-4-yl]-(1-ethyl-propyl)-amine. MS (ESDm/z 270 (M+H)". 'H NMR (CDCl, 400 MHz). 6 8.02(s, 1H), 6.26(d, 1H), 5.46(d, 1H), ~ 4.91(d, 1H), 4.16(m, 1H), 3.99(q, 2H), 1.60-1.69(m, 2H), 1.43-1.52(m, 2H), 1.32(t, 3H), oo 0.92(t, 6H). oo 15 Example 7 2-Chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine cl NT A ) ;
To a solution of [2-Chloro-5-((Z)-2-ethoxy-vinyl)-pyrimidin-4-yl]-(1 -ethylpropyl)- ~ amine(1.1g, 4.07 mmol) in EtOH 8 mL) is added concentrated HCI (0.1 mL) at ambient ) 20 temperature. The reaction mixture is sealed in a microwave reactor and heated at 100 °C for : mins. After cooling down the mixture is concentrated in vacuo to provide 2-Chloro-7-(1 - ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine. The crude product is used as itis. The material can be purified by flash chromatography (SiO2, EtOAc : Hexane = 1: 5). B :
MS (ESDm/z 224 (M+H)". "HNMR (CDCls, 400 MHz). & 8.87(s, 1H), 7.30(d, 1H), 6.69(d, 1H), 4.69(m, 1H), 1.77-1.99(m, 4H), 0.77(t, 6H) | - ~
Example 8 Co
5,5-Dibromo-2-chloro-7-(1-ethyl-propyl)-5,7-diliydro-pyrrolo[2,3-d]pyrimidin-6-one
Br : Co
Br ca” ON A | Co _ © To a mixture of 2-Chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine (crude, ~ 4.07 mmol) in t-BuOH (7 mL) is added 2 mL of H,0 at ambient temperature, then NBS (2.28 g, 12.8 mmol) is added to the orange color solution. The mixture is stirred at 28 - 30 °C for 2.5 hrs, then is concentrated and taken up in ethyl acetate, washed with NaHCO; aqueous solution, and brine. The organics are dried with Na,SO4, filtered and concentrated to provide 5,5-Dibromo-2-chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3-djpyrimidin-6-one. The - crude product is used as itis.
MS (ESDm/z 398 (M+H)". IE
Example 9 oo 2-Chloro-7+(1 -ethyl-propyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one ci N A :
To a solution of 5,5-Dibromo-2-chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3- : d]pyrimidin-6-one (crude, ~ 5.3 mmol) in acetic acid (6 mL) and THF (4 mL) is added Zn dust (1.37 g, 21 mmol) at 0 °C. The mixture is stirred at 0 °C for 2 mins then heated to room temperature, stirring for 30 mins. The mixture is filtered through celite, rinsed with ethyl acetate. The filtrate is concentrated in vacuo and the residue is purified by flash chromatography (ethyl acetate : hexane=5:95 to 40:60) to give 2-Chloro-7-(1-ethyl-propyl)- 5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one. | oo
MS (ESDm/z 240 (M+H)". 'H NMR (CDCls, 400 MHz). & 8.17(s, 1H), 4.20(m, 1H), 3.58(s, 2H), 2.10(m, 2H), 1.84(m, 2H), 0.84(t, 6H). (I Co
Examples 10-13 ) oo oo - By repeating the procedures described in example 6-9, using appropriate starting materials, the following compounds are obtained. oo 77 -
wo 2007/140222 PCT/US2007/069595
Co Structure | - MS(miz) (M+1) - cl N A 210 : a” SNF 252
NTR
C= ° 238 : oo cl N
NTR :
M ZK ° : 288 cl N N oo | :
Example 14. : | oo oo (3-Amino-phenyl)-(4-methyl-piperazin-1-yl)-methanone
NH, : oN | oo ~. A solution of 3-aminobenzoic acid(1.51 g, 11 mmol), 1-methylpiperazine(1.1 mL, 10 mmol), EDCI'HCI(2.87 g, 15 mmol) and Et;N (2.8 mL, 20 mmol) in CH,Cl5(10 mL) is stirred at room temperature for 20 hours. Then saturated NaHCOs aqueous solution is added.
The aqueous layer was extracted with CH,Cl,, and the organic extracts were dried over
Na;SOq,, filtered and concentrated under reduced pressure. The crude product is purified by : column chromatography (SiO,, MeOH: CH,Cl, =0.7:99.3 to 6:93) to give 1.75 g of the title compound as a yellow solid. - : MS (ESDm/z 220 (M+H)" oo | | 78
Examples 15-20 | -
By repeating the procedures described in example 14, using appropriate starting: - materials, the following compounds are obtained. : Structure MS(m/z) (M+1) :
NH, oo 237
J rT
NH, 0 . : o Co 7 ~~ a 250 oo } - NH, oo IR . of TR oo : NH, © Co oo
F ad } . . 238 : NH, oo 0 207 : :
I 3 ia oo
N :
TC C220 ©
Example 21 :
N-(4-Methoxy-3-nitro-phenyl)-isonicotinamide oo ~ 0” . Zz N . :
To ° ~ | Co
A mixture of 4-methoxy-3-nitroaniline(168 mg, 1 mmol) and Isonicotinoyl chloride oo hydrogen chloride(267 mg, 0.2 M in 1.5 mmol) in pyridine(1 mL) is sealed in a microwave reactor and heated at 100 °C under microwave radiation for 5 mins. Then IN NaOH aqueous solution is added to the reaction mixture. After stirring at room temperature for several - minutes, the mixture is filtered. The solid is washed with H,0 and air dried to give 263 mg : of the title compound asa yellow solid. B oo | oo
MS (ESDm/z 274 (M+H)®
Example 22 | a.
N-(4-Floro-3 -nitro-phenyl)-isonicotinamide Co : 0 ZN : : ar o :
The same procedure is repeated as described in example 21 to give the title compound © asa pink solid.
MS (ESDm/z 262 (M+H)". Co
Example 23 : : ~ N-(3 -Amino-4-floro-phenyl)-isonicotinamide - a
A mixture of 4-floro-3-nitroaniline (100 mg, 0.38 mmol) and Tin chloride(180 mg,0.95 mmol) in EtOH(1 mL) with 4 drops of concentrated HCl is heated at 80 °C for 4 - hour. Then saturated NaHCO; aqueous solution is added. The aqueous layer was extracted with EtOAc, and the organic extracts are washed with brine, dried over Na;SOy, filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (Si02, MeOH:CH,C1,=1:99 to 10:90) to give 55.5 mg of the title compound as yellow solid. © MS (ESDm/z 232 (M+H)* oo
Example 24
N-(3-Amino-4-methoxy-phenyl)-isonicotinamide :
A - | | ;
The same procedure can be repeated as described in example 23 to give the title. oo compound as a pink solid.
MS (ESD)m/z 244 (M+H)". 5s .
Example 25 | | | : 1-(4-Nitro-phenyl)-piperidin-4-one o oo | : | : 0
To a solution of 1-(4-Nitro-phenyl)-piperidin-4-ol (100 mg, 0.45 mmol) in CH,CL(2 oo mL) is added Dess-Martin periodinane(286 mg, 0.675 mmol) at for 2.5 hours. The reaction is quenched with IN NaOH SuRous solution. The aqueous layer is extracted with CH,Cl,, and the organic extracts are dried over Na,SOy, filtered and concentrated under reduced pressure.
The crude product is purified by column chromatography (Si02, EtOAc: Hexane=12:88 to 100:0) to give 84 mg of the title compound as a white solid. . oo
MS (ESDm/z 221 (M+H)" ~ Example 26 - 1-Methyl-4-[1-(4-nitro-phenyl)-piperidin-4-yl]piperazine oo | :
SOOO Co
A mixture of 1-(4-Nitro-phenyl)-piperidin-d-one(84 mg, 0.38 mmol) and 1- methylpiperazine(0.085 mL, 0.76 mmol) in MeOH(2 mL) is stirred at room temperature for 5 hours. Then to the reaction mixture is added 0.2 mL of HOAc, followed by NaCNBHj (72 mg, 1.14 mmol). The mixture is stirred at room temperature for 0.5 hour, then concentrated.
The residue is taken up in EtOAc, washed with saturated NaHCO; aqueous solution and : brine, dried over Na,SOs, filtered and concentrated under reduced pressure. The crude : product is purified by column chromatography (SiO2, 2N NH; in MeOH:CH,Cl1,=1:99 to 10:90) to give 46 mg of the title compound as a yellow solid. : © MS (ESDm/z 305 (M+H)® =
Example 27 SE os
4-[4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl]-phenylamine -
OOO
HN N N N— \_/
A suspension of 1-Methyl-4-[1-(4-nitro-phenyl)-piperidin-4-yl]-piperazine (46 mg, 0.15 mmol) and Pd/C(10%, 8 mg) in MeOH (2 mL) is stirred at room temperature under H- 2(balloon pressure) for 16 hours, then filtered through celite, washed with EtOAc, concentrated under reduced pressure to give 42 mg of the title compound as a light grey solid.
MS (ESDm/z 275 (M+H)"
Example 28 :
Benzoic acid 1-(4-amino-phenyl)-piperidin-4-yl ester o
The same procedure is repeated as described in example 23 to give the title compound ~~ as a pink solid. - IE = MS (ESDm/z 297(M+H)*.
Example 29 : : : : 3-(2-Pyrrolidin-1-yl-ethoxy)-phenylamine
NH, ° :
To a mixture of PPh; (866 mg, 3.3 mmol) in THF(6 mL) is added DIAD (0.65 mL, : 3.3 mmol) at 0 °C. The suspension was stirred for 10 minutes, then heated to room temperature. To the mixture, 4-nitrophenol(460 mg, 3.3 mmol) and 1-(2-hydroxyethyl)- pyrrolidine(0.26 mL,2.2 mmol) is added, and the mixture is stirred at room temperature for 16 hours, then concentrated. The residue is taken up in EtOAc, washed with 1N NaOH aqueous solution and brine, dried over Na,SO04, filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (SiO2,
MeOH:CH,Cl,=1:99 to 10:90) to give 277mg of 1-[2-(4-Nitro-phenoxy)-ethyl]-pyrrolidine as a white solid. Co
MS (ESDm/z 237 (M+H)"* | SE 5. The same procedure is repeated as described in example 27 by using 1-[2-(4-Nitro- . phenoxy)-ethyl]-pyrrolidine as a starting material to give the title compound as a yellow oil. :
MS (ESDm/z 207(M+H)".
Example 30-33
By repeating the procedures described in example 29, using appropriate starting } / Co materials, the following compounds are obtained. : oo
Structure MS(miz) (M+1) oo Co
NH, : :
QL. oT
AD .
NH, | oo oO. i ’
NH, Se
OL oN »6 . : .
NGL : - oo NAN
Example 34 : : (3-Nitro-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine 0s .,.0”
N
OLD | .
The mixture of 1-fluoro-3-nitrobenzene(420 mg, 3 mmol) in DMF(1.5 mL), N-(2- aminoethyl)-pyrrolidine(514 mg,4.5 mmol) and Cs2C05(977 mg, 3 mmol) is heated at 100°C under microwave radiation for 2.5 hours, then concentrated. The mixture is diluted with =~
EtOAc, washed with saturated NaHCO; aqueous solution and brine, dried over Na, SOx, - filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (Si02, MeOH:CH,C1,=1:99 to 10:90) to give 130 mg of the title compound - as a light brown oil. :
MS (ESDm/z 236 (M+H)*
Example35 - oo © [2-(4-Methyl-piperazin-1-yl)-ethyl]-(3-nitro-phenyl)-amine
Osp® | :
OL
: The same procedure is repeated as described in example 34 to give the title compound as a yellow oil. oo | oo
MS (ESDm/z 265(M+H)". ~~ Example 36 Co
N-(2-Pyrrolidin-1 -yl-ethyl)-benzene-1 ,3-diamine Co oo oo
NH, :
The same procedure is repeated as described in example 27 to give the title compound as a light brown oil. : | ~
MS (ESDm/z 206(M-+H)". | :
Example37 | | | oo
N-[2-(4-Methyl-piperazin-1-yl)-ethyl]-benzene-1,3-diamine | ~
NH,
LOY | So
Co os
The same procedure is repeated as described in example 27 to give the title compound as a light brown oil.
MS (ESDm/z 235(M+H)".
Example 38 1 “Methyl-4-(6-nitro-pyridin-3 -yl)-piperazine 0” ’ . .
CL
Z N .
A mixture of 5-bromo-2-nitropyridine(500 mg, 2.46mmol) and 1-methylpiperazine(1 mL) is heated at 80 °C for 2 hour. Then water is added. The aqueous layer is extracted with" 1 0 EtOAc, and the organic extracts were washed with brine, dried over Na,SO,, filtered and ~ concentrated under reduced pressure. The crude product is purified by column chromatography (Si02, MeOH:CH,C1,=0.7:99.3 to 6:93) to give 520 mg of the title - compound as yellow solid. | oo
MS (ESDm/z 223 (M+H)" Co
Example 39 1-[4-(6-Nitro-pyridin-3-yl)-piperazin- 1-yl]-ethanone 0 oo oN TL : _ ro | | oo
To a mixture of 5-bromo-2-nitropyridine(406 mg, 2 mmol) and 1- acetylpiperazine(256 mg, 2 mmol) in toluene(5 mL) is added Cs, COs, then Pd2(dba)3(74 mg, 0.08 mmol) and BINAP(100 mg, 0.16 mmol) are added. The mixture is degassed, and heated at 100 °C for 16 hours. Then the mixture is cooled down to room temperature, diluted with
EtOAc, and filtered through celite. The filtrate is concenimad under reduced pressure. The crude product is purified by column chromatography (Si02, MeOH:CH,Cl1,=0.7:99.3 to 6:93) to give 270 mg of the title compound as yellow solid.
MS (ESDmv/z 251 (M+H)*
Example 40 Eo | oo 5-(4-Methyl-piperazin-1-yl)-pyridin-2-ylamine : oo oo
HN N . . :
The same procedure is repeated as described in example 27 to give the title compound asalight brown solid. | | oo
MS (ESDm/z 193(M+H)". Co . oo ~~ Exampledl DE 1-[4-(6-Amino-pyridin-3-yl)-piperazin-1-yl]-ethanone :
HN. _N : ™ 0 °
The same procedure is repeated as described in example 27 to give the title compound : as a brown solid. IEE : : MS (ESDm/z 221(M+H)".
Example 42 | | | Co 1-[4-(4-Nitro-phenyl)-piperidin-1-yl]-ethanone : | oe 0 0
N N i. 700K
To a solution of 4-(4-Nitro-phenyl)-piperidin (206 mg, 1 mmol) in CH,CL(3 mL)is added AcCl(0.106 mL, 1.5mmol) at 0 °C. Then Et;N(0.253 mL, 1.8 mmol) is added slowly.
The mixture is stirred at 0 °C for 10 minutes. Then saturated NaHCO; aqueous solution is added. The aqueous layer is extracted with CH,Cl,, and the organic extracts are dried over
Na, SO, filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (SiO,, MeOH:CH,C1,=0.7:99.3 to 6:93) to give 273 mg of the title compound as yellow solid. oo
MS (ESDm/z 249 (M+H)" - .
Example 43 oo 86 h 1-[4-(4-Amino-phenyl)-piperidin-1-yl]-ethanone | Co
The same procedure is repeated as described in example 27 to give the title compound ‘as a yellow solid. DE
MS (ESDm/z 219(M+H)". | Co | oo
Example 44 7-(1-Ethyl-propyl)-2-[3-fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino] - -5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one. - Co
HN” ON A Lo
F’ g : . - oo
NT | E | BE Co
To a mixture of 2-Chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6- one (18 mg, 0.075 mmol) and TsOH (1.12 ml, 0.2 M in 1,4 dioxane) is added 3-Fluoro-4-(4- : methylpiperazinn)aniline (23.5 mg, 0.1125 mmol), and DMF (0.25 mL) at ambient ~ temperature. The reaction mixture is sealed in a microwave reactor and heated at 140 °C for : 30 mins. The mixture is diluted with EtOAc, washed with NaHCOj3; aqueous solution and : brine, dried (Na;SO4), filtered and concentrated. The crude product is purified by prep-
HPLC to give 27 mg of the title compound as a brown solid.
MS (ESDm/z 413 (M+H)". | oo 'H NMR (DMSO, 400 MHz). 8 9.48(s, 1H), 8.09(s, 1H), 7.72(d, 1H), 7.34(d, 1H), 6.96(t, 1H), 4.08(m, 1H), 3.60(s, 2H), 2.96(s, 4H), 2.51(s, 2H), 2.10(m, 2H), 1.78(m, 2H), 0.79(t, 6H). =
Examples 45-90 | Ce
By repeating the procedures described in example 44, using appropriate starting materials, the following compounds are obtained.
NTI ) a N N - Co Co
Ar : A :
Ar MS Found | oo - (M+H) - N N— . } .
CT — 0 423 :
HA a
J) oo . N .
Na 473 oo
N N—
N/M 453 . N N— . . - oN 441 | - . a N— . : .
F . -
Nn 440
Lo N 0 : .
Tei -
AN MM 410 So -
N 0 ’ ss
NN 428
N 0 : ’ a , | Co > -
N 0 -
N N— —=N /\ 396 % Q ) NA : : oo 1 354 | N ~~ 447 So —o” :
J 435
H
N As . eo)! .
AJ 417
H in
N ax . .
N—S
HO) NR 0 .
S—N N— : : i . 0 .
N N=—§—— — Co 0 n= 382 [oe]
ZN a
I Wan ¥
IB LN 337 | -
N . .
Tn s0
N OH } : N N N— . — | 410
IE | ~ 410 ’ Ona . 407 } Co oo ents oo 426 em, Sr - 439 ; Co
Oenir 412 . er ’ . 409 | } tn | oo oo
N T "438 oo EE
Oa Co : o 354 | a. { ) L,
I eo 368 =H oo = o B 408 e 368 : 0 396 EE 2 436 - :
FC pL oo
H . . 466 oo 0 ” : :
OTT
H .
SN
: MN NS 424 :
H) 4 | :
Examples 91-93
By repeating the procedures described in example 44, using appropriate starting materials, the following compounds are obtained. : | : or
Hy NT ON Co . Ar . Ol .
Ar ~[_ MS Found
So | (M+H) Co
OC /\ p 455 | : 458 _
On Co EE
CT | | 407
Examples 94-97 oo By repeating the procedures described in example 44, using appropriate starting materials, the following compounds are obtained. } . : N N
Co } oo : Ar A
Ar : MS Found oo
O40
N 0 \_/
N © 0 . .
N . N— .
0 /\ | 393 | | SE
N N— : :
Example 98-99 oT : )
By repeating the procedures described in example 44, using appropriate starting materials, the following compounds are obtained. Co oo NT - :
Ar A oo in Ar MS Found A oo Co ~~ (M+H) | . oo — | 380
N 0 :
N N-— .
Examples 100-101 :
By repeating the procedures ‘described in example 44, using appropriate starting materials, the following compounds are obtained.
NTR
: HNN N -
Ar MS Found (M+H)
CO —\ 407
N N—
wo 2007/140222 PCT/US2007/069595 aN /\ 435
N N — Co . ’ g Lo) aE oo
Example 102 . | oo | | So 1-(1-{4-[7-(1-Ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl} -piperidin-4-yl)- ethanone _.
A Lo
To a mixture of 1-[4-(4-Amino-phenyl)-piperazin-1-yl]-ethanone (70.5 mg, 0.32 mmol) and NaOtBu(38.4 mg, 0.4 mmol) in 1,4-dioxane(0.3 mL) is added a solution of 2-
Chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine(60 mg, 0.26 mmol) in 1,4- dioxane(0.6 mL) and a suspention of Pdx(dba)3(12.2 mg, 0.013 mmol) and BINAP (16.6 mg, 0.026 mmol). The mixture is degassed, and heated at 100 °C for 3 hours. Then the mixture is. cooled down to room temperature, diluted with EtOAc, and filtered through celite. The filtrate is concentrated under reduced pressure. The crude product is purified prep-HPLC to give 84.9 mg of the title compound as pale white solid. oo
MS (ESDm/z 407 M+H)* oo
Example 103-117 . + By repeating the procedures described in example 102, using appropriate starting: materials, the following compounds are obtained. : oo | - [A -
Ar MS Found (M+H) :
N N— \_/
ANN 417 $s oo 9 . 406 :
Jo
N . : . /\ 397
N N—
F ~
N= JN 380 i} $ W J \_/ “NN pf 408 o | 394
HY e 394 en
] or | oo : ° /=N oo
Example 118 | | Co . (2-Chloro-5-nitro-pyrimidin-4-y1)-(1-ethyl-propyl)-amine : oo
SE 0 _ Co | | oo oo NX N'. o : | oo | : cl N~ KX ‘To a solution of 2,4-dichloro-5-nitro-pyrimidine 2g, 10.31 mmol) in anhydrous EtOH - ~ (20ml) is added 1-ethylpropylamine (1.322ml, 11.341mmol) at 0C (ice bath) under inert atmosphere. To this is added neat DIPEA (2.694ml, 15.465mmol). The reaction is stirred at r.t. for 8hrs. The reaction mixture was concentrated in vacuo and the residue is dissoloved with EtOAc. The organic layer is washed with sat. NaHCO; and brine, dried over Na;SOy4, and concentrated in vacuo. Purification with column chromatography (SiO2, 1:3
EtOAC/Hexane) gives the desired product. | ) :
MS (ESDm/z 245.1 | | | .
Example 119 : (2-Chloto-5 -amino-pyrimidin-4-yl)-(1-ethyl-propyl)-amine : -
XH a N XK oo
- To a solution of (2-Chloro-5-nitro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine (1g, Co 4.087mmol) in anhydrous EtOH (50ml) is added Tin(II) chloride (2.324g, 12.2607mmol) and : concentrated HCI (1ml) at ambient temperature. The reaction is heated to 80 °C for 1h and quenched with 1N NaOH at 0 °C. The mixture is extracted with EtOAc, washed with brine, ~~ dried over Na2S04, and concentrated in vacuo to give the crude product. The crude is used
MS(ESDm/z 215.2 oo BE -
Example 120 : - 2-Chloro-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one
NT
. Joes } .
Cl N ~~ } : } . Co
To a microwave vial is added the crude (2-Chloro-5-amino-pyrimidin-4-yl)-(1-ethyl- propyl)-amine (0.5g, 2.329mmol) and anhydrous DMF(15ml) followed by 1,1°- carbonyldiimidazole (1.133g, 6.987mmol). Sealed vial and microwave heated at 100 °C for 10 min. The reaction mixture is diluted with EtOAc, washed with water, dried over Na2SO4, : and concentrated in vacuo. Purification with column chromatography (SiO2, 1:1
EtOAC/Hexane) gives the desired product.
MS(ESI) m/z 241.1 Co Co oo oo
Example 121 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one
NT : : :
Joos Co : a EE
By repeating the procedures described in example 44, using 2-Chloro-9-(1-ethyl- propyl)-7,9-dihydro-purin-8-one as a starting material, the desired product is obtained.
MS (ESD)4242 | | oo
Example 122 oo oT 2-Chloro-9-(1-ethyl-propyl)-7-methyl-7,9-dihydro-purin-8-one : A = | . . cl N~ A
To a solution of 2-Chloro-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one (100mg, 0.41 mmol) in anhydrous DMF (2ml) is added methyl iodide (21 ul, 0.41 mmol) followed by NaH (50%, 22mg, 0.4571mmol). The reaction is stirred under nitrogen for 1.5h. The reaction 2 mixture is quenched with ice water and extracted with EtOAc. The extracts are dried over : * Na,SO, and concentrated in vacuo to give the crude 2-Chloro-9-(1-ethyl-propyl)-7-methyl- 7,9-dihydro-purin-8-one. The crude product is used as is. oo Co © MS (ESDm/z255.1 a | IE ! oo
Example123 | » EE oo 2-[4-(4-Acetyl-piperazin-1 -yl)-phenylamino] -9-(1-ethyl-propyl)-7-methyl-7,9-dihydro-purin- - ~~ 8-one | SE oo | | - 98
HN NT A oo oo 0 CL
EN | oo a
By repeating the procedures described in example 44, using 2-Chloro-9-(1-ethyl- - propyl)-7-methyl-7,9-dihydro-purin-8-one as a starting material, the desired product is obtained. oo
MS(ESDm/z 438.2 Co | oo
Example 124 oo ) 0
Allyl-(1-ethyl-propyl)-amine oo oo
To a solution of 3-pentanone (1g, 11.61mmol) in anhydrous 1,2-dichloroethane (45ml) is added allylamine(0.872ml, 11.61 mmol) followed by NaBH(OAc)3 (3.44g, ~ 16.254mmol) at ambient temperature and under nitrogen. The reaction is stirred at room temperature overnight. The reaction mixture is quenched with IN NaOH and extracted with dichloromethane. The extract is dried over Na;SO4 and concentrated in vaccuo to allyl-(1- ethyl-propyl)-amine oo | oo : oo
Example 125
Allyl-(5-bromo-2-chloro-pyrimidin-4-yl)-(1-ehtyl-propyl)-amine : : : og
Or } Co Co aN x Co i To a solution of allyl-(1-ethyl-propyl)-amine (10 mmol) is added anhydrous isopropanol (50ml) and 5-bromo-2,4-dichloropyrimidine (2.979g, 5Smmol) followed by oo - diisopropylethylamine (2.61ml, 15mmol) at ambient temperature. The reaction is stirred : overnight and concentrated in vacuo. The residue is purified with column chromatography - (S8i02, 1:5 EtOAC/Hexane) to give the desired product. ~~ :
MS (ESDm/z 320.0 oo Example 126 10° 2-Chloro-7-(1-ethyl-propyl)-5-methyl-7 H-pyrrolo[2,3-d]pyrimidine : ol ZF x ) oo
To a solution of allyl-(5-bromo-2-chloro-pyrimidin-4-yl)-(1-ehtyl-propyl)-amine (2.76g, 8.7 mmol) in anhydrous DMF (15ml) was added 8 mol % of Pd(OAc)2 (156mg, 0.69 mmol) and 8 mol% of PPh3 (182mg, 0.69 mmol) and triethylamine (2.4 ml, 17.3 mmol) a
The reaction is stirred at 100 °C overnight. The reaction mixture is diluted with EtOAc, washed with water, dried over Na2S04, and concentrated in vacuo. Purification with column chromatography (SiO2, 1:2 EtOAC/Hexane) gives the desired product. : E
MS (ESI) m/z 238.2 a Co
Example 127 oo BN 1-(4-{4-[7-(1 -Ethyl-propyl)-5-methyl-7H-pyrrolo [2,3-d] pyrimidin-2-ylamino]-phenyl }- : piperazin-1-yl)-ethanone oo | oo
Pe | EE
NE A | -
N : :
A
By repeating the procedures described in example 102, using 2-Chloro-7-(1-ethyl- . - propyl)-5-methyl-7H-pyrrolo[2,3-d] pyrimidine as a starting material, the desired product is : obtained.
MS (ESDm/z 421.2
Example 128 a (2-Chloro-5-prop-1-ynyl-pyrimidin-4-yl)-(1-ethyl-propyl)-amine oo =z
NTR v
A Z cr” ON XK -
To a microwave vial is added a solution of (5-Bromo-2-chloro-pyrimidin-4-yl)-(1- . ethyl-propyl)-amine (0.5g, 1.80 mmol) in anhydrous toluene (10ml), tributyl(1-propynyl)-tin (1.1 ml, 3.6 mmol) and 2 mol% of Pd(PPh3)4 (41.5 mg, 0.036 mmol). The reaction is heated at 120 °C for 1hr by employing microwave. The reaction mixture is diluted with EtOAc, washed with sat. NaHCOj3; aqueous solution and water, dried over Na,SOy, and concentrated in vacuo. Purification with column chromatography (SiO2, 1:5 EtOAC/Hexane) gives 0.32 g of the desired product.
MS(ESDm/z 238.2 oo
Example 129 Co : 2-Chloro-7-(1-ethyl-propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine ER -
Ca A x . . : . . : Co
Ina microwave vial is added (2-Chloro-5-prop-1-ynyl-pyrimidin-4-yl)-(1-ethyl- ~ propyl)-amine (0.22 g, 0.92 mmol), anhydrous DMF (3ml), and Cul (53 mg, 0.27 mmol).
The reaction is heated at 160 °C for 1hr by employing microwave. The reaction mixture is oo diluted with EtOAc, washed with sat. NaHCO3 aqueous solution and water, dried over
Na,SO4, and concentrated in vacuo. Purification with column chromatography (SiO,, 1:4
EtOAC/Hexane) gives 43 mg of the desired product. oo -
MS (ESDm/z 238.2. EE © Example130 | . 1-(4-{4- [7-( 1-Ethyl-propyl)-6-methyl-7H-pyrrolo [2,3-d] pyrimidin-2-ylamino}-phenyl}- piperazin-1-yl)-ethanone : wo A a. : x
N | So
By repeating the procedures described in example 102, using 2-Chloro-7-(1-ethyl- propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine as a starting material, the desired product is obtained. : oo : Lo
MS (ESDm/z 421.4 : :
C102
B Example 131 [7-(1-Ethyl-propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)- amine | : ; oo 0 xX _ oo
By repeating the procedures described in example 102, using 2-Chloro-7-(1-ethyl- propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine as a starting material, the desired product is obtained. a oo )
MS (ESDm/z 379.1 SE EE
Example 132 oo oo oo [2-Chloro-5-(3,3-diethoxy-prop-1-ynyl)-pyrimidin-4-y1]-(1-ethyl-propyl)-amine Co oo + OEt - . Co
NT - a A a.
To a mixture of (5-Bromo-2-chloro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine (420 mg, 1.5 mmol) and propiolaldehyde diethyl acetal(0.32 mL, 2.25 mmol) in DMF (6 mL) is added PdCILy(PPh;)»(105 mg, 0.15 mmol) and Cul(28 mg, 0.15 mmol), followed by Et;N(0.42 mL, 3 mmol). The mixture is degassed and heated at 55 °C for 16 h. Then the mixture is cooled down to room temperature, diluted with EtOAc, washed with water and brine. The organic layer is dried N a;S0y), filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (Si02, EtOAc:Heptane=5:95 to 40:60) to give 182 mg of the title compound as a light brown oil. :
MS (ESDmv/z 326 (M+H)" oo oo : Example 133 - : 2-Chloro-6-diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine
To a solution of [2-Chloro-5-(3,3-diethoxy-prop-1-ynyl)-pyrimidin-4-yl]-(1-ethyl- propyl)-amine(326 mg, 1 mmol) in THF (2 mL) is added a solution of 1M TBAF in THF(5 “mL, 5 mmol) at ambient temperature. The reaction mixture is heated at 68 °C for 2 hours.
After cooling down, the mixture is concentrated in vacuo. The crude product is purified by © column chromatography (SiO2, EtOAc:Heptane=5:95 to 40:60) to give 307 mg of the title ~ compound asa colorless oil. )
MS (ESDm/z 326 (M+H)". oo oo
Example 134 | | oo 1-(4-{4-[6-Diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3 -d]pyrimidin-2-ylamino]- : phenyl}-piperazin-1-yl)-ethanone Co
NT OEt
N
CA
By repeating the procedures described in example 102, using -Chloro-6- diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine as a starting material, the desired product is obtained. oo
MS (ESDm/z 509 (M+H)"
Example 135 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carbaldehyde
HN v7 A | :
To a solution 1-(4-{4-[6-Diethoxymethyl-7-(1-ethyl-propyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-ylamino]-phenyl}-piperazin-1-yl)-ethanone (178 mg, 0.35 mmol) in 1,4 EE dioxane (2.8 mL) is added 0.8 mL of concentrated HCI at ambient temperature. The reaction mixture is stirred at ambient temperature for 30 mins. The mixture is neutralized with IN
NaOH aqueous solution and saturated NaHCO; aqueous solution, extracted with EtOAc. The organic layer is washed with brine, dried Na,SO4, and concentrated under reduced pressure to give 160 mg of the title compound as a yellow solid. Lo -
MS (ESDm/z 435 (M+H)". .
RE So N _—
Example 136 - . B
N~-NOMe :
HN NT A H | oo 0 Co
A So
A mixture of 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidine-6-carbaldehyde (25 mg, 0.057 mmol), methoxylamine I hydrochloride (20 mg, 0.22 mmol) and 6N HCI (0.03 mL) in EtOH(1 mL) is stirred at ambient temperature for 6h. The mixture is quenched with saturated NaHCO; aqueous solution, extracted with CH,Cl,. The organic layer is washed with brine, dried over NaSQOyq,
and concentrated under reduced pressure to give the crude product. The crude product is oo purified by prep-HPLC to give 12 mg of the title compound asa bright yellow solid. -
MS (ESDm/z 464 (M+H)". | oo
Example137 | oo 7-(1-Ethyl-propyl)-2-[3-fluoro-4-(4-methyl-piperazin-1 -yl)-phenylamino]-5,7-dihydro- . pyrrolo[2,3-d]pyrimidin-6-one
HNN BS | | oo )
N } : .
CO | oo
To a solution of S-bromo-2,4-dichloropyrimidine (4.56 g, 20 mmol) in ethanol (9 mL) is ‘10 added 1-ethylpropylamine (2.6 mL, 22 mmol) and N,N-diisopropylethylamine (7 mL, 40 mmol) at ambient temperature. The reaction mixture is stirred at ambient temperature for 16 © h and concentrated in vacuo. The residue is purified by flash chromatography (SiO,
EtOAc/hexane 3:97 to 30:70) to give (5-bromo-2-chloro-pyrimidin-4-yl)-(1-ethyl-propyl)- amine. LCMS: 280 (M+H)" 'H NMR (CDCl;, 400 MHz) 38.1 (s, 1H), 5.24 (d, 1H), 4.1 (m, 1H), 1.58 (m, 4H), 0.93 t, 6H). oo A oo To a solution of tributyl-((Z)-2-ethoxy-vinyl)-stannane (4.25 g, 8.8 mmol) in CH3;CN (10 mL) is added (5-bromo-2-chloro-pyrimidin-4-y1)-(1-ethyl-propyl)-amine 2.25 g, 8 mmol), EtNCI (1.33g, 8 mmol) and Pd(PPh3),Cl, (280 mg, 0.4 mmol) at ambient temperature. The reaction mixture is purged with Nj, sealed in a microwave reactor and heated at 100 °C for 20 min. After cooling to room temperature, the mixture is concentrated : in vacuo and the residue is purified by flash chromatography (SiO,, EtOAc/hexane 5:95 to 40:60) to give [2-Chloro-5-((Z)-2-ethoxy-vinyl)-pyrimidin-4-yl]-(1-ethyl-propyl)-amine. © LCMS: 270 (M+H)"® oo "HNMR (CDCl; 400 MHz). & 8.02 (s, 1H), 6.26 (d, 1H), 5.46 (d, 1H), 4.91 (d, 1H), 4.16 (m, 1H), 3.99 (q, 2H), 1.60-1.69 (m, 2H), 1.43-1.52 (m, 2H), 1.32 (t, 3H), 0.92 (t, 6H) : To a solution of [2-chloro-5-((Z)-2-ethoxy-vinyl)-pyrimidin-4-yl]-(1 -ethylpropyl)- amine (1.1 g, 4.07 mmol) in EtOH (8 mL) is added concentrated HCI (0.1 mL) at ambient oo temperature. The reaction mixture is sealed in a microwave reactor and heated at 100 °C for 10 min. After cooling to room temperature, the mixture is concentrated in vacuo to provide 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine. The crude product is used as it is. :
The crude product can be purified by flash chromatography (SiO,, EtOAc/Hexane 1: 5).
LCMS: 224 (M+H)' oo oo oo 'H NMR (CDCl3, 400 MHz). & 8.87 (s, 1H), 7.30 (d, 1H), 6.69 (d, 1H), 4.69 (m, 1H), 1.77- 1.99 (m, 4H), 0.77 (t, 6H) oo
To a mixture of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine (crude, ~ : 4.07 mmol) in t-BuOH (7 mL) was added 2 mL of HO at ambient temperature, then NBS (2.28 g, 12.8 mmol) was added to the orange color solution. The mixture is stirred at 30 °C for 2.5 h, then is concentrated and taken up in ethyl acetate, washed with NaHCO; aqueous solution, .and brine. The organic portion is dried with Na,SO,, filtered and concentrated to provide 5,5-dibromo-2-chloro-7-(1 _ethyl-propyl)-5,7-dihydro-pyrrolo [2,3-d] pyrimidin-6-one.
The crude product is used as iis, a :
LCMS: 398 (M+H)". oo oo IEE
To a solution of 5,5-dibromo-2-chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3- d]pyrimidin-6-one (crude, ~ 5.3 mmol) in acetic acid (6 mL) and THF (4 mL) is added Zn dust (1.37 g, 21 mmol) at 0 °C. The mixture is stirred at 0 °C for 2 min then warmed up to room temperature, stirred for 30 min. The mixture is filtered through a pad of Celite, rinsed i with ethyl acetate. The filtrate is concentrated in vacuo and the residue is purified by flash chromatography (SiO,, EtOAc/hexane 5:95 to 40:60) to give 2-chloro-7-(1-ethyl-propyl)-5,7- : dihydro-pyrrolo [2,3-d]pyrimidin-6-one. : LCMS: 240 (M+H)" oo | oe 'H NMR (CDCl, 400 MHz). 6 8.17 (s, 1H), 4.20 (m, 1H), 3.58 (s, 2H), 2.10 (m, 2H), 1.84 (m,2H),0.84 (6H.
To a mixture of 2-chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6- one (18 mg, 0.075 mmol) and TsOH (1.12 ml, 0.2 M in 1,4 dioxane) is added 3-fluoro-4-(4- methylpiperazine)aniline (23.5 mg, 0.1125 mmol), and DMF (0.25 mL) at ambient = temperature. The reaction mixture is sealed in a microwave reactor and heated at 140 °C for 30 min. The mixture is diluted with EtOAc, washed with NaHCO; aqueous solution and brine. The otganics is dried over Na,SOs, filtered and concentrated. The crude product is purified by preparative HPLC to give 27 mg of 7-(1-ethyl-propyl)-2-[3-fluoro-4-(4-methyl- piperazin-1-yl)-phenylamino]-5,7-dihydro-pyrrolo[2,3 -d]pyrimidin-6-one as a brown solid. :
LCMS: 413 M+H)". | | | oo
So 107
'H NMR (DMSO, 400 MHz). 5 9.48 (s, 1H), 8.09 (s, 1H), 7.73 (d, 1H), 7.36 (d, 1H), 6.96 (t, 1H), 4.08 (m, 1H), 3.60 (s, 2H), 3.32 (m, 4H), 2.96 (m, 4H), 2.25 (s, 3H), 2.11 (m, 2H), 1.78 (m, 2H), 0.79 (t, 6H). oo
Examples 138-199 : | | oo oo
By repeating the procedures described in example 137, using appropriate starting materials, the following compounds are obtained. : nL “(M+1) 138 - Co 395 . . } CT . oo . : 139 | | | 382 | -
NT TX
© 140 : 380 - . . ’ CONT YY 41 = 23 iE oo J . } .
Ne
142 - TT {= } . xX } . . } . 9 Cl 143 ~ 354. 144 : 353 ’ | JO ’ 145 — 23 ’ ’ NT . :
EN . } . ) ol 146 To 430 oo \_/ 147 : WS 433 : } : J . aa 148 NN 441 r ’ F Ao .
NL
: J
149 Co 365
NX . } .
AX ’ 150 SN 393 151 So — 278 oo . CNTY . 152 410 - . NT .
HN N XN So 153 352
PN
Co 1. HN N 1 Co
So 154 380
CT
: . Cm N 1 ‘ : o NT } .
155 207 -
TS
: HN NZ N . : 156 . oo 435 . . . NT o - . [ 0) | - ~ 157 TT 393
PN oo HN "A : . . IR . _ oo 158 ~ 380
NT TX . 159 — EE . . [i : ’ HN N N
AN
I | N oo oo Cm
160 | 423 :
NT ] : oo _ 161 AN 447 = oo
NN - } . 162 : 435 : . NTS . =N . 163 466 . C= : . x . : . oles . 164 . 364 .
NTT
0 . . HN "A
Oy 165 } ry 378 : QL . ’ | } oo | | m2
NY } . 0 167 | "478 = . . aa he " | | oo — 382 — .
HN N A ne ) ~~ 417 wn N ° : } . 0 _N . . 170 396 . NX
HN “A :
HO
171 AN Co 337 . . - HN’ N AN . . 3 ) 172 oo 410 . } : NT ’ } HN IP } . . 73 459 - . xX . . .
A
0=§=0 . . 4 174 410
NT . . ’ . 175 1 459 ’ NT XxX . .
Co CD- o—t—o o } oo : 16 en 426
T- . } .
177 417 Co
NX .
HN "J } :
J | 3 178 PN — Bw 7 C- 407 . . A N ° ’ . . ’ TN, | | | | : . 39 . . NT ~ \ : : : - CD . | 412 . Co | i . rx . . : .
A. 182 : : IN . 407
TA,
183 458
NT TX
J
HN N N } . = oo 184 PN 409 . : HN ON A : . 185 ~ 438 _/ : 417 )
NYY .
HN. . ° . ’ \, / . 187 : : PS . 382 apd 188 A | 408 | :
Pe Z N ° : . : . HN N A : . ’ : . .
H
189 CN 368 oo
HN IPS Co . : 190 ~ EES A . oN “AN :
H
191 To | 354 So : HN " Co : 0 nN } -
H : . 192 ” - — | 368 . HN "L Co ! . ’ oo : 193 — 236 oo . N A . :
C | oo o NTN } . 194 NN 451 ’ } . HN "A : ob : Q ‘4 195 EN 466
HN "L co ’ :
Id ’
Q
NT XY . 197 — PUR | we
NT TX . 198 | B - 424 } NTO . : . oo J } : Bh
Nes BEE - a2
A
Example 200 oo : 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-5,5-dimethyl-5,7-dihydro- pyrrolo[2,3-d]pyrimidin-6-one Co
AJ =e
HN N A ’ Ba CL 7
CJ Co
A
To a solution of 2-chloro-7-(1-ethyl-propyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (40 mg, 0.17 mmol) in THF (1.5 mL) is added NaH (60 % dispersion in mineral oil, 20 mg, 0.42 mmol) at 0 °C. The reaction mixture is stirred for 30 min and then cooled to 0 °C. After the addition of iodomethane (0.023 mL, 0.37 mmol) at 0 °C, the mixture is stirred for 3 hr. The reaction mixture is quenched with aqueous ammonium chloride solution and extracted with ethyl acetate. The organics is washed with aquous sodium carbonate solution and brine, dried over anhydrous | sodium sulfate, evaporated in vacuo. The residue is purified by flash chromatography (SiO, EtOAc/Hexane 1:10) to.give 20 mg of 2-chloro-7-(1-ethyl-propyl)- . 5,5-dimethyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one. : 'H NMR (CDCl, 400 MHz). & 8.11 (s, 1H), 4.18 (m, 1H), 2.14 (m, 2H), 1.80 (m, 2H), 1.42 (s, 6H), 0.82 (t, 6H). a
To a solution of 2-chloro-7-(1-ethyl-propyl)-5,5-dimethyl-5,7-dihydro-pyrrolo[2,3- d]pyrimidin-6-one (20 mg, 0.075 mmol) in 1,4-dioxane (1 mL) and DMF (0.2 mL) are added 1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone (24.5 mg, 0.11 mmol) and p-toluenesulfonic acid (17 mg, 0.089 mmol). The reaction mixture is sealed in a microwave reactor and heated at 140 °C for 30 min. The mixture is diluted with EtOAc and washed with IN NaOH solution. The organics is dried over Na,SO;, filtered, and concentrated. The residue is purified by prep-HPLC to give 30 mg of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1- ethyl-propyl)-5,5-dimethyl-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one as a pale yellow solid.
LCMS: 451 (M+H)* Co 'H NMR (CDCl, 400 MHz). § 7.95 (s, 1H), 7.49 (d, 2H), 6.93 (d, 2H), 6.91 (br s, 1H), 4.15 (m, 1H), 3.78 (t, 2H), 3.63 (t, 2H), 3.13 (m, 4H), 2.19 (m, 2H), 2.14 (s, 3H), 1.77 (m, 2H), 1.38 (s, 6H), 0.83 (t, 3H). :
Example 201 _
BE C119
1-(1-{4-[7-(1-Ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperidin-4-yl)- ~ ethanone | | oo So
HN “ - - os To a mixture of 1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone (70.5 mg, 0.32 mmol) and sodium tert-butoxide (38.4 mg, 0.4 mmol) in 1,4-dioxane (0.3 mL) are added a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine (60 mg, 0.26 mmol) in : ~ l,4-dioxane (0.6 mL), Pd(dba); (12.2 mg, 0.013 mmol) and BINAP (16.6 mg, 0.026 mmol).
The mixture is degassed, and heated at 100 °C for 3 h. The mixture is cooled to room temperature, diluted with EtOAc, and filtered through a pad of Celite. The filtrate is N concentrated under reduced pressure. The crude product is purified by preparative HPLC to : give 84.9 mg of 1-(1-{4-[7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]- phenyl} -piperidin-4-yl)-ethanone as a pale white solid.
LCMS: 407.3 (M+H)" "HNMR (CDCls, 400 MHz). § 8.59 (s, 1H), 7.66 (d, 2H), 7.25 (brs, 1H), 6.97 (d, 2H), 6.96 ~~ (d, 1H), 6.44 (d, 1H), 4.50 (m, 1H), 3.81 (t, 2H), 3.65 (t, 2H), 3.14 (m, 4H), 2.17 (s, 3H), 1.90 ~ (m, 4H), 0.82 (t, 6H).
Example 202 Co [7-(1 -Ethyl-propyl)-7 H-pyrrolo[2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine
HN" SN Co 0
N :
H
: To a mixture of 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (133 mg, 0.48 mmol) and sodium tert-butoxide (57.6 mg, 0.6 mmol) in 1,4-dioxane (0.5 mL) is oo added a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine (90 mg, 04 mmol) in 1,4-dioxane (1.0 mL), Pdy(dba); (18.3 mg, 0.02 mmol) and BINAP (25 mg, 0.04 mmol). The mixture is degassed, and heated at 100 °C for 3 h. The mixture is cooled to room temperature, diluted ‘with EtOAc, and filtered through celite. The filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography (SiO, ~ EtOAc : Hexane = 1 : 1) to give 167 mg of 4-{4-[7-(1-ethyl-propyl)-7H-pyrrolo[2,3- * dpyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as a pale yellow solid.
LCMS: 465.5 (M+H)* | : oo
To a solution of 4-{4-[7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]- ) phenyl} -piperazine-1-carboxylic’ acid tert-butyl ester (167 mg, 0.36 mmol) in dichloromethane (3 mL) is added trifluoroacetic acid (1 mL). The reaction mixture is stirred for 1 h and concentrated in vacuo. The residue is diluted with dichloromethane, washed with
NaHCO; solution, dried over Na;SO,, and concentrated in vacuo. Purification by preparative
HPLC afforded 130 mg of [7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl}-(4- : piperazin-1-yl-phenyl)-amine as a yellowish solid. -
LCMS: 365.2 (M+H)" oo
Examples 203 - 262 | oo
By repeating the procedures described in example 201 and 202, using appropriate starting materials, the following compounds are obtained. Co - a : (M+1 203 455.2 . - i | ) A | . . 204 394
NTO \ - .
NE oly
I C121 )
205 . ~ SL 395 206 408
ES wn N Co ‘ py A B oo
O
A oo ’ ©0207 : ‘ - 380 . HN No “N : . .
N. : } a. J : 208 : 397 209 | | 417 } HN IS . - } oN : . } oo . 0 xy. . :
ZN So
RB
: A N. }
AN
211 364 Co ’ ’ HN " . ’ ’ oo : 212 394 - . . Cun AN } : oC . - . . oo } wn N ’ : : —~ 214 — — 6 : . HN “ } 215 So Cf 431 } NX \ : }
OD I
216 406
Co Co OD :
. co. HN “A . a 5 | | on - — 7 | oo
ANAS
A
220 = a3F . I” “A - oo 0 Na ) 1221 | oD : — : 3953 ~ C [= To mE oo
Co - 124
23 |. ” — - eT 1
CO
0 antl 225 — | 333 oo 226 | | Tra . . A, : } } 227 4224 —
ES oo 728 — | _ aia ns
229 a 224 oo . NT TY . : : sx 1 230 | | 3512 oo 231 : . - 423.2 [gi . .
CD
232 a 3912 - 233 — | PY 3803 ’ A CD yA] 234 8 380.3 ’ } . A ' . | © NH, :
N . . . .
235 379.2
Ap 236 433.3 ’ - we TN - . 237 213
CD : . . } : Ao N : : . 238 — 4194 } HN No TN 0 T 239 | | | 3774 ‘ } : . Be N } .
CJ
Bh C127 oo
240 ~ : 3913 . : : HN Na : . 241 433.4
CD
} } . wr N 242 NA oo 391.3 243 : 392.3 :
HN No TN } . . : N HN . .
I J
244 3933
Co NNN :
PN
: HN N NT 0 245 429.2 : HN NZ TN : oo | 128
246 ’ 377.2 oo
HN NE N . Co : ’ . . H . 247 - - 3793 : . © N N\ n 0 a - ’ : ~ 248 1 2073
NNT : 249 ~~ 205
Qo I 250 | 393.2 : : i SW . . : 0) J © 251 0 .364 oo py & | oo 0 . i @ !
C129
252 NX 406 1 : HN N N : - ; oo A O lO 253 } | NTR 377 : HN N ; Co } ‘ . : : Az N | oo 0 . . PN } 255 | Co 0 oo B 378 oo : . . : . AL N - XN : i
N 0 . i N . n © 256 Co i NTR E 363.23
A ~
257 8 | 319.06 oo oN ; Co : 2 ‘ \N . : \ 1 258 oo ‘ NTR 346.17 :
HN N
; o Co 259 : Ce AN : 294.17 =
N N
260 N 203.17
COHNT ON OT oo : Co 261 | TN 35023
HN N O . 1 ga oo - 262 | AS 322.20
N N . . : NN
Example 263 | : 1-(4-{4-[7-(1-Ethyl-propyl)-5-methyl-7H- yrrolo[2,3-d]pyrimidin-2-ylamino}-phenyl}- : - p p piperazin-1-yl)-ethanone -
wo 2007/140222 PCT/US2007/069595
HN N A .. : ) oo "To a solution of 3-pentanone (1g, 11.6 mmol) in anhydrous 1,2-dichloroethane (45 mL) is added allylamine (0.872 mL, 11.6 mmol) followed by NaBH(OAc); (3.44 g, 16.3 mmol) at ambient temperature. The reaction mixture is stirred at room temperature overnight. The reaction mixture is quenched with IN NaOH and extracted with dichloromethane. The extract is dried over Na;SO4 and concentrated in vacuo to give 1.27g of allyl-(1-ethyl- propyl)-amine. The crude product is used as it is. Co :
To a solution of allyl-(1-ethyl-propyl)-amine (1.27 g, 10 mmol) is added anhydrous isopropanol (50 mL) and 5-bromo-2,4-dichloropyrimidine (3.0 g, 5 mmol) and diisopropylethylamine (2.61 mL, 15 mmol) at ambient temperature. The reaction mixture is : stirred - overnight and concentrated in vacuo. The residue is purified with column ~ chromatography (SiO, EtOAC/hexane 1:5) to give 2.76 g of allyl-(5-bromo-2-chloro- . pyrimidin-d-yl)-(1-ehtyl-propyl)-amine. LCMS: 320.0 (M+H)" | oo
To a solution of allyl-(5 -bromo-2-chloro-pyrimidin-4-yl)-(1 -chtyl-propyl)-amine (2.76 g, 8.7 mmol) in anhydrous DMF (15mL) is added Pd(OAc), (156 mg, 0.69 mmol) and
PPh; (182 mg, 0.69 mmol) and triethylamine (2.4 mL, 17.3 mmol). The reaction mixture is. stirred at 100 °C overnight. The reaction mixture is diluted with EtOAc, washed with water, dried over Na,S0Oq, and concentrated in vacuo. Purification with column chromatography : (SiO,, EtOAC/hexane 1:2) gives 0.95 g of 2-chloro-7-(1-ethyl-propyl)-5-methyl-7H- pyrrolo[2,3-d]pyrimidine. | | oo : : ~ LCMS: 238.2 (M+H)" oo oo
By repeating the procedures described in example 65, using 2-chloro-7-(1-ethyl- propyl)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine as a starting material, 1-(4-{4-[7-(1-ethyl- propyl)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl} _piperazin- 1-yl)-ethanone is obtained. oo oo | | 132
LCMS: 421.2 (M+H)" | | | -
Examples 264 - 319 | oo Co
By repeating the procedures described in example 115, using appropriate starting materials, the following compounds are obtained. _
C(M+1) 264 393.3 265 - — 41926 } fo, 267 : So 377.24 : wo No ; =]
LJ
268 — | 391.26 n MN : . 269 405.28 : oo wn N 0
So 270 363.23 : wa? \ 0 - : ol 271 : 350.21 . won N : “ N } : . } : } . N } : oO ] 272 392.26 : oo " X \ . . NE N ’
I 0 273 385 :
Co EN : HN N
N -
Co 1
274 | 433.28 0 N oo
HN nN . ’ :
N : 3 lo BE Co 1 oA : } 275 : } 391.22 : . I Ny ; : : HN NS \ : } i
N } ; 0
A
276 ~ 349.21 -
SA oo
Co n A ~ i 277 : : 2932 : HN NZ : ) 278 | 376.6 oo . } BEY NZ : Co So . 0 279 : : . 349.2 : oo un” SNF TN : a } 0
280 347.20 : . : HN NF oN . 7 - . N=—N : : 281 333.2 . . HN NG }
Co | / Co
N—N : 282 332.2
HN NZ TN
A
H : 283 378.24
HN NZ N ‘
Co 5 a
C] . I 284 377.24
HN NC N a . BELEN | . 0 285 395
HN NZ N oC } oa
286 . - : } 455.17 . CL a. Oo a. . HN NZ > . : | x 0 ] o=s=o . . : 287 } : 456.1 i» Ne N . | : . oo p O | Cl
N ) | . } . } . o=s=o0 . ’ : 288 372.07 . HN Ne N } . RP o=s=0 } oo : . NH, : " | . 289 © 441.21 : :
HN NS N : . . . ) . } - | : .
PA ’ 0” °N : . 290 . Co 405.24
So HN NEN . oo . . . | . wn } ’ Co
291 AE 20626 . : } HN N's o : : 292. 406.22 oo - WEN - oo 203 — | 323.2 Co
As N . . . 294 — 323. : } 0 ‘ : 9 205 3381 oo
Co . 0" HN NT TN : : o 706 | 2952 } } . } } N N NZ N . : BN . : ~ NN . : 297 = | 3082 . . - » N NZ N . - 298 294.2 ~ RE
Co | 138 :
299 | 271 B
SE 08
A~ N . . : } : : BE : Cl . C0 : 300 : 294.2 . N N N : 7 Co 301. 318.2 } HN ~N7 N : -
I | A | - 302 37922 ‘ . : " rN : oo : } wn N } } : . | Ql O oo SE 303 344.2 : . i" No N } . : Co x 304 oo | 295.2 4 TN EE 7 . 305 : 378.2
OQ
306 315.2 0
N ors ’ pI .
307 — 28828 rs . . ar N . : . - 308 | | 28631
Al oo 309 oo ~ 308.03
IN A No } .
H . : 310 — 3642
AN N : : oA $3 | : | - 311 ! 3362
NTR
- HN N . "N— | . - 312 : : 359.2 . " AN N\ : iy wo
N Co 313 B 392.25
NT N\ - . ]
MH
314 Co } 391.26 - Co . wo : Co Co : : w J A. : 315 . 408.24 :
NZ
- HN N N oo oJ . Co 316 ! 407.26 : oo | od } HN N N - . 317 40825 rd | oo . wn ~N
NF Ol Co
TN oH oo .
A : 318 | 409.23 wa N oo al aL
Co . NG OH : 319 : . i . ‘ 406.3 . . rs oo . we N : : Co 2S
Example 320 i. :
C41
(5-Methyl-7-pyridin-2-yl-7H-pyrrolo [2,3-d]pyrimidin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)- amine | : oo
NTR : . ~ =
Qo | A solution of 5-bromo-2,4-dichloropyrimidine (5.0 g, 22: mmol), allylamine (1.98 mL, 264 © mmol), and diisopropylethylamine (5.6: mL, 33.0 mmol) are stirred in ethanol (100 mL) at 50 °C overnight. The solvent is removed in vacuo and the residue is partitioned between ethyl acetate and saturated aqueous ammonium chloride solution. The organic layer is washed with brine, dried over anhydrous sodium sulfate and evaporated to provide Allyl-(5-bromo-2- chloro-pyrimidin-4-yl)-amine as a white crystalline solid (89%), which is used without - further purification. . A mixture of Allyl-(5-bromo-2-chloro-pyrimidin-4-yl)-amine (1 g, 4 mmol), palladium(II) acetate, (90 mg, 0.40 mmol), triphenylphosphine 21 1 mg, 0.80 mmol) and triethylamine (1.1 mL, 8.0 mmol) in DMF (10 mL) is heated at 100 °C overnight. After cooling to room temperature the reaction mixture is diluted with ethyl acetate and washed with brine. The organic phase is dried (anhydrous Na,SOy) and the solvent is evaporated.
The crude product is purified by flash chromatography (gradient elution EtOAC:Heptanes 0:0 to 1:1) on silicagel to afford 2-Chloro-5-methyl-7H-pyrrolo[2,3-d] pyrimidine as a white : solid (40%).
A mixture of 2-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine (80 mg, 0.48 mmol), 2- bromopyridine (113 mg, 0.72 mmol), copper(I) iodide (9.1 mg, 0.48 mmol), K3PO,4 (2.02 g, : 23.84 mmol), and trans-1,2-diaminocyclohexane (5.44 mg, 0.48 mmol) in 1,4-dioxane (7 mL) is stirred at 90 °C for 1.5 hrs. After cooling to room temperature the reaction mixture is diluted with ethyl acetate and washed with brine. The organic phase is dried (anhydrous
Na,SOy) and the solvent is evaporated. The crude product is purified by flash chromatography (gradient elution ethyl acetate:hetanes 0:1 to 1:4) on silicagel to afford 2
Chloro-5-methyl-7-pyridin-2-yl-7H oo - ~ -pyrrolo[2,3-d]pyrimidine as a white solid (55%).
A mixture of 2-Chloro-5-methyl-7-pyridin-2-yl-7H-pyrrolo[2,3-d]pyrimidine (15 mg, 0.06 mmol), 4-(6-Amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (20.5 mg, 0.075mmol), Pd,(dba); (2.8 mg, 0.003 mmol), BINAP (3.82 mg, 0.0061 mmol), sodium tert- butoxide (8.84 mg, 0.092 mmol), and 1,4-dioxane (4 mL) under nitrogen is heated in a sealed tube apparatus at 100 °C for 2.5 h. After cooling to room temperature the reaction mixture is diluted with ethyl acetate and washed with brine. The organic phase is dried (anhydrous
Na,S04) and the solvent is evaporated. The crude product is dissolved in DCM (2 mL) and
TFA (0.5 ml was added). The solution is stirred at room temperature. The reaction mixture is diluted with ethyl acetate and washed with brine. The organic phase is dried (anhydrous
Na;SOy) and the solvent is evaporated. The crude product is purified by hplc to afford (5-
Methyl-7-pyridin-2-yl-7TH-pyrrolo[2,3-d]pyrimidin-2-yl)-(5-piperazin-1-yl-pyridin-2-yl)- Co ‘amine as a pale yellow solid (27%, two steps). HNMR (400 MHz, DMSO-d6) 8.80-8.81 (m, 2H), 8.51 (s, 1H), 8.12 (d, J= 5.0 Hz, 1H), 8.0-8.11(m, 1H), 8.0 (d, J = 2.9 Hz, 1H), 7.90 (s, 1H), 7.49 (d, J=2.4 Hz, 1H), 7.32 (d, J = 2.4 Hz, 1H), 3.04-3.06 (m, 4H), (2.86-2.89 (m, 4H), 2.32 (s, 3H). MS (ESI) m/z 387.09 [M+H]".
Examples 321 — 325 | | Co
By repeating the procedure described in example 320, using 2-Chloro-5-methyl-7H- pyrrolo[2,3-d] pyrimidine and appropriate starting materials, the following compounds are prepared. : (M+1) 321 ~ 393.16 . N AN N\ : . An? \ } : —~ 72 . ‘
N . N .
I
0 322 ~ 386.11
TD
AZ N
CO oo 1
N .
323 ~ ST 393.03 Co . : NEY oi .
OJ Cl 324. 376.04
Ys . NA wn N - EG
QL] 325 ~r 366
Co "OTN ; . : EN A : - ~ J NH . N N ~ ol Ae . N . 0
Example 326 1-[7-cyclopentyl-2-(4-piperazin-1-yl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-y1]- ethanone :
On : ps .
HN N : .
Q
SL
2-chloro-7-(cyclopentyl)-7H-pyrrolo[2,3-d]pyrimidine is prepared from cyclopentyl arhine : and 5-bromo-2,4-dichloropyrimidine using a method similar to that for the preparation of 2- chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine given in example 1.
To a solution of aluminium chloride (400 mg, 2.99 mmol) and acetyl chloride (711uL, 10 mmol) in dichloromethane (2 mL) is added 2-chloro-7-(cyclopentyl)-7H-pyrrolo{2,3-
d]pyrimidine (221 mg, 1.0 mmol) in dichloromethane (5 mL), dropwise. After 20 minutes oo saturated aqueous sodium bicarbonate is added to pH9-10 and the solution is extracted with dichloromethane. The organic phase is dried, anhydrous Na;SO;4 and concentrated to obtain : 1-(2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethanone (255mg, 97%) as an off-white amorphous solid (97%). "H-NMR and LCMS . 1 -[7-cyclopentyl-2-(4-piperazin- 1-yl-phenylamino)-7H-pyrrolo[2,3-d] pyrimidin-5 - yl]-ethanone is preapared from 1-(2-Chloro-7-cyclopentyl-7H-pyrrolo [2,3-d]pyrimidin-5-yl)- : ethanone and 4-(4-Aminophenyl)-piperazine-1 -carboxylic acid tert-butyl ester using a method similar to that for the preparation of Example 202. [M+H"] 405.2. oo | oo | DE
Example 327 oT | So (7-Cyclopentyl-5-isopropyl-7H-pyrrolo [2,3-d]pyrimidin-2-y1)-(5 -piperazin-1-yl-pyridin-2- : yl)-amine ( 2-Chloro-7-cyclopentyl-5-isopropyl-7H-pyrrolo[2,3-d]pyrimidine is prepared from 2-chloro- ~~ 7-(cyclopentyl)-7H-pyrrolo[2,3-d]pyrimidine and 2-chloropropane using a method similar to oo that for the preparation of 1-(2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)- | : ethanone given in Example 325. oo oo : (7-Cyclopentyl-5-isopropyl-7H-pyrrolo [2,3 -d]pyrimidin-2-y1)-(5-piperazin-1-yl- ~ pyridin-2-yl)-amine is prepared from 2-Chloro-7-cyclopentyl-5-isopropyl-7H-pyrrolo[2,3- dipyrimidine and 4-(6-Amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester : using a method similar to that for the preparation of Example 202. [MH+] 406.21 oo 55 : (M+1) oo us
328 | — | e126 * Example 329 | : : [7-(1 ~Ethyl-propyl)-6-methyl-7H-pyrrolo [2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)- amine oo oo oo (J | EE
LE oo
To a microwave vial is added a solution of (5-bromo-2-chloro-pyrimidin-4-yl)-(1- - ethyl-propyl)-amine (0.5 g, 1.80 mmol) in anhydrous toluene (10 mL), tributyl(1-propynyl)- tin (1.1 mL, 3.6 mmol) and Pd(PPh3)4 (41.5 mg, 0.036 mmol). The reaction mixture is heated at 120 °C for 1h by employing microwave. The reaction mixture is diluted with EtOAc, = = washed with NaHCO; aqueous solution and water, dried over Na,SOq4, and concentrated in vacuo. Purification with column chromatography (SiO, EtOAC/hexane 1:5) gave 0.32 g of (2-chloro-5 -prop-1-ynyl-pyrimidin-4-yl)-(1-ethyl-propyl)-amine
LCMS: 238.2 (M+H)* Co oo ~ To a microwave vial are added (2-chloro-5-prop-1-ynyl-pyrimidin-4-yl)-(1-ethyl- propyl)-amine (0.22 g, 0.92 mmol), anhydrous DMF (3mL), and Cul (53 meg, 027 mmol).
The reaction is heated at 160 °C for 1h by employing microwave. The reaction mixture is diluted with EtOAc, washed with NaHCO; aqueous solution and water, dried over Na,SQOq, - and concentrated in vacuo. Purification with column chromatography (SiO,, EtOAC/hexane 1:4) | gives 43 mg of 2-chloro-7-(1-ethyl-propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine.
LCMS:2382 (M+H)* | oo
By repeating the procedures described in example 202, using 2-chloro-7-(1-ethyl- . propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine as a starting material, [7-(1-ethyl-propyl)-6- methyl-7H-pyrrolo [2,3-d]pyrimidin-2-y1]-(4-piperazin-1 yl-phenyl)-amine is obtained. ue
© LCMS: 379.1 (M+H)" : | -
Examples 330 - 332 | I ; -
By repeating the procedures described in example 329, using appropriate starting materials, the following compounds are obtained.
Lo (M+) 330 421.4
FS \ .- .
Jr ’ : . | oo . _L . - } 331 —~ T4063
NT \ - . : 332 AN 377.1 : . ~ N N } oer
Example 333 oo : 1-[7-Cyclopentyl-6-methyl-2-(4-piperazin-1 -yl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-5- yl]-ethanone ) 0
MY
HN N } - 0 s
N | So oo
Bh | Cw
2-Chloro-7-cyclopentyl-6-methyl-TH-pyrrolo[2,3-d]pyrimidine is prepared from cyclopentyl amine and 5-bromo-2,4-dichloropyrimidine using a method similar to that for the preparation of 2-chloro-7-(1-ethyl-propyl)-6-methyl-7H-pyrrolo[2,3-d]pyrimidine. oo ~~ given in example 328. - 1-(2-Chloro-7-cyclopentyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethanone is prepared from 2-Chloro-7-cyclopentyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidine and acetyl - chloride using a method similar to that for the preparation of 1-(2-Chloro-7-cyclopentyl-7H- pyrrolo[2,3-d]pyrimidin-5-yl)-ethanone given in Example 325. 1-[7-Cyclopentyl-6-methyl-2-(4-piperazin-1-yl-phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]-ethanone is prepared from 1-(2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3- d]pyrimidin-5-yl)-ethanone and 4-(4-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester using a method similar to that given for the preparation of Example 202. (MH+) 419.2
Example 334 | oo oT (5-chloro-7-cyclopentyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-(4-piperazin-1-yl- phenyl)-amine jpas oo
SEN
NN
:
O oo oo
To a solution of 2-Chloro-7-cyclopentyl-6-methyl-7H-pyrrolo [2,3-d]pyrimidine (164 mg, 0.70 mmol) in dichloromethane (3 mL) is added N-chlorosuccinimide (0.4M in DCM, 1.1 - eq) over 1h.. The reaction mixture is allowed to stir for 3 days at room temperature. The. reaction mixture is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate followed by brine. The organic phase is concentrated and the crude product is purified by normal phase chromato graphy (SiO, EtOAc/heptane) to obtain 2,5-Dichloro-7- cyclopentyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidine (158mg, 84%). (5 -chloro-7-cyclopentyl-6-methyl-7H-pyrrolo [2,3-d]pyrimidin-2-yl)~(4-piperazin-1- . ~ yl-phenyl)-amine is prepared from 2,5-Dichloro-7-cyclopentyl-6-methyl-7H-pyrrolo[2,3-d] oo oo - 148 and and 4-(6-Amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester usinga ~~ method similar to that for the preparation of Example 202. (MH+) 412.2
Example 335 | : | | } | 7-(1-ethyl-propyl)-2-(4-piperazin-1-yl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-6- ) carboxylic acid dimethyl amide | )
To a mixture of (5-bromo-2-chloro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine (420 mg, 1.5 mmol) and propargylaldehyde diethyl acetal (0.32 mL, 2.25 mmol) in DMF (6 mL) is added
PACL(PPhs), (105 mg, 0.15 mmol) and Cul (28 mg, 0.15 mmol), followed by Et:N (0.42 mL, 3 mmol). The mixture is degassed, and heated at 55 °C for 16 h. After cooling to room temperature, the reaction mixture is diluted with EtOAc, washed with water ‘and brine. : The organic layer is dried over Na,SOy, filtered and concentrated under reduced pressure. The crude product is purified by column chromatography (SiO,, EtOAc/heptane 5:95 to 40:60) to give 182 mg of [2-chloro-5-(3,3-diethoxy-prop-1-ynyl)-pyrimidin-4-y1]-(1ethyl-propyl)- ~ amine as a light brown oil. oo | So ~ LCMS: 326 M+H)" . | Co
To a solution of [2-chloro-5-(3,3-dicthoxy-prop-1-ynyl)-pyrimidin-4-yl]-(1-cthyl- oo propyl)-amine (326 mg, 1 mmol) in THF (2 mL) is added IN TBAF in THF (mL, 5 mmol) - at ambient temperature. The reaction mixture is heated at 70 °C for 2 h. After cooling down, the mixture is concentrated in vacuo and purified by BIOTAGE column (EtOAc/heptane 5:5 to 40:60) to give 307 mg of 2-chloro-6-diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine as a light yellow oil. B oo =
LCMS: 326 (M+H)". | So : To a solution of 2-chloro-6-diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- ~~ oo d]pyrimidine (67 mg, 0.2 mmol) in 1,4-dioxane (0.7 mL) is added conc. HCI (0.2 mL) at ambient temperature. The reaction ‘mixture is stirred for 30 min, then neutralized with 2N' ‘NaOH aqueous solution and saturated NaHCO; aqueous solution. The mixture is extracted =~ with EtOAc. The extracts are washed with brine, dried over Na;SO,, filtered and concentrated in vacuo to give 54 mg of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- Co - d]pyrimidine-6-carbaldehyde as a yellow solid. The crude product is used as it is.
LCMS: 252 M+H)". - To a mixture of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-6- carbaldehyde (283 mg, 1.11 mmol) in DMF (3 mL) is added oxone (820 mg, 133 mmol) at room temperature. The mixture is stirred at room temperature for 5 h and is quenched with - 20% Na,S,0; aqueous solution. After stirring for 10 min, the reaction mixture is acidified with IN HCI aqueous solution (pH = 5). The mixture is extracted with dichloromethane, dried over Na;SO, and concentrated in vacuo. The solid is filtered, washed with acetonitrile, . and dried under vacuum to give 130 mg of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carboxylic acid as a pale brown solid. oo . © LCMS: 268 (M+H)". | | - + To a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-6- carboxylic acid (80 mg, 0.30 mmol), BOP (159 mg, 0.36 mmol) and NN- ~~ diisopropylethylamine (0.078 mL, 0.45 mmol) in DMF(3 mL) is added 0.164 mL of 2 N dimethylamine in THF solution at room temperature. The mixture is stirred at room temperature for 3h, quenched with IN NaOH aqueous solution, and extracted with EtOAc. ~The organic extracts are washed with brine, dried over Na,SO,, filtered, and concentrated under reduced pressure. The crude product is purified by column chromatography (SiOz, 5% | MeOH in CH,Cl;) to give 64 mg of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carboxylic acid dimethylamide. : © LOMS: 295.1 (MAH). | oo
By repeating the procedures described in example 202, using 2-chloro-7-(1-ethyl- propyl)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide as a starting material, 25° 7-(1-ethyl-propyl)-2-(4-piperazin-1 -yl-phenylamino)-7H-pyrrolo [2.3 -d]pyrimidine-6- carboxylic acid dimethyl amide is obtained. - -
LCMS: 436.3 (M+H)". | | I
Examples 336 — 359 oo B
By repeating the procedures described in example 335, using appropriate starting materials, the following compounds are obtained. oo (M+1) oo - 150
336 —_ oo 464.3
N \ oo 3 : 337 S 462.3 } . NT TX \ : wr N OD . oT —< 5 334727 oo
LL
. . HN nN” N. "= - 339 Tx ° 44828 | .
JH to : CET = oe
N . oO 340 NX ° 449.26 . oo HN Na = Co
OJ
"341 OO 433.27 151 oo
CoN | | OO | 45030 oo a | - 343 ~~ 478.3 344 ) 4763 345 — _ - | | 484.3 346 - o 222
Ta | | oe Oo — S143 Co oo CQ I 348 — 4983
Oo Sl
349 ok — | 03 — 5h ve 350 | RY — 552.3 1 RY co 351° ar 4853
CO B oo 352 , 4853
J . : 353 : . 485.3
So oo 354 ~ 596.4
Sm 3 | oo
LQ | A 355 - , 502.4
C&A 356 Co ep : C442 oo 0 I EE oo 153
357 | —— 523
TT 358 : 540.3 359 — . i 1 552.3 ;
O
Example 360 | I : 1-(4-{4-[6-Diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]- phenyl} -piperazin-1-yl)-ethanone . Nn OEt } }
HN N A OEt . ’ oo :
A oo oo
By repeating the procedures described in example 201, using 2-chloro-6-diethoxymethyl-7- (1-ethyl-propyl)-7TH-pyrrolo[2,3-d]pyrimidine as a starting material, -1-(4-{4-[6- diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo [2,3-d]pyrimidin-2-ylamino]-phenyl}- CL piperazin-1-yl)-ethanone is obtained. oo : } : ~ LCMS: 509 (M+H)" oo
Example 361 : Co : Ce 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- : d]pyrimidine-6-carbaldehyde
AN o 7 | ) | hE on 0 oo Cl
A | oo | oo
To a solution 1-(4-{4-[6-diethoxymethyl-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2- ylamino]-phenyl}-piperazin-1-yl)-ethanone (0.178 g, 0.35 mmol) in 1,4 dioxane (2.8 mL) is added 0.8 mL of concentrated HCI at ambient temperature. The reaction mixture is stirred at ambient temperature for 30 min. The mixture is neutralized with 1 N NaOH aqueous solution and saturated NaHCO; aqueous solution, extracted with CH,Cl,. The extracts are washed with brine, dried over Na, SOs, and concentrated under reduced pressure to give 160 mg of 2- [4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1 _ethyl-propyl)-7H-pyrrolo[2,3 -d]pyrimidine- 6-carbaldehyde as a yellow solid. CL oo
LCMS: 435 (M+H)". - SR
Example 362 =~ 1-(4-{4-[7-(1-Ethyl-propyl)-6-hydroxymethyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]- phenyl}-piperazin-1-yl)-ethanone | -
ANT SNF a OH - oo oO
Lo A | oo oo oo
To a solution of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidine-6-carbaldehyde (20 mg, 0.046 mmol) in MeOH (1 mL) is added
NaBH4 (3.5 mg, 0.092 mmol). The reaction mixture is stirred for 1 h and concentrated in : vacuo. The residue is purified by preparative HPLC to give 15 mg of 1-(4-{4-[7-(1-ethyl- propyl)-6-hydroxymethyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazin-1-yl)- ethanone. | | :
LCMS: 437.3 (ME).
Example 363 | - I 1-(4-{4-[7-(1-Ethyl-propyl)-6-oxazol-5-yl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-pheny1}- piperazin-1-yl)-ethanone oo | )
HN N . : . ye
N | : ® I oo ~ To a solution of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propy1)-7H- oo pyrrolo[2,3-d]pyrimidine-6-carbaldehyde (30 mg, 0.07 mmol) in MeOH (1 mL) are added p- toluenesulfonyl isocyanide (16 mg, 0.08 mmol) and K,CO; (29 mg, 0.21 mmol). The reaction mixture is heated at reflux for 1.5 h and concentrated in vacuo. The residue is Bh : purified by preparative HPLC to give 21 mg of 1-(4-{4-[7-(1-ethyl-propyl)-6-oxazol-5-yl-
Co 7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl} -piperazin-1-yl)-ethanone as a pale brown solid. | oo
LCMS: 4742 M+H)". oo | | | | | oo
Example 364 oo 1-{4-[4-(7-(1-Ethyl-propyl)-6-{1 -methoxyimino-ethyl }-7H-pyrrolo[2,3-d]pyrimidin-2- oo ylamino)-phenyl]-piperazin-1-yl}-ethanone oo -
OMe oN x hoo
PN : | :
A mixture of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carbaldehyde (25 mg, 0.057 mmol), methoxylamine hydrochloride (20 mg, 0.22 mmol) and 6N HCI (0.03 mL) in EtOH(1 mL) is stirred at ambient temperature for 6h.
oo The mixture was quenched with saturated NaHCO; aqueous solution, extracted with CHCl. : The extracts were washed with brine, dried over Na,SOsq, and concentrated under reduced pressure to give the crude product. The crude product is purified by preparative HPLC to give 12 mg of | 1-{4-[4-(7-(1-ethyl-propyl)-6-{ 1-methoxyimino-ethyl}-7H-pyrrolo[2,3-5 d]pyrimidin-2-ylamino)-phenyl]-piperazin-1-yl} -ethanone as a bright yellow solid. . oo
LCMS: 464 (MHH)'. EE
Example 365 So oo So - 1-{4-[4-(7-(1-Ethyl-propyl)-6-{[(furan-2-ylmethyl)-amino]-methyl}-7H-pyrrolo[2,3- : dlpyrimidin-2-ylamino)-phenyl]-piperazin-1-yl}-ethanone : : | :
NT
LR
To a solution of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidine-6-carbaldehyde (30 mg, 0.07 mmol) in THF ( | mL) is added furfurylamine (0.03 mL, 0.35 mmol), NaBH(OAc); (45 mg, 0.21 mmol), and acetic acid a mL). The reaction mixture is stirred for 16 h and concentrated in vacuo. The residue is purified by preparative HPLC to give 20 mg of 1-{4-[4-(7-(1-ethyl-propy1)-6-{ [(furan-2- ylmethyl)-amino]-methyl }-7H-pyrrolo[2,3 -d]pyrimidin-2-ylamino)-phenyl] -piperazin- 1 -yl }- ethanone as a pale yellow solid.
LCMS: 516.3 (M+H)". oo | IE | oo | -
Examples 366 - 372 | oo
By repeating the procedures described in example 365, using appropriate starting materials, the following compounds are obtained. : : (M+1) as
366 | EEE — ] To - BN oo 367 | T4364 Se
IE | on | | oo oo 368 5794 0 " lo Sho
QO
X oo 369 - iy 5133 0 370 - 504.3
Oo
AN
371 | 2 5033 0
AN
372 516.6
JI
O
A
Example 373 | - 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- a Lo d]pyrimidine-6-carboxylic acid methyl ester oo
XN 0 : . )
HN" TN ~ o— : x i oo | . So
To a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid (13 mg, 0.049 mmol) in MeOH (0.5 mL) is added (trimethylsilyl)diazomethane (0.07 mL of a ©. 20Min hexanes). The reaction mixture is stirred for 2 h and concentrated in vacuo to give 13 mg of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester. The crude product is used as it is. Co ]
LCMS: 282.2 (M+H)". ~ SE
To a solution of -[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone (12.1 mg, 0.055 mmol) in 1,4-dioxane (0.5 mL) is added a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carboxylic acid methyl ester (13 mg, 0.046 mmol) in 1,4-dioxane (0.6 mL),
Pdy(dba); (2.2 mg, 0.0023 mmol), Xantphos (2.7 mg, 0.046 mmol) and Cs,CO; (22.5 mg, 0.069 mmol). The mixture is degassed, and heated at 100 °C for 3 h. ‘The mixture is cooled to room temperature, diluted with EtOAc, and filtered through a pad of Celite. The filtrate is concentrated under reduced pressure. The crude product is purified by preparative HPLC to give 86 mg of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino}-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester as a pale white solid. oo
LCMS: 465.4 (M+H)*.
Example 374 oo oo 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidine-6-carboxylic acid oo : a oo 159
XN 0 oo Co / 3 | | oo : co
A Co ~ To a solution of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H- © pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester (19 mg, 0.041 mmol) in MeOH (1.5 : mL) is added 2 N LiOH aqueous solution (0.5 mL). The reaction mixture is stirred overnight and concentrated in vacuo. The residue is purified by preparative HPLC to give 13.6 mg of 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- a ~ dpyrimidine-6-carboxylic acid. oo oo LCMS: 451.4 (M+H)". | | N
Example 375 So oo 7-(1-Ethyl-propyl)-2-(4-piperazin-1-yl-phenylamino)-7H-pyrrolo[2,3-d] pyrimidine-6- ~~ carboxylic acid oo
HN” ON OH = : Co ® oo .
To a solution of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester (16 mg, 0.034 mmol) in THF (1.5 mL) is added 2 N LiOH aqueous solution (1 mL). The reaction mixture is stirred for 36 h and ‘concentrated in vacuo. The residue is purified by preparative HPLC to give 9.4 mg of 7-(1- ethyl-propyl)-2-(4-piperazin-1-yl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid.
LCMS: 409.4 (M+H)".
Example 376 oo oo
1-(4- {4-7 1-Ethyl-propyl)-6-(1 -hydroxy-ethyl)-7H-pyrrolo [2,3-d]pyrimidin-2-ylamino]- : phenyl} -piperazin-1-yl)-ethanone Co Ce x OH oo (J So oA | oo
To a mixture of (5-bromo-2-chloro-pyrimidin-4-y1)-(1-ethyl-propyl)-amine (0.44 g, 1.58 mmol), Pd(PhsP),Cl, (0.11 g, 0.16 mmol), and Cul (0.03 g, 0.16 mmol) in DMF (14 mL) is added 3-butyn-2-ol (0.19 mL, 2.37 mmol) and triethylamine (0.44 mL, 3.16 mmol). The reaction mixture is stirred at 55 °C for 16 h, diluted with CH,Cl,, filtered through a pad of
Celite, and concentrated in vacuo. Purification by flash chromatography (SiO,
EtOAc/Hexane 1:3) gave 0.23 g of 4-[2-chloro-4-(1-ethyl-propylamino)-pyrimidin-5-yl]-but- 3-yn-2-ol as yellowish oil. | | | Co
LCMS: 268 (M+H)". a I
To a solution of 4-[2-chloro-4-(1-ethyl-propylamino)-pyrimidin-5-yl]-but-3-yn-2-ol (0.23 g, 0.85 mmol) in THF (0.5 mL) is added 1M TBAF (4.3 mL). The reaction mixture is heated at reflux for 16 h, diluted with water, extracted with EtOAc. The extracts are dried over Na,SO; and concentrated in vacuo. The residue is purified by flash chromatography (SiO, EtOAc/Hexane 1:3) to provide 0.12 g of 1-[2-chloro-7-(1-ethyl-propyl)-7H- pyrrolo[2,3-d]pyrimidin-6-yl]-ethanol. Ce
LCMS: 268 (M+H)". Co
By repeating the procedures described in example 65, using 1-[2-chloro-7-(1-ethyl- propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ethanol as a starting material, 1-(4-{4-[7-(1-ethyl- propyl)-6-( 1 -hydroxy-ethyl)-7H-pyrrolo [2,3-d] pyrimidin-2-ylamino]-phenyl } -piperazin- 1- yl)-ethanone is obtained. | oo Co
LCMS: 451.4 (M+H)". | oo
Example 377 | oo 1-[2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-ethanone | oo oo 161
WN 0 Co
N . oA | | oo ~ To a solution of 1-[2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ethanol (61 mg, 0.2 mmol) in CHCl, (2. mL) is added Dess-Martin' periodinane (242 mg, 0.5 mmol).
The reaction mixture is stirred for 1 h, quenched with 10 % NaS,0;: saturated NaHCO; (1:1) aqueous solution, and extracted with CH,Cl. The extracts are washed with water and brine, : dried over Na,SO;, and concentrated in vacuo. The residue is purified by flash oo chromatography (SiO, EtOAc/Hexane 1:3) to afford 58 mg of 1-[2-chloro-7-(1-ethyl- propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ethanone. Co oo oo :
LCMS: 266 M+H)". . BE - By repeating the procedures described in example 201, using 1-[2-chloro-7-(1-ethyl- . propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ethanone as a starting material, 1-[2-[4-(4-acetyl- piperazin-1-yl)-phenylamino]-7-(1-ethyl-propyl)-7H-pyrrolo [2,3-d]pyrimidin-6-yl]-ethanone is obtained. | Co
LCMS: 449.4 (M+H)". | | -
Example 378 | | Co . [7-(1-Ethyl-propyl)-6-(1-methoxy-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl- oo phenyl)-amine a a | | -
To N 20 To a solution of 1-(4-{4-[7-(1-ethyl-propyl)-6-(1-hydroxy-ethyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino]-phenyl}-piperazin-1-yl)-ethanone (19 mg, 0.042 mmol) in MeOH (1 - mL) is added 4N HCI in dioxane (1 mL). The reaction mixture is stirred at 60 °C for 2h. The = mixture is loaded on Solid Phase Extraction column (Sorbent: benzensulfonic acid), washed with MeOH, eluted with EtOAc:MeOH:Et3N (1 1 :0.05), concentrated in vacuo. The residue is purified by preparative HPLC to give 10 mg of [7-(1-ethyl-propyl)-6-(1-methoxy-ethyl)- 7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine. Bn :
LCMS: 423.4 (M+H)", ) :
Examples 379-382 N a.
By repeating the procedures described in example 378, using appropriate starting materials, the following compounds are obtained. . (M+1) 3719 | - 4513 h N\ oo : oo | ZT : | Co 380 - 1363 . . NTS NN ‘ : . 381 | 509.4 CL | : ‘ n SE 382 : 409.3
IN : :
BEE h 163
Example 383 (7-Cyclopentyl-6-isopropenyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-(4-piperazin-1-yl- phenyl)-amine : , (5-Bromo-2-chloro-pyrimidin-4-yl)cyclopentylamine is prepared from cyclopentyl amine and 5-bromo-2,4-dichloropyrimidine using a method similar to that for the preparation of (5-
Bromo-2-chloro-pyrimidin-4-yl)-(1-ethylpropyl)amine given in Example 137. -
To a solution of (5-Bromo-2-chloro-pyrimidin-4-yl)cyclopentylamine (1g, : © 3.616mmol) is added lithium chloride (153.7 mg, 3.616 mmol) and potassium acetate (887.12 mg, 9.03 mmol) in DMF (50 mL). The solution is degassed and back-filled with N».
Palladium(II) acetate (40.6 mg, 0.18 mmol) is added and the solution is degassed and back- filled with nitrogen three times. 3-pentyn-2-ol (1.0 mL, 10.8 mmol) is added and the reaction solution is heated at 120°C for 5 hours. LC-MS analysis indicated the absence of starting material and the formation of a pair of regio-isomeric products. After cooling to room temperature, the mixture is filtered through Celite, diluted with water, and extracted with ethyl acetate EtOAc three times. The organic layers are combined, washed with brineand ~~ dried over anhydrous sodium sulfate. The solvent is evaporated and the crude material is purified using silica gel chromatography(30% ethyl acetate / 70% hexanes to give 1-(2- Chloro-7-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-ethanol as a pale powder (150mg, 14.8%). [M+H]"=280.07. - 1-(2-Chloro-7-cyclopentyl-5-methyl-7H-pyrrolo[2,3 -d]pyrimidin-6-y1)-ethanone is prepared by Dess-Martin periodinane oxidation of 1-(2-Chloro-7-cyclopentyl-5-methyl-7H-. pyrrolo[2,3-d]pyrimidin-6-yl)-ethanol using a procedure similar to that described for 1-[2- chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ethanone in the synthesis of
Example 376. [M+H]"=278.03.
A solution of 1-(2-Chloro-7-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-y1)- ethanone (40 mg, 0.144 mmol), 1-[4-(4-Amino-phenyl)-piperazin-1-yl}-ethanone (37.9 mg, 0.172 mmol), Pd,(dba); (6.7 mg, 0.007 mmol), BINAP (9.15 mg, 0.014 mmol) and NaOtBu : (20.7mg, 0.216mmol) in 1,4-dioxane (4 mL) is degassed and back-filled with nitrogen three : times. The reaction mixture is heated to 80 °C for 2 hours. After cooling to room temperature water is added and the reaction mixture is extracted with ethyl acetate three - times. The organic layers are combined, washed with brine and dried over anhydrous sodium sulfate. The solvent is evaporated and the crude material is purified by preparative HPLC to : provide’ 1-{2-[4-(4-Acetyl-piperazin-1 _yl)-phenylamino]-7-cyclopentyl-Smethyl-7H- pyrrolo[2,3-d]pyrimidin-6-yl}-ethanone (16mg, 24%). [M+H]"=461 13. : :
To a solution of 1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-7-cyclopentyl- oo
Smethyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl }-ethanone (12 mg, 0.026 mmol) in ‘methanol a : mL) is added HCI (2 mL, 2M in dioxane), dropwise. The solution is heated to reflux for 2 h.
The solvent is evaporated and the crude product is purified on HPLC to give a TFA salt of (7-
Cyclopentyl-6-isopropenyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-(4-piperazin-1-yl- ) phenyl)-amine as a yellow solid (7 mg, 42%). [M+H]"=419.17.
Example 384 : oo ) 7-Cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3- ) d]pyrimidine-6-carboxylic acid methyl ester oo : EE
NTR 9p
Bessd :
XN oo :
N
A solution of (5-Bromo-2-chloro-pyrimidin-4-yl)cyclopentylamine (8g, 28.93mmol), lithium chloride (1.23 g, 28.9 mmol), potassium carbonate (10 g, 72 mmol) and palladium acetate (324.68 mg, 1.45 mmol) in DMF (300 mL) is degassed and back-filled filled with nitrogen three times. Methyl-2-butynoate(8.5 mL, 87 mmol) is added and the reaction solution is heated at 120 °C for 5 h. LC-MS indicated the formation of two regioisomers and no starting material remaining. After cooling to room temperature the solution is filtered through Celite, diluted with water and extracted with ethyl acetate three times. The organic layers are” combined, washed with brine and dried over anhydrous sodium sulfate. The solvent is oo evaporated and the crude product is purified using silica gel chromatography (~20% ethyl acetate / 80%hexane) to give 2-chloro-7-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine- : 6-carboxylic acid methyl ester as a yellow solid (2.11g, 25%). [M+H]'=294.04. ies
A mixture of 2-chloro-7-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxylic acid methyl ester (110 mg, 0.374 mmol), 4-(6-Amino-pyridin-3-yl)-piperazine-1- carboxylic acid tert-butyl ester (114.66 mg, 0.412 mmol), Pdy(dba)s(17.144 mg, 0.02 mmol),
Xantphos (21.67mg, 0.037 mmol) and cesium carbonate (183 mg, 0.562 mmol) in dioxane (5 - mL) is degassed and back- filled with nitrogen three times. The reaction mixture is heated to 100°C for 4 h. Water is added and the solution is extracted with ethyl acetate three times. . The organic layers are combined, washed with brine and dried over anhydrous sodium sulfate. The solvent is evaporated and the crude product is dissolved in a small amount of ethyl acetate. White solid precipitates out and filters to give 2-[5-(4-tert-Butoxycarbonyl- - piperazin-1-yl)-pyridin-2-ylamino] -7-cyclopentyl-5-methyl-7H-pyrrolo[2,3 -d]pyrimidine-6- carboxylic acid methyl ester as a white solid (35mg, 17%) which was carried onto the next : step without further purification. [M+H]"=536.35. Bh | oo
Co ~~ To asolution of 2-[5-(4-tert-Butoxycarbonyl-piperazin- 1-yl)-pyridin-2-ylamino]-7- cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester (35 mg, 0.065 mmol) in DCM (8 mL) is added TFA (2 mL) dropwise. The solution is stirred at } room wmperature for 2 hours. Solvent is evaporated and the crude material is purified by oo preparative HPLC to give the TFA salt of 7-Cyclopentyl-5-methyl-2-(5-piperazin-1-yl- ) pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester as yellow solid (32mg, 74%). [M+H]"=436.2458. oo oT | Co Example385: | BEE a 7-Cyclopentyl-6-methyl-2-(5-piperazin- 1 _yl-pyridin-2-ylamino)-7H-pyrrolo [2,3- . d]pyrimidine-5-carboxylic acid methyl ester BE
NT
O- ) | | | a
Xe 2-chloro-7-cyclopentyl-6-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid methyl ester is prepared using the procedure shown for the preparation of its regio-isomer 2-chloro-7- = cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester given in : the procedure for the synthesis of Example 384. Co h 7-Cyclopentyl-6-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3- d]pyrimidine-5-carboxylic acid methyl ester is prepared from 2-chloro-7-cyclopentyl-5- methyl-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid methyl ester using a procedure similar to that given for the preparation of 7-Cyclopentyl-5-methyl-2-(-piperazin-1-yl-pyridin-2- ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid methyl ester, Example 384. : [M+H]"=436.25. Co
Example 386 oo [7-Cyclopentyl-5-methyl-6-(5-methyl-[1,3,4]oxadiazol-2-y1)-7H-pyrrolo[2,3d]pyrimidin-2- yI]-(5-piperazin-1-yl-pyridin-2-yl)-amine oo EE
HN NN N :
Z Co :
To a suspension of 2-[5-(4-tert-Butoxycarbonyl-piperazin-1 -yl)-pyridin-2-ylamino]-7- cyclopentyl-5-methyl-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid methyl ester (250 mg, 0.467 mmol) (prepared as described in the procedure for the synthesis of Example 384), in
MeOH/H,0/DCM (70 mL) is added a solution of lithium hydroxide (39.2 mg, 0.93 mmol) in . water (1 5 mL). The reaction mixture is heated to reflux for 4 hours. The reaction mixture is allowed to cool to room temperature and concentrated in vacuo. The resulting solution is acidified to pH~3 using saturated aqueous citric acid solution. The solution is evaporated and the residue is purified by preparative HPLC to give 2-[5-(4-tert-Butoxycarbonyl-piperazin-1- yl)-pyridin-2-ylamino]-7-cyclopentyl-5-methyl-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid as a yellow solid (105 mg, 53%). [M+H]'=522.3
To a solution of 12 2-[5-(4-tert-Butoxycarbonyl-piperazin-1-yl)-pyridin-2-ylamino}- 7-cyclopentyl-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid (120 mg, 0.23 mmol), HBTU (130.9 mg, 0.345 mmol) and HOAt (46.97 mg, 0.345 mmol) in dry DMF (15 mL) is added a solution of acetic hydrazide (34.09 mg, 0.46 mmol) and
Co diisopropylethylamine (121ul, 0.693 mmol) in dry DMF Ig mL). The reaction mixture is stirred at room temperature overnight. The reaction mixture is diluted with water and extracted with ethyl acetate three times. The organic layers are combined, washed with brine and dried over anhydrous sodium sulfate. The solvent is evaporated and the crude product is purified by preparative HPLC to give 4-{6-[6-(N '-Acetyl-hydrazinocarbonyl)-7-cyclopentyl- 5-methyl-7H-pyrrolo[2,3-d] pyrimidin-2-ylamino]-pyridin-3 -yl }-piperazine- 1-carboxylic acid tert-butyl ester as a yellow solid (120mg, 75.4%). [M+H]"=578.32.
A mixture of 4-{6-[6-(N '. Acetyl-hydrazinocarbonyl)-7-cyclopentyl-5 -methyl-7H- pyrrolo[2,3-d]pyrimidin-2-ylamino]-pyridin-3-yl } -piperazine-1-carboxylic acid tert-butyl ester (80mg, 0.139mmol) and polyphosphoric acid (20 mL) os heated to 120°C for 1 h. The _ reaction mixture is diluted with cold water in an ice-water bath and neutralized to pH~8 with 6 N sodium hydroxide solution. The aqueous solution is extracted with ethyl acetate three times. The organic layers are combined, washed with brine and dried over anhydrous sodium sulfate. The solvent is evaporated and the crude product is washed with MeOH to give [7- ~ Cyclopentyl-5-methyl-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-7H-pyrrolo[2,3d] pyrimidin-2-yl]- (5-piperazin-1-yl-pyridin-2-yl)-amine as a yellow solid (28 mg). The methanolic solutionis ~~ purified by preparative HPLC to give a TFA salt of [7-Cyclopentyl-5-methyl-6-(5-methyl- [1,3 ,4Joxadiazol-2-y1)-7H-pyrrolo[2,3d] pyrimidin-2-yl]-(5-piperazin- 1-yl-pyridin-2-yl)- amine as a yellow solid (20 mg). [M+H]"=460.2572.
Examples 387 — 408 are prepared using methods similar to those described in the syntheses of Examples 383-386 and standard synthetic methodology used in the synthesis of | azole heterocycles with appropriate choice of starting materials. oo (M+1) 387 : 420.25 . @ Cl 388 436
CoE () oo | 168
[389 {= 4483 00 1 390 oC ° 223
A
: J 3 Co . HN N N OH ‘ ‘
ITH 1 x
CO
391 - ~ o 421.25 : 392 ~ 449.28
NTR \ 0 . } : . A? oT So
NT } en oo 393 ~ 403.24 : NF .
N= oS N : } .
J & 394 awaited : EN
TO D—=
HNT ON N
. WF O . :
wO 2007/140222 PCT/US2007/069595 395. oo Awaited : | HN NG :
So PLN : 396 - Awaited . : " ~~ 2 —\ }
Co wn? ~ : Na oo 397 ~A 333.2. oo To N rN oo wo N OH : « : 0 . 398. : . 444.25 399 : | : 445.25 oo 1m
400 : o 473.3 ’ . NTR :
HN N N . : . :
NT oo ol 1] C oo : 401 : 459.25 .
Oo Lo x >= Co : a" 5 —N : So 202 | : 45826 oo 403 459.26
Oo . } a N } } HN N . - . } NT & . . } . i } mw. © 404 ~H 458.23 So
N x A i } . } i WN N \ } : ’ NF . O) ) oo Co. . 405 — n= 459.26 we, ‘ : . N= Mw \ : \. / AN
N : :
Bh 171
406 | q BE 25927 . NX A Ney } ) oo 407 - : 46026 - : NTR N\ O~n . . . . <I oo 408 °§-o 435.25 \
Example 409 ) | oo 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one
N . 5-0
HN” ON A : oo eo : :
To a solution of 2,4-dichloro-5-nitro-pyrimidine (2 g, 10.3 mmol) in anhydrous EtOH 0 mL) is added 1-ethylpropylamine (1.3 mL, 11.3 mmol) and N,N-diisopropylethylamine (2.7 mL, 15.5 mmol) at 0 °C. The reaction mixture is stirred for 8 h and concentrated in vacuo.
The residue is dissoloved with EtOAc, washed with saturated NaHCOj3 and brine, dried over
Na,SO4, and concentrated in vacuo. Purification with column chromatography (SiO, - EtOAC/Hexane 1:3) gives 1.5 g of (2-chloro-5-nitro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine. ~ LCMS: 245.1 (M+H)"
Im
To a solution of (2-chloro-5-nitro-pyrimidin-4-yl)-(1-ethyl-propyl)-amine (1 g, 4.1 mmol) in anhydrous EtOH (50mL) is added Tin(Il) chloride (2.3 g, 12.3 mmol) and concentrated HCI (1mL) at ambient temperature. The reaction is heated to 80 °C for 1 h and : quenched with IN NaOH at 0 °C. The mixture is extracted with EtOAc, washed with brine, | dried over Na; SO, and concentrated in vacuo to give 0.5 ° of (2-chloro-5-amino-pyrimidin- - 4-y1)-(1-cthyl-propyl)-amine. The crude is used as is.
LCMS: 215.2 (M+H)" oo
To a microwave vial is added the crude (2-chloro-5-amino-pyrimidin-4-yl)-(1-ethyl- propyl)-amine 0.5 g, 2.3 mmol) and anhydrous DMF (15mL) followed by 1,1°- carbonyldiimidazole (1.1 g, 7.0 mmol). Sealed vial and microwave are heated at 100 °C for 10 min.: The reaction mixture is diluted with EtOAc, washed with water, dried over Na,SOx, and concentrated in vacuo. Purification with column chromatography (SiO,, EtOAC/Hexane 1:1) gives 0.3 g of 2-chloro-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one. LCMS: 241.1
M+)’ oo | EE
To a mixture of 2-chloro-9-(1-ethyl-propyl)-7 9-dihydro-purin-8-one (95 mg, 0.4 mmol) and TsOH (1.6 mL, 0.2 M in 1,4-dioxane) in DMF (0.25 mL) is added 1-[4-(4-amino- phenyl)-piperazin-1-yl]-ethanone (105 mg, 0.5 mmol). The reaction mixture is sealedina = microwave reactor and heated at 140 °C for 30 min. The mixture is diluted with EtOAc and washed with NaHCO; aqueous solution and brine. The organic layer is dried over Na;SOsa, filtered and concentrated. The crude product is purified by preparative HPLC to give 52mg of 2-[4-(4-acetyl-piperazin-1 -yl)-phenylamino] -9-(1 _ethyl-propyl)-7,9-dihydro-purin-8-one as a brown solid. | ’
LCMS: 4242 (M+H)" CL
Examples410-418 oo
By repeating the procedures described in example x1, using appropriate starting materials, the following compounds are obtained. | - oo
M+1) _ 3
A BE 395.5 oo
SO . } To
NH : 382.2 | -
Coe 412 ] 4382 ’ NxM } . . 413 } - : SN 383.2
CC ~A 383.2 } >" 415 Co - :
AN | 460.2 leo
— | 112
NNN } . a17 — | f 424.2 : YC | oo
PN oo oo . 4092 . NNN } ’
CF
: Example 419 : Bh 2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-9-(1-ethyl-propyl)-7-methyl-7,9-dihydro-purin- 8-one : oo :
N /
N
. xX Co } : : . (J oo
To a solution of 2-chloro-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one (100 mg, 0.41 mmol) in anhydrous DMF (2 mL) is added methyl iodide (21 ul, 0.41 mmol) and NaH (50% dispersion in mineral oil, 22 mg, 0.46 mmol). The reaction is stirred for 1.5 h. The reaction mixture is quenched with ice water and extracted with EtOAc. The extracts are dried over : Na;SO, and concentrated in vacuo to give 104 mg of 2-chloro-9+(1-ethyl-propyl)-7-methyl- 7,9-dihydro-purin-8-one. The crude product is used as is. 'LCMS: 255.1 (M+H)* - | | I a Co | 175
To a mixture of 2-chloro-9-(1-ethyl-propyl)-7-methyl-7,9-dihydro-purin-8-one (102 mg, 0.4 mmol) and TsOH (1.6 mL, 0.2 M in 1,4-dioxane) in DMF (0.25 mL) is added 1-[4- (4-amino-phenyl)-piperazin-1 -yl]-ethanone (105 mg, 0.5 mmol). The reaction mixture is sealed in a microwave reactor and heated at 140 °C for 30 min. The mixture is diluted with -
EtOAcand washed with NaHCO; aqueous solution and brine. The organics are dried over :
Na;S0s, filtered and concentrated. The crude product is purified by preparative HPLC to give 50 mg of 2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-9-(1-ethyl-propyl)-7,9-dihydro- purin-8-one. : LCMS: 437.6 (M+H)* | B ) | | oo
Example 420 | oo oo 9-(1 Ethyl-propyl)-7-methyl-2-[4-(4-methyl-piperazin- 1 -yl)-phenylamino]-7,9-dihydro- ~ purin-8-one | oo : NX J Co -
A ol - : : vo | So
By repeating the procedures described in example x11, wing appropriate starting materials, 9-(1-ethyl-propyl)-7-methyl-2- [4-(4-methyl-piperazin- 1-yl)-phenylamino]-7,9-dihydro-purin- © 8-one is obtained.
LCMS: 409.5 (M+H)"
Exampled2] | | ; 1-(4-{4-[9-(1 -Ethyl-propyl)-9H-purin-2-ylamino] -phenyl}-piperazin-1-yl)-ethanone
HN ON ~ Co oo oo
A Co
To a solution of 2-chloro-9-(1-ethyl-propyl)-7,9-dihydro-purin-8-one (0.5 g, 23 mmol) in
DMF (5 mL) is added triethyl orthoformate (3.8 mL, 23 mmol) and TsOH (0.88 g, 2.6 mmol). The reaction is stirred overnight. The reaction mixture is quenched with ice water ) and extracted with EtOAc. The extracts are dried over Na,SO4 and concentrated in vacuo.
Purification by flash chromatography (SiO,, EtOAC/Hexane 1:3) gives 0.39 g of 2-chloro-9- : (1-ethyl-propyl)-9H-purine. )
LCMS: 225.1 M+H)" + To a mixture of 2-chloro-9-(1-ethyl-propyl)-9H-purine (90 mg, 0.4 mmol) and TsOH : (1.6mL, 0.2 M in 1,4-dioxane) in DMF (0.25 mL) is added 1-[4-(4-amino-phenyl)-piperazin- 1-yl]-ethanone (105 mg, 0.5 mmol). The reaction mixture is sealed in a microwave reactor and heated at 140 °C for 30 min. The mixture is diluted with EtOAc and washed with
NaHCO; aqueous solution and brine. The organics are dried over Na;SOs,, filtered and concentrated. The crude product is purified by preparative HPLC to give 40 mg of 1-(4-{4- [9-(1-ethyl-propyl)-9H-purin-2-ylamino]-phenyl}-piperazin-1-yl)-ethanone. : ~ LCMS: 407.5 (M+H)" oo oo
Example 422 | | : : [9-(1-Ethyl-propyl)-9H-purin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine
NNN | | } or | | oo
HN” ON ~ . i . .
CJ
C177
By repeating the procedures described in example x13, using appropriate starting materials,[9-(1 -ethyl-propyl)-9H-purin-2-yl]- [4-(4-methyl-piperazin-1 -yl)-phenyl] -amine is obtained. - | | oo © LCMS: 379.5 (M+H)' | | | -
The following examples of compounds were also produced using the materials and methods as described above. : oo
Structure Example MS oo ) | Number - : 423 SE ar N gg oo
Ne a 424 - 364
JO ws NT TN Co | CL
S| | oo
H - 425 492.3075
Ao N l | | oo 0
AL a. : oo 178
426 392.2561 oo 1 A . - 7 O Hs
N ’ 427 463.2818 a N
A Co 428 :
Oo oo”. } }
HN cL . : : . : ho . : }
C179
229 3 Lo ol N . : . . n 430 377.1,
A
N : }
LJ
431 478.2925 a N : “1 O
Na : [ 0) oo
Ak _ 432 442.1345 oo
GP
EN N
DC oo oo _) oo
N
9 BN a 433 © 398.1864 Co a N Co eG 1S | oo 436 - 486.22 :
HN N N . - . : NF S oo . . g | Co xr : . : . . 437 385.2 B So
As N . : . . . | aE ~ - .
J a
H } Co : : . 438 391.2605 a N oo oo oo 181
439 491.3114 a N : . . } : . Pe | ae ~T2a0 206.21 oo ae N : : a oe
So — 422 443 a
NT OX . }
C12 -
I 444 no 422.2306 :
AI | oo ~ o | oo 445 522.283
LOS N oH . ’ . } : . hs 446 471 Co
HN NZ N . : .
NF Js : - > || :
J Co oo : _ 183 mT 447 387.04 | | _
NT TX . :
N\ : : EE 448 521208 - ig .
N \ © rb . ~ 1 | oo | So ) | | 449 0,
A | | oo ] 578.3204 | A
Beata Cl 87s SN
XL
A oo oo | | 184 }
451 549.3301 :
HN N > }
A ’ . Co : 452 453 | A
HN NN
454
HN NZ “N } i : .
— 55 —— oo
Nu | 456
To 457 CT
NOS oo rd . .
IN oo SE
QO oo a oo 1s a
SN
0 | a
Se 0 462 491.3124 23 : 3 | oo “hd a — Ww 53:32 oo
A | . | ’ . 516.34 | oo
Ne P . . <C
Q 0
A. | oC . 265 550.3506
SNL :
JO
> 5 ) 323.19
NT \
o 467 448.28 | Co
So BE ; 468 54834] : (>
EO oo 1 T469 5412626
NS : \ :
I ’ 1 os . | Co . : 7 SN : } ' oe n Pa do =O § | | | ; - 434 294.1718
— — 435 | 293.1757 | oo ie] a
Cam | | - * BIOLOGICAL ACTIVITY oo ~ Binding of cytokines and certain growth factors to their respective receptors trigger activation of Janus kinases, which phosphorylate members of the STAT family. - :
Phosphorylated STAT molecules dimerize and migrate to the nucleus where they bind to
DNA and initiate transcription of responsive genes. Inhibitors of pathways downstream of cytokine/growth factor receptors have therapeutic potential for several indications. An enzymatic assay for JAK-3 and JAK-2 has been developed to identify T-cell selective : inhibitors. GST fusion constructs of the kinase domains of both enzymes are usedand a .. biotinylated, tyrosine containing peptide serves as substrate. Phosphorylation of this peptide by the respective kinase is quantified with an europium-labeled anti-phosphotyrosine ) antibody (Eu-PT66) as energy donor and a streptavidin-allophycocyanine conjugate (SA-
APC) as energy acceptor. The assay has been established in a 384 well format.
Inthe JAK LANCE™ assay, a biotinylated peptide is incubated together with compounds and ATP in buffer. The phosphorylation reaction starts after addition of JAK kinase. After incubation at RT the reaction is stopped with EDTA and the product detected by addition Streptavidin-Allophycocyanin and Europium-labeled antiphosphotyrosine antibody. The signal is measured using an EnVision Reader. Exc: 320nm, Em, Donor: 615nm and Em, Acceptor: 665nm in time resolved fashion with a delay of 60s anda window . of 100s. oo
Data acquired for the compounds of the invention using these assays are shown in © Tables A and B. | - oo I oo 190
In order to test the CDK4 activity of the compounds of the invention, an ELISA based assay can be utilized, where the enzyme is a purified active CDK4/Cyclin-D1 kinase complex and the substrate is a purified Retinoblastoma (Rb) protein. The active CDK4/Cyclin-D1 kinase complex phosphorylates the Rb substrate at Serine780 residue, and then the - phosphorylated Rb/S780 is detected via an antibody specific to the phosphorylated site. The compounds that inhibit the CDK4 kinase activity would inhibit the signal output of the assay. . Data acquired for the compounds of the invention using this assay are shown in Table C.
In order to test the CDK2 activity of the compounds of the invention, the CDK2 assay
BE a flourescence polarization assay, where the enzyme is a purified active CDK2/Cyclin-A kinase complex and the substrate is a synthesized peptide derived from Histone HI. This assay utilizes the IMAP technology from Molecular Devices. The active CDK2/Cyclin-A complex phosphorylates the peptide substrate, which is conjugated with the TAMRA tag. ~~ The phosphorylated site is then recognized by a metal containing molecule that interacts with the TAMRA tag to induce a high flourescence polarization. The compounds that inhibit the
CDK2 kinase activity would inhibit the flourescence output of the assay. Data acquired for the compounds of the invention using this assay are shown in Table C. p-pRb/S780 ELISA Cellular Assay
Maxisorp plates (Nunc 442404) are coated with 50ul of lug/mL total phospholated So ~ Retinoblast Protein (pRb) antibody (4H1 Cell Signaling 9309L) diluted in DPBS (Phosphate * Buffered Saline) overnight at 4°C. The next day plates are blocked with Superblock in
TBST (Pierce 37535) for one hour to overnight — changing block once during that time. Cr
Cells are plated at 50-60% confluency in a 96 well plate (Corning 3585) in 100uL complete ) media (media containing fetal bovine serum (Gibco 1600-044), 2mM L-Glutamine (Gibco 25030), and 1% Penicillin/Streptomycin (Gibco 15140-122) and grown overnight ina | - humidified chamber at 37°C and 5% CO,. Compounds (in DMSO) are diluted in media to create a 7 point dilution series of compound with concentrations ranging from 110uM to ~0.027uM. 10ul of the diluted compounds are added to the cells, with final concentrations on cells renging from 10uM to 0.002uM. Cells are treated for 24 hrs in a humidified chamber at 37°C and 5% CO,. Following compound incubation, cells are lysed with 40uL/well lysis buffer (50mM Tris-HCL pH 7.5 (Invitrogen 15567-027), 120mM NaCl (Promega V4221), oe
ImM EDTA (Gibco 15575-038), 6mM EGTA (Fisher 02783-100 ), 1% Nonidet P40 (Fluka
R02771). Plates are placed on Titerplate shaker (Labline model 4625) for 5 minutes at 4°C to - v1 lyse cells. After lysis, 10ul of cell lysate and S0ul 1xPBS/10% Superblock (Gibco 10010 and Pierce 37535) is added to each well of the precoated and blocked Maxisorp plate and allowed to bind at room temperature for 2 hours on Oribtron Rotator II (Boekel Industries
Model 260250). Plates are then washed 3x with 1x TBST (Teknova T9201) using Biotek platewasher equipped with a Biostack. The final wash is not aspirated. The final wash is ) removed by flicking off and tapping plate on paper towels. ppRbS780 antibody (Cell
Signaling 9307L) is diluted 1:1000 in 1xPBS/10% Superblock (Gibco 10010 and Pierce : 37535) and 50ul is added to each well. Plates are then incubated 1 hour on Oribtron Rotator 11 (Boekel Industries Model 260250). Plates are then washed as previously described. Goat anti-rabbit HRP (Promega W401 B) is diluted 1:2500 1xPBS/10% Superblock (Gibco 10010 and Pierce 37535) and 50ul is added to each well. Plates are then incubated 30 minutes on ‘Oribtron Rotator II. Plates are then washed as previously described. 50uL Ultra TMB oo
ELISA (Pierce 34028) is then added to each well. Plates are incubated 5-20 minutes until blue color develops. 50ul 2M Sulfuric acid (Mallinckrodt 2468-46) is then added to each well to stop the reaction. Absorbance at 450nm for each plate is read on Spectramax Plus : (Molecular Devices). The results of this assay are summarized in Table E. -
BrdU assay } | oo oo
Cell Proliferation ELISA BrdU (colorimetric) kit from Roche Diagnostic (Cat. #: ~ 11647229001, 9115 Hague Road, Indianapolis, IN 50414) is used for this assay. Briefly, cells are plated in 96 well plates at 50-60% confluency in RMPI 1640 media. The next day, cells are treated with compounds at a desired concentration range and then incubated for 24 hrs in a humidified chamber at 37°C and 5% CO;. Following the protocol provided by the kit, cells are labeled with BrdU labeling agent for 2 hrs, and then fixed with 200uL of
FixDenat for 30 min at room temperature. 100uL of anti-BrdU antibody is added to the cells and incubated for 2 hrs at room temperature. The cells are then washed three times with 200uL/well of PBS, and then 100uL of color developing solution is added per well. After 5- 10 min incubation, the absorbance is read at 370nM using Spectramax Plus (Molecular
Devices). The results of this assay are summarized in Table E. | Co oo 192
TABLE E | oo
ELISA | HTRF/IC50 | CDK2cyA :
Bh Co assay fumol I-1] IMAP / hCDK1/B /
Lo | 1C50 IC50 IC50 [umol | : umol I- umol 1] | 1 200 [1 «0 (206 ~~ |>t0 [0 l>1w0 oj 00 <0] 000 «of [20 000 <0] 000] <0] 22 00 [ <0) 00001 «al ogee <0 0 >10 26 ~~ [ <0] | «ol | : oo |=s 00 | <0] | <«o] 266 00 | | <4] «ol <0] 27 [> | 0 I 28 ~~ |>t0 J 0000 | 0] 263 [>t | Jt [ oo 260 | <0] 0 J>10 [ 264 000 [> | 0 J>t0 [ I 48 00 >t 7 00001 0 (262 [>t | = [>tw0 23 00] <0] | <0] (254 >to | Tal eet. | «al <M al] %2 000 [> 1 0000 «al cope. [1 sto |] 000 [1 [st [0]
SEC EC I Rl fe 000] <0] 0 Also oo 193 -
39 ~~ J» | <0ls>q0 81 00 | f>t0 7 I 0 38 0 [>t0 0 A] «10] (3% 00 f>t0 000 A «0
EE ET) EE (280 0 | <0]>10 [>10 | | oo
EE ES
Ge [aaa a wo wm | aa a ae pw [
Z| ao] | a] wer | alg a0 ea a ws ww 3 wm ao 0] gp oo 0 pw 7 | wo] =o] ao] wo] <olr 24 00 [>t J>t0 | 1 1 oy: sr sl «ef 226 | <0] <0f>q0 227 000 | 1 <0] «0 28 000 1 <0] <0] 0. | 7 Al «ef mC =ihw mal al we alae wr a wea aq) } om ww |] ws | wo |] wei ap
BoA [aap aio we hs [ao ww eae ms eh ws wl. | oo ws |< aol
Z| pi [ao] oo 194
61 | qx «0 7. [I <ol> | oo (86 [<0] «af 287 0 [<0] <0] #8 00 <0) «0 (2388 [0 <l <0f «to 89 0 Al <e] «a oo|40 0 1 <0l>t0 we ao] wo a
AE EE EE
(to <0f>10
EE ST
EX El rT
EE rT sé [Al <0 440. 00 1 fst oo%e 0001 <10]>10 [ 87 I <0l>4
EE TT
EX ST ea ar we eh [
EE EE eT 46 0000 | | 10] «of000 | <0] «of 447 0 0ser 1 [sp stl
EE EE I TE
3 1 1 <ls10 |] % | <0] <0] fea 1 1 to] <0] 26 [I 0]s>10 27 [ 0]>t0 | 1
Cop Tm we [ew a we [Sia - 304 | 0 f*10 [>10 [>10 | » 3000 1 sls 10 sm. se] <0] 0 <1] (22 | [>10 {>10 [>10 36 [10 J>10 [>10 | oo 34 0 | 1 <l>10 [>10 | oo wee aw a0 a a
SEA | [Cl [eo 278 | [0 <0>10 [>10 32 0] <0] <0f>10 eT a ae] ao [fe ao ao]
Sz | cols [sw [0 bo eo
ET he wo wm el ao] eo oo wr ihw [ew w= a] ao wo | <ls ws 2 | [0 ors [sis m1 [0 os sis [lors {sts
Be | <W0lo15 [sts pe [| = ae] ww]
Tal a] wo
BT ao] en mE chs [sw w= ao] aw
Cm TT as bw 2 | [0] wo] ew ar Al a «a ar fe a a ws wa] ao)
Com TEA wo] eo we | [Al a] ao wm 1 ao] ao
CETTE Tao] eo
CoE TET se wl 0 | [El ao] an 0 | T= wo]
Gs [ao] «wo [Ei] wo w= ie] wo
EE Ea] <n mm | ao] ao] ao] am [Al ao] «wo ws [0 ao] «wo wr 1 los [si
G1 0 os [sts
Be 1 [Al ile oo
Ses [Je a] a] we | eal al
Equivalents EE - : ~ Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods - described herein. Such equivalents are intended to be encompassed by the scope of the following claims. IEEE | oo : Incorporation by Reference 0
The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein in their entireties by reference.
Claims (20)
- I. A compound of Formula I: XX 4 eA ZF { @ or a pharmaceutically acceptable salt or solvate thereof, wherein: the dashed line indicates a double bond; Ais N; R* and R? are each, independently, selected from the group consisting of hydrogen, hydroxyl, C;-Cs-alkyl, C5-Cg-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted C;-Cs- alkyl, substituted Cs-Cg-cycloalkyl, substituted heterocyclyl, substituted aryl and substituted heteroaryl; R* is selected from the group consisting of hydrogen, C;-Cs-alkyl, substituted C;-Cs- alkyl, C3-Cg-cycloalkyl, substituted C;-Cg-cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; X is CR, and Y is CR'% R'is hydrogen or C;-Cs-alkyl and R'? is -BC(O)NR"’R"; wherein B is a bond, C-Cs-alkyl or branched C,-Cs-alkyl; wherein R" and R™ are each, independently, selected from the group consisting of hydrogen, C,-Cs-alkyl, C3-Cs-cycloalkyl, heterocyclyl, aryl, heteroaryl, substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and substituted heteroaryl.
- 2. The compound of claim 1, wherein R* is branched or linear C,-Cs-alkyl, wherein the branched C;-Cs-alkyl group may be interrupted by one or more heteroatoms, and/or substituted with one or more heteroatoms, halogens, C3-Cg cycloalkyl groups, substituted Cs- Cs cycloalkyl groups, C3-Csg hetrocyclyl groups, aryl groups, heteroaryl groups, substituted aryl groups, or substituted heteroaryl groups.
- 3. The compound of claim 1, wherein R* is selected from the group consisting of hydrogen, C;-Cs-alkyl, Cs-Cg-cycloalkyl, C;-Cg-substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
- 4. The compound of claim 3, wherein R* is branched or linear C,-Cs-alkyl, wherein the branched C;-Cs-alkyl group may be interrupted by one or more heteroatoms, and/or substituted with one or more heteroatoms, halogens, C3-Cg cycloalkyl groups, substituted Cs- Cs cycloalkyl groups, C3-Csg hetrocyclyl groups, aryl groups, heteroaryl groups, substituted aryl groups, or substituted heteroaryl groups.
- 5. The compound of claim 1, wherein R* is selected from the group consisting of hydrogen, branched C;-Cs-alkyl, branched C;-Cs-alkyl substituted by phenyl and C3-Cs- cycloalkyl.
- 6. The compound of claim 1, wherein R* is CH)(CH,CH3),, C(H)(CH,CH5)Ph, CH,CH3, cyclopropyl, cyclopentyl or cyclohexyl.
- 7. The compound of claim 1, wherein R* is H.
- 8. The compound of claim 1, wherein R’ is an aryl group, which is further independently substituted one or more times by halogen, C;-Cs-alkoxy, RY-amine, R'*-heterocycle, or RY. heteroaryl, wherein RY isa bond, C(O), N(H)C(O), N(H)SO,, OC(O) or (CH»)14, wherein the (CH»);.4 group may be interrupted by O, N(CHj3) or N(H).
- 9. The compound of claim 8, wherein the aryl group is phenyl.
- 10. The compound of claim 11, wherein the phenyl group is independently substituted one or more times with fluoro, methoxy, diethylamine, R"-piperazinyl, R"*-morpholinyl, R'*-piperidinyl, R"*-triazolyl, R'*-phenyl, R'*-pyridinyl, R'*-piperazinyl, R'*-indazolyl, RY- pyrrolidinyl or R"-imidazolyl, wherein the piperazinyl, morpholinyl, piperidinyl, triazolyl, phenyl, pyridinyl, piperazinyl, indazolyl, pyrrolidinyl or imidazolyl groups may be further substituted with C;-Cy-alkyl, C(O)C;-Cs-alkyl, S(O),C;-Cy4-alkyl, OH, C(O)(CH,);3CN or NH)C(O)C;-Cy-alkyl.
- 11. The compound of claim 9, wherein the phenyl group is substituted by N(H)C(O)aryl, C(O)N(H)C,;-Cs-alkyl, C(O)N(C;-Cy-alkyl), or C(O)N(H)C3-Ce-cycloalkyl.
- 12. The compound of claim 1, wherein the compound is selected from the group consisting of e 5" og CDH Q oll 4A ® ¢ nl Ca > 570" N ) Beas 2 Hh CA ! 0 Pe D+Q .Fate Cl @ J ; - N QT gn. 0) - CO) ah EY - °GF - OAT » BN ETE v $ Sak Nic j ) ®Po $ LYe () 0 A A x XK NT 2SY 5B @® ( x x X x BossaSI-“hgNT ° Ses ans HN N 5 | of 0 J s = ) 0 H and A 3
- 13. A compound according to any one of claims 1 to 12 for use in the treatment of an autoimmune, transplant rejection or cancer disorder.
- 14. A compound for use according to claim 13, wherein the autoimmune disease is selected from the group consisting of autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis, multiple sclerosis, neuritis, uveitis ophthalmia, polyendocrinopathies, purpura, Reiter’s Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism, systemic lupus erhythematosus, Goodpasture’s syndrome, Pemphigus, Receptor autoimmunities, autoinunune hemolytic anemia, autoimmune thrombocytopenic purpura, theumatoid arthritis, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison’s disease, infertility, glomerulonephritis, bullous pemphigoid, Sjogren’s syndrome, diabetes millitus, adrenergic drug resistance, chronic active hepatitis, primary biliary cirrhosis, vitiligo, vasculitis, post- MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, chronic active hepatitis, primary biliary cirrhosis and T-cell mediated hypersensitivity diseases.
- 15. A compound for use according to claim 13, wherein the transplant rejection is selected from the group consisting of graft versus host disease, rejection related to xeno transplantation, rejection related to organ transplant, rejection related to acute transplant, heterograft or homograft rejection and ischemic or reperfusion injury incurred during organ transplantation.
- 16. A compound for use according to claim 13, wherein the cancer is selected from the group consisting of bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small- cell lung, glioma, colorectal and pancreatic cancer.
- 17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
- 18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 adapted for simultaneous or sequential administration with an antiinflammatory, antiproliferative, chemotherapeutic agent, immunosuppressant, anti-cancer, cytotoxic agent or kinase inhibitor other than a compound according to any one of claims 1 to 12 or salt thereof.
- 19. The pharmaceutical composition of claim 18, wherein said compound according to any one of claims 1 to 12 or salt thereof is administered, simultaneously or sequentially, with one or more of a PTK inhibitor, cyclosporin A, CTLA4-Ig, antibodies selected from anti- ICAM-3, anti-IL-2 receptor, anti-CD45RB, anti-CD?2, anti-CD3, anti-CD4, anti-CD80, anti- CD86, and monoclonal antibody OKT3, agents blocking the interaction between CD40 and gp39, fusion proteins constructed from CD40 and gp39, inhibitors of NF-kappa B function, non-steroidal antiinflammatory drugs, steroids, gold compounds, antiproliferative agents, FK506, mycophenolate mofetil, cytotoxic drugs, TNF-a inhibitors, anti-TNF antibodies or soluble TNF receptor, rapamycin, leflunimide, cyclooxygenase-2 inhibitors, paclitaxel, cisplatin, carboplatin, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, mitomycin C, ecteinascidin 743, porfiromycin, S-fluorouracil, 6- mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosidine, epothilone, vindesine, leurosine, or derivatives thereof.
- 20. A package comprising a compound according to any one of claims 1 to 12, packaged with instructions for use in the treatment of an autoimmune, transplant rejection or cancer disorder.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80860506P | 2006-05-26 | 2006-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG172632A1 true SG172632A1 (en) | 2011-07-28 |
Family
ID=38779335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011037637A SG172632A1 (en) | 2006-05-26 | 2007-05-24 | Pyrrolopyrimidine compounds and their uses |
Country Status (38)
Country | Link |
---|---|
US (2) | US8324225B2 (en) |
EP (1) | EP2029145B1 (en) |
JP (2) | JP2009538341A (en) |
KR (1) | KR101466412B1 (en) |
CN (1) | CN101594871B (en) |
AR (2) | AR061124A1 (en) |
AU (1) | AU2007267645C1 (en) |
BR (1) | BRPI0712816B8 (en) |
CA (1) | CA2652044C (en) |
CL (1) | CL2007001504A1 (en) |
CR (1) | CR10433A (en) |
CU (1) | CU23831B1 (en) |
EA (1) | EA016301B1 (en) |
EC (1) | ECSP088910A (en) |
ES (1) | ES2623133T3 (en) |
GE (1) | GEP20115283B (en) |
GT (1) | GT200800258A (en) |
HN (1) | HN2008001752A (en) |
HR (1) | HRP20170631T1 (en) |
IL (1) | IL195086A (en) |
JO (1) | JO3235B1 (en) |
MA (1) | MA30557B1 (en) |
ME (1) | ME00486B (en) |
MX (1) | MX2008015076A (en) |
MY (1) | MY150650A (en) |
NO (1) | NO343182B1 (en) |
NZ (1) | NZ572549A (en) |
PE (1) | PE20080263A1 (en) |
PL (1) | PL2029145T3 (en) |
PT (1) | PT2029145T (en) |
SG (1) | SG172632A1 (en) |
SM (1) | SMP200800069B (en) |
TN (1) | TNSN08481A1 (en) |
TW (1) | TWI398252B (en) |
UA (1) | UA95632C2 (en) |
UY (1) | UY30369A1 (en) |
WO (1) | WO2007140222A2 (en) |
ZA (1) | ZA200809382B (en) |
Families Citing this family (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483B (en) | 2005-12-13 | 2014-12-17 | 因塞特公司 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
AR063141A1 (en) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
KR101549876B1 (en) | 2007-06-13 | 2015-09-03 | 인사이트 코포레이션 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
WO2009024824A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
CN101945867A (en) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
MX2010008719A (en) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors. |
EP2255830A1 (en) * | 2008-03-03 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Concomitant drug |
MX2010010975A (en) * | 2008-04-07 | 2010-11-01 | Amgen Inc | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors. |
TW201002713A (en) | 2008-04-09 | 2010-01-16 | Organon Nv | Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors |
CN102083429B (en) | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido inhibitors |
WO2009152027A1 (en) * | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
DK2331547T3 (en) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidine Compounds as CDK Inhibitors |
WO2010045451A1 (en) * | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
GB0903759D0 (en) * | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
CN102458443A (en) | 2009-05-13 | 2012-05-16 | 北卡罗来纳大学查珀尔希尔分校 | Cyclin dependent kinase inhibitors and methods of use |
AR076794A1 (en) | 2009-05-22 | 2011-07-06 | Incyte Corp | DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE AND COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM |
RS59632B1 (en) | 2009-05-22 | 2020-01-31 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
MX2012005100A (en) | 2009-10-29 | 2012-06-08 | Palau Pharma Sa | N-containing heteroaryl derivatives as jak3 kinase inhibitors. |
WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
EP3202460B1 (en) | 2010-02-11 | 2019-06-12 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
UY33226A (en) * | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPUTERS DEUTERATED AS INHIBITORS OF THE CDK4 / 6 |
UY33227A (en) | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
TWI766281B (en) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
JP5918214B2 (en) * | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | Combinations comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4 / 6) inhibitor and an MTOR inhibitor for treating cancer |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
CN103002875B (en) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Topical formulations of JAK inhibitors |
CN106008533B (en) * | 2010-10-25 | 2018-01-23 | G1治疗公司 | CDK inhibitor |
AR083797A1 (en) * | 2010-11-10 | 2013-03-20 | Novartis Ag | DIMETHYL ACID SUCCINATE 7-CYCLOPENTIL-2- (5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO) -7H-PIRROLO- [2,3-D] PIRIMIDIN-6-CARBOXILICO, PROCESS FOR PREPARE IT, INTERMEDIARIES OF SUCH SYNTHESIS AND PREPARATION PROCESS OF THE SAME |
AU2011329763A1 (en) | 2010-11-17 | 2013-05-09 | Brigham And Women's Hospital | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP5917544B2 (en) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
CN103476776B (en) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor |
CN102093364B (en) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
DK2675793T3 (en) | 2011-02-17 | 2018-11-12 | Cancer Therapeutics Crc Pty Ltd | FAK INHIBITORS |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
CN103547580B (en) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | Substituted fused tricyclic compounds, a combination thereof thing and medical usage |
ES2543569T3 (en) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3 |
MX2013013331A (en) * | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Azaindole derivatives as tyrosine kinase inhibitors. |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
CA2840620A1 (en) | 2011-07-01 | 2013-01-10 | Novartis Ag | Combination therapy |
BR112013033940A2 (en) | 2011-07-01 | 2017-02-14 | Novartis Ag | combination therapy comprising a cdk4 / 6 inhibitor and a pi3k inhibitor for use in cancer treatment |
EP2729466B1 (en) | 2011-07-08 | 2015-08-19 | Novartis AG | Novel pyrrolo pyrimidine derivatives |
WO2013017480A1 (en) * | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017479A1 (en) * | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
AU2012318896B2 (en) | 2011-10-03 | 2017-03-02 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
BR112014028424A2 (en) | 2012-05-22 | 2018-04-24 | Univ North Carolina Chapel Hill | Pyrimidine compounds for cancer treatment |
CN104349775B (en) * | 2012-06-14 | 2017-06-06 | 伊莱利利公司 | The inhibitor of JAK1 and JAK2 |
EP2880448B1 (en) | 2012-08-03 | 2022-06-29 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
WO2014053968A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | Pyrazolopyrimidine compounds for the treatment of cancer |
SG10202111768XA (en) | 2012-11-15 | 2021-11-29 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
JP2016516005A (en) | 2013-02-25 | 2016-06-02 | ノバルティス アーゲー | Novel androgen receptor mutation |
US9708326B2 (en) | 2013-02-25 | 2017-07-18 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CA2903901A1 (en) * | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
LT2964650T (en) | 2013-03-06 | 2019-04-25 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
SG10201906270VA (en) | 2013-03-21 | 2019-08-27 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
WO2014172479A1 (en) | 2013-04-16 | 2014-10-23 | Memorial Sloan-Kettering Cancer Center | Companion diagnostic for cdk4 inhibitors |
JP6204568B2 (en) | 2013-04-25 | 2017-09-27 | ベイジーン,リミテッド | Fused heterocyclic compounds as protein kinase inhibitors |
US8895611B1 (en) | 2013-07-17 | 2014-11-25 | King Fahd University Of Petroleum And Minerals | Cytotoxic compounds for treating cancer |
SI3030227T1 (en) | 2013-08-07 | 2020-08-31 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
CN103408546A (en) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 2-phenylaminopurine PLK1 (Polo-like kinase 1) inhibitors and applications thereof |
EP4130044A1 (en) | 2013-09-13 | 2023-02-08 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
LT3122359T (en) | 2014-03-26 | 2021-03-25 | Astex Therapeutics Ltd. | Combinations of an fgfr inhibitor and an igf1r inhibitor |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
WO2015157127A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015180642A1 (en) * | 2014-05-28 | 2015-12-03 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
US10555931B2 (en) | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
EA032693B1 (en) | 2014-07-24 | 2019-07-31 | Бета Фарма, Инк. | 2h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
MX2017004600A (en) | 2014-10-06 | 2017-06-30 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith. |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
CN105111215B (en) * | 2014-12-12 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | A kind of crystal form and preparation method thereof of cyclin-dependent kinase inhibitor |
CN104610265A (en) * | 2014-12-31 | 2015-05-13 | 芜湖杨燕制药有限公司 | Compound and preparation method thereof |
CN104606197A (en) * | 2014-12-31 | 2015-05-13 | 芜湖杨燕制药有限公司 | Application of compound in tumor resistance |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
CA2976109A1 (en) * | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors |
CN106146515B (en) * | 2015-04-17 | 2020-09-04 | 常州隆赛医药科技有限公司 | Preparation and application of novel kinase inhibitor |
ES2811845T3 (en) | 2015-09-23 | 2021-03-15 | Janssen Pharmaceutica Nv | Tricyclic heterocycles for treating cancer |
KR20180052631A (en) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | Non-heteroaryl substituted 1,4-benzodiazepines and their use for the treatment of cancer |
CN113549069A (en) * | 2015-12-27 | 2021-10-26 | 重庆复创医药研究有限公司 | Kinase inhibitor |
CN106928219B (en) * | 2015-12-31 | 2021-08-20 | 上海医药集团股份有限公司 | Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application |
WO2017156263A1 (en) | 2016-03-09 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Enigma and cdh18 as companion diagnostics for cdk4 inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
MX2018011992A (en) | 2016-04-01 | 2019-01-24 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith. |
JP6995058B2 (en) | 2016-04-01 | 2022-02-21 | シグナル ファーマシューティカルズ,エルエルシー | (1S, 4S) -4- (2-(((3S, 4R) -3-fluorotetrahydro-2H-pyran-4-yl) amino) -8-((2,4,6-trichlorophenyl) amino) -9H-Purin-9-yl) -1-Methylchlorohexane-1-Carboxamide solid form and its usage |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
AU2017314178B2 (en) | 2016-08-16 | 2021-11-18 | Beigene Switzerland Gmbh | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
DK3500299T3 (en) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Combination of zanubrutinib with an anti-CD20 or an anti-PD-1 antibody for use in the treatment of cancer |
CA3034875C (en) | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
MA46285A (en) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | POLYTHERAPY |
MX2019004602A (en) | 2016-10-20 | 2019-06-17 | Pfizer | Anti-proliferative agents for treating pah. |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
WO2018094227A1 (en) | 2016-11-17 | 2018-05-24 | The University Of North Carolina At Chapel Hill | Alkyl pyrrolopyrimidine analogs and methods of making and using same |
PL3558997T3 (en) | 2016-12-20 | 2021-07-19 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
US11052091B2 (en) | 2016-12-21 | 2021-07-06 | Ono Pharmaceutical Co., Ltd. | BRK inhibitory compound |
US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
WO2018139660A1 (en) * | 2017-01-30 | 2018-08-02 | 国立大学法人京都大学 | Novel compound, and method for producing regulatory t cells |
MA47776A (en) | 2017-03-16 | 2020-01-22 | Eisai R&D Man Co Ltd | POLYTHERAPIES FOR THE TREATMENT OF BREAST CANCER |
BR112019026483A2 (en) | 2017-06-16 | 2020-07-14 | Beta Pharma, Inc. | pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY |
SG11202002767RA (en) * | 2017-09-28 | 2020-04-29 | Shanghai Haiyan Pharmaceutical Technology Co Ltd | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof |
EP3692041A1 (en) | 2017-10-04 | 2020-08-12 | Celgene Corporation | Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
SG11202002864PA (en) | 2017-10-04 | 2020-04-29 | Celgene Corp | Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl] amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3746072B1 (en) | 2018-01-29 | 2023-04-12 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
MX2020007973A (en) | 2018-01-30 | 2020-12-07 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicot inyl)piperidine-4-one). |
WO2019157020A1 (en) | 2018-02-06 | 2019-08-15 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
UA127925C2 (en) | 2018-03-30 | 2024-02-14 | Інсайт Корпорейшн | Treatment of hidradenitis suppurativa using jak inhibitors |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
US10723739B2 (en) | 2018-05-14 | 2020-07-28 | Apotex Inc. | Processes for the preparation of Ribociclib and intermediates thereof |
WO2019222524A1 (en) * | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Alkyl pyrrolopyrimidines as pan-tam inhibitors and their application in cancer treatment |
CN110577524B (en) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | Kinase selective inhibitor |
CN109438447B (en) * | 2018-09-11 | 2020-10-16 | 北京工业大学 | Preparation method and application of 5, 7-dihydro-6H-pyrrolo [2,3-d ] pyrimidine-6-ketone derivative |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US20220056037A1 (en) * | 2018-12-28 | 2022-02-24 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
EP3902805A4 (en) * | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
TW202100520A (en) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
AU2020267661A1 (en) | 2019-05-08 | 2021-12-23 | Vimalan Biosciences, Inc. | JAK inhibitors |
KR102503349B1 (en) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
TW202110849A (en) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna-dependent protein kinase inhibitor |
CN110305140B (en) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | Dihydropyrrolopyrimidines selective JAK2 inhibitors |
JP2022544174A (en) * | 2019-08-08 | 2022-10-17 | ビマラン バイオサイエンシーズ,インク. | JAK inhibitor |
AR119765A1 (en) | 2019-08-14 | 2022-01-12 | Incyte Corp | IMIDAZOLIL PYRIMIDINILAMINE COMPOUNDS AS CDK2 INHIBITORS |
GB201911868D0 (en) * | 2019-08-19 | 2019-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US20230024521A1 (en) * | 2019-09-25 | 2023-01-26 | Vimalan Biosciences, Inc. | Jak inhibitors |
MX2022004390A (en) | 2019-10-11 | 2022-08-08 | Incyte Corp | Bicyclic amines as cdk2 inhibitors. |
WO2021073593A1 (en) * | 2019-10-17 | 2021-04-22 | 南京明德新药研发有限公司 | Aminopyrimidine compound as cdk2/4/6 triple inhibitor |
EP4059935A4 (en) * | 2019-11-13 | 2024-02-28 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | Pyrrolopyrimidine compound as btk inhibitor and use thereof |
CA3164617A1 (en) * | 2019-12-16 | 2021-06-24 | Lunella Biotech, Inc. | Selective cdk4/6 inhibitor cancer therapeutics |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
KR102409595B1 (en) * | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | Novel purinone derivatives as protein kinase CSF-1R inhibitor |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
CZ309356B6 (en) * | 2020-09-15 | 2022-09-28 | Ústav experimentální botaniky AV ČR, v. v. i | Substituted purine compounds as protein kinase inhibitors, their use as medicaments and pharmaceutical preparations containing these derivatives |
CN112375081B (en) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | Pyrrole [2,3-d ] pyrimidine derivative with CDK4, 6 or 9 inhibiting activity and preparation method and application thereof |
CN116685323A (en) * | 2020-12-21 | 2023-09-01 | 江苏恒瑞医药股份有限公司 | Purinone derivative, preparation method and medical application thereof |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
JP2024507935A (en) | 2021-02-25 | 2024-02-21 | インサイト・コーポレイション | Spirocyclic lactams as JAK2 V617F inhibitors |
EP4313987A2 (en) | 2021-04-01 | 2024-02-07 | KRKA, d.d., Novo mesto | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof |
US20240228502A1 (en) * | 2021-04-22 | 2024-07-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | 2-phenylamino pyrrolopyrimidines as ack1 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
WO2023241620A1 (en) * | 2022-06-14 | 2023-12-21 | Suzhou Keen Therapeutics Co., Ltd. | Biologically active compounds and methods thereof |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
WO2024056090A1 (en) * | 2022-09-16 | 2024-03-21 | 华东师范大学 | Pyrrolopyrimidine derivative as rsk inhibitor and use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05306226A (en) * | 1992-04-27 | 1993-11-19 | Takeda Chem Ind Ltd | Therapeutic agent for chronic immunological disease |
JP4187657B2 (en) * | 2002-03-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | Bicyclic pyridines and pyrimidines as p38 kinase inhibitors |
WO2005023806A2 (en) | 2003-09-05 | 2005-03-17 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
CA2538820A1 (en) * | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
US7319102B1 (en) | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
US7968557B2 (en) * | 2004-02-14 | 2011-06-28 | Novartis Ag | Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors |
EP1725562A1 (en) | 2004-03-05 | 2006-11-29 | Taisho Pharmaceutical Co., Ltd | Pyrrolopyrimidine derivatives |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
BRPI0517272A (en) | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | hiv-inhibiting bicyclic pyrimidine derivatives |
US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
JP5190271B2 (en) | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 5-membered cycloadded heterocyclic pyrimidines as kinase inhibitors |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
JP2006241089A (en) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | Pyrroloprymidine derivative or its salt |
WO2007030438A2 (en) | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
GB0520164D0 (en) | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
WO2007058990A2 (en) * | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
MX2008011525A (en) * | 2006-03-09 | 2008-09-18 | Pharmacopeia Inc | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders. |
EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
MX2010008719A (en) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors. |
-
2007
- 2007-05-23 JO JOP/2007/0193A patent/JO3235B1/en active
- 2007-05-23 TW TW096118407A patent/TWI398252B/en active
- 2007-05-24 CA CA2652044A patent/CA2652044C/en active Active
- 2007-05-24 PE PE2007000646A patent/PE20080263A1/en active IP Right Grant
- 2007-05-24 CN CN2007800193572A patent/CN101594871B/en active Active
- 2007-05-24 ES ES07811927.8T patent/ES2623133T3/en active Active
- 2007-05-24 EA EA200802332A patent/EA016301B1/en not_active IP Right Cessation
- 2007-05-24 ME MEP-2008-766A patent/ME00486B/en unknown
- 2007-05-24 PL PL07811927T patent/PL2029145T3/en unknown
- 2007-05-24 SG SG2011037637A patent/SG172632A1/en unknown
- 2007-05-24 NZ NZ572549A patent/NZ572549A/en unknown
- 2007-05-24 KR KR1020087031411A patent/KR101466412B1/en active IP Right Grant
- 2007-05-24 EP EP07811927.8A patent/EP2029145B1/en active Active
- 2007-05-24 JP JP2009512291A patent/JP2009538341A/en active Pending
- 2007-05-24 PT PT78119278T patent/PT2029145T/en unknown
- 2007-05-24 UA UAA200813340A patent/UA95632C2/en unknown
- 2007-05-24 AR ARP070102252A patent/AR061124A1/en active IP Right Grant
- 2007-05-24 BR BRPI0712816A patent/BRPI0712816B8/en active IP Right Grant
- 2007-05-24 WO PCT/US2007/069595 patent/WO2007140222A2/en active Application Filing
- 2007-05-24 AU AU2007267645A patent/AU2007267645C1/en active Active
- 2007-05-24 MY MYPI20084701 patent/MY150650A/en unknown
- 2007-05-24 MX MX2008015076A patent/MX2008015076A/en active IP Right Grant
- 2007-05-24 US US12/302,223 patent/US8324225B2/en active Active
- 2007-05-24 GE GEAP200710989A patent/GEP20115283B/en unknown
- 2007-05-24 SM SM200800069T patent/SMP200800069B/en unknown
- 2007-05-25 UY UY30369A patent/UY30369A1/en active IP Right Grant
- 2007-05-25 CL CL200701504A patent/CL2007001504A1/en unknown
-
2008
- 2008-11-03 IL IL195086A patent/IL195086A/en active IP Right Grant
- 2008-11-03 ZA ZA2008/09382A patent/ZA200809382B/en unknown
- 2008-11-10 CR CR10433A patent/CR10433A/en unknown
- 2008-11-21 TN TNP2008000481A patent/TNSN08481A1/en unknown
- 2008-11-24 GT GT200800258A patent/GT200800258A/en unknown
- 2008-11-24 CU CU2008000223A patent/CU23831B1/en active IP Right Grant
- 2008-11-25 HN HN2008001752A patent/HN2008001752A/en unknown
- 2008-11-26 EC EC2008008910A patent/ECSP088910A/en unknown
- 2008-12-01 MA MA31431A patent/MA30557B1/en unknown
- 2008-12-02 NO NO20085030A patent/NO343182B1/en unknown
-
2012
- 2012-04-20 US US13/452,100 patent/US20120207763A1/en not_active Abandoned
-
2013
- 2013-01-23 JP JP2013010317A patent/JP5740417B2/en active Active
-
2017
- 2017-04-05 AR ARP170100874A patent/AR108179A2/en unknown
- 2017-04-21 HR HRP20170631TT patent/HRP20170631T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007267645B2 (en) | Pyrrolopyrimidine compounds and their uses | |
CA3158254C (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors | |
ES2374480T3 (en) | PIRAZOL DERIVATIVES AND USE OF THE SAME AS INHIBITORS OF CYCLINE-DEPENDENT KINASES. | |
TWI574691B (en) | Anti - tumor agents for intermittent administration of FGFR inhibitors | |
ES2626006T3 (en) | 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors | |
JP5109109B2 (en) | A novel imidazopyrazine as a cyclin-dependent kinase inhibitor | |
AU2022219987A1 (en) | Cdk inhibitors and methods of use thereof | |
EP2986300B1 (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
TWI736578B (en) | Certain protein kinase inhibitors | |
EA023574B1 (en) | 6-CYCLOBUTYL-1,5-DIHYDROPYRAZOLO[3,4-d]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | |
CN104910137A (en) | CDK kinase inhibitor | |
Yuan et al. | Design, synthesis and biological evaluation of pyridone–aminal derivatives as MNK1/2 inhibitors | |
US20160280719A1 (en) | Pyrrolopyrrolone derivatives and their use as bet inhibitors | |
CN102869664A (en) | Pyrazolopyrimidine kinase inhibitors | |
WO2023096995A1 (en) | Compositions and methods comprising substituted n-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues |